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ABSTRACT	  
Introduction.	  Aortic	  stenosis	  is	  characterised	  both	  by	  progressive	  narrowing	  of	  the	  valve	  and	  the	  
hypertrophic	  response	  of	  the	  left	  ventricle.	  The	  purpose	  of	  this	  thesis	  was	  to	  study	  the	  contribution	  
of	  inflammation	  and	  calcification	  to	  valve	  narrowing	  using	  Positron	  Emission	  and	  Computed	  
Tomography	  (PET/CT)	  and	  to	  investigate	  the	  hypertrophic	  response	  using	  cardiovascular	  magnetic	  
resonance	  (CMR).	  	  
	  
Methods.	  PET/CT	  studies.	  Patients	  with	  aortic	  sclerosis	  and	  mild,	  moderate	  and	  severe	  stenosis	  were	  
prospectively	  compared	  to	  matched	  control	  subjects.	  Aortic	  valve	  severity	  was	  determined	  by	  
echocardiography.	  Calcification	  and	  inflammation	  in	  the	  aortic	  valve	  and	  coronary	  arteries	  were	  
assessed	  by	  sodium	  18-­‐fluoride	  (18F-­‐NaF)	  and	  18-­‐fluorodeoxyglucose	  (18F-­‐FDG)	  uptake	  using	  PET.	  	  
	  
CMR	  studies.	  Consecutive	  patients	  with	  moderate	  or	  severe	  aortic	  stenosis	  undergoing	  CMR	  were	  
enrolled	  into	  a	  registry.	  Patients	  who	  received	  gadolinium	  contrast	  were	  categorised	  into	  absent,	  mid-­‐
wall	  or	  infarct	  patterns	  of	  late	  gadolinium	  enhancement	  (LGE)	  by	  blinded	  independent	  observers.	  
Patients	  follow-­‐up	  was	  completed	  using	  patient	  questionnaires,	  source	  record	  data	  and	  the	  National	  
Strategic	  Tracing	  Scheme.	  After	  excluding	  those	  patients	  with	  concomitant	  triggers	  to	  LV	  remodeling,	  
the	  extent	  and	  patterns	  of	  hypertrophy	  were	  investigated	  based	  upon	  measurements	  of	  indexed	  LV	  
mass,	  indexed	  LV	  volume	  and	  the	  relative	  wall	  mass.	  	  
	  
Results.	  PET/CT	  studies.	  121	  subjects	  (20	  controls;	  20	  aortic	  sclerosis;	  25	  mild,	  33	  moderate	  and	  23	  
severe	  aortic	  stenosis)	  were	  studied.	  Quantification	  of	  tracer	  uptake	  within	  the	  valve	  demonstrated	  
excellent	  inter-­‐observer	  reproducibility	  with	  no	  biases	  and	  limits	  of	  agreement	  of	  ±0.21	  (18F-­‐NaF)	  
and	  ±0.13	  (18F-­‐FDG)	  for	  maximum	  tissue-­‐to-­‐background	  ratios	  (TBR).	  Activity	  of	  both	  tracers	  was	  
higher	  in	  patients	  with	  aortic	  stenosis	  than	  control	  subjects	  (18F-­‐NaF:	  2.87±0.82	  vs	  1.55±0.17;	  18F-­‐
FDG:	  1.58±0.21	  vs	  1.30±0.13;	  both	  P<0.001).	  18F-­‐NaF	  uptake	  displayed	  a	  progressive	  rise	  with	  valve	  
severity	  (r2=0.540,	  P<0.001)	  with	  a	  more	  modest	  increase	  observed	  for	  18F-­‐FDG	  (r2=0.218;	  P<0.001).	  
Amongst	  patients	  with	  aortic	  stenosis,	  91%	  had	  increased	  18F-­‐NaF	  (>1.97)	  and	  35%	  increased	  18F-­‐
FDG	  (>1.63)	  uptake.	  Increased	  18F-­‐NaF	  uptake	  was	  also	  observed	  in	  the	  coronary	  arteries	  in	  a	  subset	  
of	  patients	  with	  atherosclerosis.	  These	  patients	  (n=40)	  had	  higher	  rates	  of	  prior	  cardiovascular	  events	  
(p=0.016)	  and	  angina	  (p=0.023),	  and	  higher	  Framingham	  risk	  scores	  (p=0.011).	  
	  
CMR	  studies.	  143	  patients	  (aged	  68±14	  years;	  97	  male)	  were	  followed	  up	  for	  2.0±1.4	  years	  and	  27	  
died.	  Compared	  to	  those	  with	  no	  LGE	  (n=49),	  univariate	  analysis	  revealed	  that	  patients	  with	  mid-­‐wall	  
fibrosis	  (n=54)	  had	  an	  eight-­‐fold	  increase	  in	  all-­‐cause	  mortality	  despite	  similar	  aortic	  stenosis	  severity	  
and	  coronary	  artery	  disease	  burden.	  Patients	  with	  an	  infarct	  pattern	  (n=40)	  had	  a	  six-­‐fold	  increase.	  
Mid-­‐wall	  fibrosis	  (HR	  5.35	  [95%	  CI	  1.16-­‐24.56];	  P=0.03)	  emerged	  as	  an	  independent	  predictor	  of	  all	  
cause	  mortality	  by	  multivariate	  analysis.	  The	  pattern	  of	  LV	  remodelling	  was	  studied	  in	  91	  patients	  
(61±21	  years;	  57	  male)	  and	  displayed	  wide	  variation	  comprising	  normal	  ventricular	  geometry	  (n=11),	  
concentric	  remodelling	  (n=11),	  asymmetric	  remodelling	  (n=11),	  concentric	  hypertrophy	  (n=34),	  
asymmetric	  hypertrophy	  (n=14)	  and	  LV	  decompensation	  (n=10).	  The	  magnitude	  of	  the	  hypertrophic	  
response	  was	  unrelated	  to	  the	  severity	  of	  aortic	  valve	  narrowing.	  
	  
Conclusions.	  Modern	  imaging	  techniques	  have	  provided	  important	  insights	  in	  to	  the	  pathology	  
underlying	  aortic	  stenosis	  and	  suggest	  that	  valvular	  calcification	  and	  myocardial	  fibrosis	  have	  a	  key	  
role.	  Both	  represent	  important	  potential	  targets	  for	  future	  therapeutic	  interventions.	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Introduction	  
1.0	  OVERVIEW	  
Calcific	  aortic	  stenosis	  (AS)	  is	  the	  most	  common	  form	  of	  valve	  disease	  in	  the	  western	  world	  and	  
represents	  a	  major	  healthcare	  burden.	  Over	  the	  last	  decade,	  the	  number	  of	  aortic	  valve	  
replacements	  performed	  in	  the	  United	  States	  of	  America	  has	  doubled	  and,	  with	  an	  increasingly	  
elderly	  population,	  the	  prevalence	  of	  AS	  is	  likely	  to	  double	  again	  in	  the	  next	  20	  years.1	  However,	  the	  
underlying	  pathophysiology	  of	  AS	  remains	  incompletely	  defined,	  and	  there	  are	  currently	  no	  effective	  
medical	  treatments	  capable	  of	  altering	  its	  course.	  Furthermore	  we	  lack	  reliable	  markers	  that	  can	  
predict	  disease	  progression,	  the	  future	  need	  for	  surgery,	  or	  mortality.	  There	  is	  therefore	  a	  pressing	  
need	  to	  re-­‐evaluate	  the	  underlying	  pathophysiological	  processes	  involved.2	  	  
	  
Aortic	  stenosis	  is	  characterized	  by	  progressive	  narrowing	  of	  the	  aortic	  valve	  that	  increases	  the	  
pressure	  afterload	  on	  the	  left	  ventricle.	  Myocytes	  enlarge	  and	  wall	  thickness	  increases	  in	  a	  
hypertrophic	  response	  that	  initially	  restores	  wall	  stress	  but	  ultimately	  proves	  maladaptive.	  The	  rate	  
at	  which	  patients	  with	  aortic	  stenosis	  move	  towards	  symptoms,	  adverse	  events	  and	  the	  need	  for	  
surgery	  is	  determined	  both	  by	  the	  severity	  of	  the	  valve	  narrowing	  and	  by	  the	  myocardial	  
hypertrophic	  response.3,	  4	  Both	  processes	  are	  of	  clinical	  importance	  and,	  whilst	  linked,	  they	  are	  under	  
the	  influence	  of	  different	  pathological	  factors.	  	  
	  
With	  advances	  in	  technology	  and	  motion	  correction,	  modern	  non-­‐invasive	  imaging	  techniques	  such	  
as	  cardiovascular	  magnetic	  resonance	  (CMR)	  and	  positron	  emission	  tomography	  (PET)	  have	  become	  
applicable	  to	  the	  heart.	  This	  has	  afforded	  the	  opportunity	  to	  improve	  our	  understanding	  of	  the	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pathogenesis	  underlying	  aortic	  stenosis	  in	  a	  non-­‐invasive	  manner.	  Specifically	  combined	  PET	  and	  
computed	  tomography	  (PET/CT)	  allow	  processes	  such	  as	  inflammation	  and	  calcification	  to	  be	  
investigated	  within	  small	  anatomical	  structures	  such	  as	  the	  aortic	  valve,	  whilst	  cardiovascular	  
magnetic	  resonance	  (CMR)	  allows	  for	  the	  assessment	  of	  left	  ventricular	  remodelling	  and	  for	  the	  
identification	  of	  replacement	  myocardial	  fibrosis.	  	  
	  
The	  purpose	  of	  this	  thesis	  was	  to	  use	  these	  imaging	  techniques	  to	  gain	  insights	  in	  to	  pathophysiology	  
of	  aortic	  stenosis	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1.1	  NARROWING	  OF	  THE	  AORTIC	  VALVE	  
ANATOMY	  OF	  THE	  NORMAL	  VALVE	  
	  
Normal	  aortic	  valves	  are	  made	  up	  of	  three	  cusps	  (Figure	  1.1),	  the	  arrangement	  of	  which	  results	  in	  
even	  distribution	  of	  mechanical	  stress	  to	  the	  valve	  ring	  and	  the	  aorta.5	  Each	  cusp	  is	  <1	  mm	  thick	  and	  
appears	  smooth,	  thin	  and	  opalescent,	  with	  very	  few	  cells	  and	  the	  following	  clearly	  defined	  tissue	  
layers.	  On	  the	  aortic	  and	  ventricular	  aspects	  of	  the	  valve	  is	  the	  endothelium,	  which	  is	  continuous	  
with	  that	  of	  the	  aortic	  endothelium	  and	  left	  ventricular	  endocardium.	  Moving	  into	  the	  valve,	  the	  
fibrosa	  consists	  of	  fibrous	  tissue	  with	  fibroblasts	  and	  collagen	  fibers	  arranged	  concentrically.	  The	  
ventricularis	  on	  the	  ventricular	  side	  of	  the	  leaflet	  is	  composed	  of	  elastin	  rich	  fibers	  arranged	  radially,	  
perpendicular	  to	  the	  collagen	  fibers	  in	  the	  fibrosa.6	  A	  further	  layer,	  the	  spongiosa,	  can	  be	  found	  at	  
the	  base	  of	  the	  valve	  between	  the	  fibrosa	  and	  the	  ventricularis.	  It	  is	  a	  layer	  of	  loose	  connective	  tissue	  
containing	  mucopolysaccharides,	  mesenchymal	  cells	  and	  fibroblasts,	  whose	  function	  is	  to	  resist	  
compressive	  forces	  within	  the	  cusps	  (Figure	  1.1).	  At	  their	  base	  the	  valve	  leaflets	  are	  attached	  to	  a	  
dense	  collagenous	  network,	  called	  the	  annulus,	  which	  facilitates	  their	  attachment	  to	  the	  aortic	  root	  
and	  the	  dissipation	  of	  mechanical	  force	  (Figure	  1.1).	  
	  
	   	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   16	  




A)	  Long-­‐axis	  view	  of	  the	  aortic	  valve	  showing	  the	  left	  and	  right	  coronary	  cusps.	  The	  valve	  cusps	  have	  a	  four-­‐layered	  structure.	  On	  
the	  aortic	  aspect	  of	  the	  valve	  the	  endothelium	  is	  continuous	  with	  that	  of	  the	  aorta	  and	  the	  coronary	  arteries,	  which	  arise	  above	  
the	  valve	  in	  the	  coronary	  sinuses.	  Moving	  towards	  the	  ventricular	  aspect	  of	  the	  valve	  is	  the	  fibrosa,	  which	  consists	  of	  fibroblasts	  
and	  collagen	  fibers.	  The	  spongiosa	  is	  predominantly	  found	  at	  the	  base	  of	  the	  leaflets	  and	  contains	  proteoglycans,	  which	  absorb	  
compressive	  forces	  within	  the	  valve.	  Finally	  the	  ventricularis	  is	  found	  on	  the	  ventricular	  aspect	  of	  the	  valve	  and	  contains	  elastin	  
fibers	  orientated	  perpendicularly	  to	  the	  collagen.	  	  	  
B)	  Short-­‐axis	  views	  of	  the	  right,	  left	  and	  non-­‐coronary	  cusps	  of	  the	  aortic	  valve.	  Aortic	  aspect	  of	  the	  valve	  displays	  the	  concentric	  
arrangement	  of	  collagen	  fibers	  in	  the	  fibrosa	  layer	  of	  the	  valve.	  	  Ventricular	  aspect	  showing	  the	  radial	  arrangement	  of	  elastin	  
fibers	  in	  the	  ventricularis	  layer	  of	  the	  valve.	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PATHOLOGY	  	  
In	  calcific	  aortic	  stenosis,	  the	  valve	  cusps	  become	  progressively	  thickened,	  fibrosed	  and	  calcified.	  This	  
results	  in	  increased	  valve	  stiffness,	  reduced	  cusp	  excursion,	  and	  progressive	  valve	  orifice	  narrowing	  
that	  contrasts	  with	  the	  cusp	  fusion	  seen	  with	  rheumatic	  heart	  disease.	  Historically,	  calcific	  aortic	  
stenosis	  has	  been	  attributed	  to	  prolonged	  “wear	  and	  tear”	  and	  age-­‐associated	  valvular	  degeneration.	  
However,	  recent	  evidence	  suggests	  that	  it	  is	  instead	  the	  result	  of	  active	  inflammatory	  processes	  
involving	  biochemical,	  humoral	  and	  genetic	  factors	  (Figure	  1.2).	  	  
	  
Mechanical	  Stress	  &	  Endothelial	  Damage	  
The	  early	  stages	  of	  aortic	  stenosis	  are	  in	  many	  ways	  similar	  to	  atherosclerosis.	  Like	  atherosclerosis,	  
the	  initiating	  event	  is	  believed	  to	  be	  endothelial	  damage	  resulting	  from	  increased	  mechanical	  stress	  
and	  reduced	  shear	  stress.	  This	  results	  in	  a	  characteristic	  distribution	  of	  lesions	  within	  the	  stenotic	  
valve.	  Shear	  stress	  is	  highest	  in	  the	  cusps	  adjacent	  to	  the	  coronary	  ostia	  due	  to	  the	  influence	  of	  
coronary	  artery	  flow.	  Consequently	  the	  non-­‐coronary	  cusp	  has	  lower	  shear	  stress	  and	  is	  most	  
frequently	  involved	  in	  aortic	  stenosis.	  Mechanical	  tissue	  stress	  is	  highest	  around	  the	  flexion	  areas	  of	  
the	  cusps	  near	  their	  attachment	  to	  the	  aortic	  root	  and	  50%	  of	  lesions	  can	  also	  be	  observed	  in	  this	  
region.7	  However,	  the	  bicuspid	  aortic	  valve	  perhaps	  best	  illustrates	  the	  role	  of	  mechanical	  stress	  in	  
the	  pathogenesis	  of	  aortic	  stenosis.	  This	  common	  congenital	  abnormality	  is	  characterized	  by	  a	  two-­‐
cusp	  structure	  that	  results	  in	  a	  less	  efficient	  distribution	  and	  concentration	  of	  mechanical	  forces	  
within	  the	  valve	  such	  that	  aortic	  stenosis	  develops	  almost	  invariably	  in	  these	  patients	  and	  on	  average	  
two	  decades	  earlier	  than	  in	  those	  with	  a	  tri-­‐leaflet	  valve.	  8,	  9	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Figure	  1.2.	  Summary	  of	  the	  pathological	  processes	  occurring	  within	  the	  valve	  during	  aortic	  stenosis	  
	  
Mechanical	  stress	  results	  in	  endothelial	  damage	  that	  allows	  infiltration	  of	  lipid	  and	  inflammatory	  cells	  in	  to	  the	  valve	  to	  form	  lipid	  plaques.	  Lipid	  oxidization	  further	  increases	  
inflammatory	  activity	  within	  these	  lesions	  and	  the	  secretion	  of	  pro-­‐inflammatory	  and	  pro-­‐fibrotic	  cytokines.	  The	  latter	  drives	  the	  differentiation	  of	  fibroblasts	  in	  to	  myofibroblasts	  that	  
secrete	  increased	  amounts	  of	  collagen	  I	  and	  III	  under	  the	  influence	  of	  angiotensin.	  In	  addition	  matrix	  metallopoteineases	  (MMP)	  and	  tissue	  inhibitors	  of	  metalloproteinases	  (TIMP)	  
have	  a	  complex	  role	  in	  disrupting	  the	  existing	  circumferential	  arrangement	  of	  these	  fibers.	  The	  result	  is	  an	  accumulation	  of	  disorganized	  fibrous	  tissue	  within	  the	  valve,	  and	  Myxoid	  
fibrous	  degeneration	  resulting	  in	  thickening	  and	  increased	  cusp	  stiffness.	  The	  calcification	  process	  begins	  in	  the	  early	  stages	  of	  the	  disease	  driven	  by	  the	  secretion	  of	  micro-­‐vesicles	  by	  
macrophages,	  which	  act	  as	  a	  subsequent	  nidus	  for	  calcification.	  However,	  acceleration	  of	  this	  process	  is	  stimulated	  by	  the	  differentiation	  of	  myofibroblasts	  into	  osteoblasts	  under	  the	  
influence	  of	  pro-­‐calcific	  pathways	  including	  osteoprotegerin/RANK/RANKL,	  Runx	  2-­‐cbfal	  2,	  Wnt3-­‐Lrp5-­‐b	  catenin,	  and	  TNFα.	  	  Osteoblasts	  subsequently	  coordinate	  calcification	  of	  the	  
valve	  as	  part	  of	  a	  highly	  regulated	  process	  akin	  to	  skeletal	  bone	  formation,	  with	  expression	  of	  many	  of	  the	  same	  mediators	  such	  as	  osteocalcin,	  alkaline	  phosphatase	  (Alk	  P)	  and	  bone	  
morphogenic	  protein	  (BMP)	  2.	  With	  time	  maturation	  of	  valvular	  calcification	  occurs	  so	  that	  by	  the	  end	  stages	  of	  the	  disease	  lamellar	  bone,	  microfractures	  and	  hemopoeitic	  tissue	  can	  
all	  be	  observed	  with	  the	  valve.	  These	  pathogenic	  processes	  are	  sustained	  in	  the	  thickened	  valve	  by	  angioneogenesis,	  with	  new	  vessels	  localising,	  in	  particular,	  to	  regions	  of	  
inflammation	  surrounding	  calcific	  deposits.	  Haemorrhage	  has	  also	  been	  demonstrated	  in	  severe	  disease	  and	  may	  have	  a	  role	  in	  driving	  disease	  progression.	  	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   19	  
Inflammation	  
Endothelial	  injury	  or	  disruption	  may	  allow	  lipids	  to	  penetrate	  the	  valvular	  endothelium	  and	  accumulate	  
in	  areas	  of	  inflammation.10,	  11	  The	  lipoproteins	  implicated	  in	  atherogenesis,	  including	  low-­‐density	  
lipoprotein	  (LDL)	  and	  lipoprotein	  (a),	  are	  present	  in	  early	  aortic	  valve	  lesions	  10	  and	  undergo	  oxidative	  
modification.11	  These	  oxidised	  lipoproteins	  are	  highly	  cytotoxic	  and	  capable	  of	  stimulating	  intense	  
inflammatory	  activity	  and	  subsequent	  mineralization	  (Figure	  1.2).12	  	  
	  
A	  combination	  of	  endothelial	  damage	  and	  lipid	  deposition	  triggers	  inflammation	  within	  the	  valve.	  
Expression	  of	  adhesion	  molecules	  allows	  infiltration	  of	  the	  endothelial	  layer	  by	  monocytes	  that	  
differentiate	  into	  macrophages,13	  and	  T	  cells	  that	  release	  pro-­‐inflammatory	  cytokines	  including	  
transforming	  growth	  factor	  (TGF)-­‐β1,14	  tumor	  necrosis	  factor	  (TNF)-­‐α	  and	  interleukin	  (IL)-­‐1β.15	  These	  
inflammatory	  cells	  and	  cytokines	  ultimately	  help	  to	  stimulate	  and	  establish	  the	  subsequent	  fibrotic	  
and	  calcific	  processes	  that	  drive	  increasing	  valve	  stiffness	  (Figure	  1.2).	  	  
	  
An	  inflammatory	  basis	  for	  aortic	  stenosis	  is	  supported	  by	  studies	  demonstrating	  increased	  C-­‐reactive	  
protein	  concentrations	  in	  the	  valves	  and	  systemic	  circulation	  of	  patients	  with	  aortic	  stenosis,16,	  17	  
increased	  temperature	  in	  stenotic	  aortic	  valve	  cusps	  18	  and	  more	  recently	  by	  non-­‐invasive	  imaging	  
studies	  using	  combined	  positron	  emission	  tomography	  and	  computed	  tomography	  (PET/CT).	  18F-­‐
Fluorodeoxyglycose	  (18F-­‐FDG)	  is	  a	  PET	  ligand	  that	  serves	  as	  a	  marker	  of	  macrophage	  activity,	  and	  has	  
become	  an	  established	  means	  of	  measuring	  inflammation	  in	  aortic	  and	  carotid	  atheroma.19	  A	  recent	  
study	  has	  now	  used	  this	  technique	  to	  examine	  inflammation	  in	  the	  aortic	  valve	  and	  demonstrated	  an	  
increased	  in	  valvular	  18F-­‐FDG	  activity	  in	  patients	  with	  aortic	  stenosis	  compared	  to	  controls.20	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Angioneogenesis	  and	  Valve	  Hemorrhage	  
Further	  histological	  studies	  have	  suggested	  that	  the	  inflammatory	  processes	  within	  the	  valve	  are	  
sustained	  by	  angioneogenesis.	  Thin	  neovessels	  are	  commonly	  observed	  in	  regions	  of	  intense	  
inflammation	  surrounding	  calcific	  deposits	  and	  demonstrate	  a	  positive	  correlation	  with	  T	  lymphocyte	  
density.	  Furthermore	  both	  intercellular	  adhesion	  molecule	  (ICAM)-­‐1	  and	  vascular	  cell	  adhesion	  
molecule	  (VCAM)-­‐1	  expression	  is	  increased	  in	  these	  vessels	  suggesting	  that	  they	  act	  as	  an	  important	  
portal	  of	  entry	  for	  inflammatory	  cells.21,	  22	  In	  addition	  hemorrhage	  related	  to	  these	  vessels	  has	  
emerged	  as	  a	  potentially	  important	  pathological	  mechanism,	  being	  present	  in	  78%	  of	  patients	  with	  
severe	  aortic	  stenosis	  and	  associated	  with	  neovascularization,	  macrophage	  infiltration	  and	  more	  
rapid	  rates	  of	  disease	  progression	  (Figure	  1.2).23	  	  
Fibrosis	  
The	  stenotic	  aortic	  valve	  is	  characterized	  by	  extensive	  thickening	  due	  to	  accumulation	  of	  fibrous	  
tissue	  and	  remodelling	  of	  the	  extracellular	  matrix.	  In	  all	  three	  layers	  of	  the	  valve,	  abundant	  
fibroblast-­‐like	  cells	  are	  found.	  They	  contain	  vimentin	  and	  are	  commonly	  referred	  to	  as	  valve	  
interstitial	  cells	  (VICs).	  A	  sub-­‐population	  of	  these	  cells	  become	  activated	  by	  the	  inflammatory	  activity	  
within	  the	  valve	  and	  differentiate	  into	  myofibroblasts.24	  Whilst	  fibroblasts	  control	  the	  synthesis	  of	  
collagen	  in	  the	  normal	  valve,	  myofibroblasts	  are	  believed	  to	  be	  responsible	  for	  the	  accelerated	  
fibrosis	  observed	  in	  pathological	  states.25	  In	  addition,	  matrix	  metalloproteinases	  are	  secreted	  by	  
myofibroblasts	  and	  inflammatory	  cells,	  and	  have	  an	  important	  and	  complex	  role	  in	  the	  restructuring	  
of	  the	  valve	  leaflet	  matrix	  (Figure	  1.2).15,	  26,	  27	  	  
	  
The	  renin-­‐angiotensin	  system	  is	  thought	  to	  modify	  this	  fibrotic	  process.	  Tissue	  angiotensin-­‐
converting	  enzyme	  (ACE)	  and	  angiotensin	  II	  are	  both	  up	  regulated	  in	  stenotic	  aortic	  valves,	  and	  
angiotensin	  receptors	  have	  been	  identified	  on	  valve	  myofibroblasts.28	  Angiotensin	  directly	  stimulates	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myofibroblast	  proliferation	  and	  collagen	  synthesis	  via	  these	  receptors	  but	  also	  has	  indirect	  effects	  via	  
the	  increased	  expression	  of	  pro-­‐fibrotic	  factors	  such	  as	  TGF-­‐β.29	  	  
	  
Calcification	  
Valve	  calcification	  plays	  a	  key	  role	  in	  the	  development	  of	  aortic	  stenosis	  and	  can	  be	  quantified	  using	  
computed	  tomography.	  The	  degree	  of	  valvular	  calcification	  correlates	  with	  valve	  severity,	  30	  	  disease	  
progression31	  and	  the	  development	  of	  symptoms	  and	  adverse	  events.32	  Moreover	  disorders	  of	  
mineral	  metabolism	  including	  Paget’s	  disease,33	  osteoporosis,34	  vitamin	  D	  polymorphisms	  35	  and	  
hemodialysis	  36	  are	  all	  associated	  with	  an	  increased	  prevalence	  of	  aortic	  stenosis	  and	  more	  rapid	  
progression	  of	  calcification	  within	  the	  valve.34	  
	  
Although	  other	  processes	  predominate,	  microscopic	  areas	  of	  calcification	  can	  be	  observed	  in	  the	  
early	  stages	  of	  aortic	  sclerosis	  and	  these	  co-­‐localize	  to	  areas	  of	  lipid	  deposition	  and	  inflammation.	  In	  
a	  sixth	  of	  patients	  with	  sclerosis,	  the	  calcification	  process	  accelerates,	  hemodynamic	  obstruction	  
ensues	  and	  the	  valve	  becomes	  stenotic.37	  This	  progression	  is	  thought	  to	  be	  driven	  by	  the	  
differentiation	  of	  myofibroblasts	  into	  osteoblasts	  38,	  39	  under	  the	  influence	  of	  the	  Wnt3-­‐Lrp5-­‐β	  
catenin	  signaling	  pathway,40	  the	  osteoprotegerin	  (OPG)/Receptor	  Activator	  of	  Nuclear	  factor	  Kappa	  B	  
(RANK)/RANK	  ligand	  (RANKL)	  pathway	  41	  and	  increased	  levels	  of	  TNF-­‐α	  (Figure	  2).42	  Osteoblasts	  
subsequently	  co-­‐ordinate	  calcification	  as	  part	  of	  a	  highly	  regulated	  process,	  akin	  to	  new	  bone	  
formation43,	  44	  with	  the	  local	  production	  of	  many	  factors	  more	  commonly	  associated	  with	  skeletal	  
bone	  metabolism	  including	  osteopontin,	  osteocalcin,	  bone	  sialoprotein	  and	  bone	  morphogenic	  
protein	  2	  (BMP-­‐2).44-­‐47	  In	  addition	  serum	  concentrations	  of	  Fetuin	  A,	  an	  inhibitor	  of	  calcification,	  are	  
reduced	  in	  patients	  with	  aortic	  stenosis.48	  Interestingly	  a	  reduction	  in	  this	  protein	  is	  commonly	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observed	  in	  patients	  with	  severe	  renal	  dysfunction	  and	  may	  provide	  an	  explanation	  for	  the	  
accelerated	  vascular	  and	  valvular	  calcification	  associated	  with	  this	  condition.49,50	  	  
	  
As	  aortic	  sclerosis	  progresses	  to	  mild	  aortic	  stenosis,	  calcification	  is	  comprised	  of	  nodules	  containing	  
hydroxyapatite	  deposited	  on	  a	  bone-­‐like	  matrix	  of	  collagen,	  osteopontin	  and	  other	  bone	  matrix	  
proteins.45,	  46,	  51	  Remodelling	  of	  this	  calcification	  occurs	  as	  aortic	  stenosis	  progresses	  until	  by	  the	  later	  
stages	  of	  disease,	  lamellar	  bone,	  microfractures	  and	  hemopoeitic	  tissue	  can	  all	  be	  identified	  within	  
the	  valve.46	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1.3	  LEFT	  VENTRICULAR	  HYPERTROPHY	  
Aortic	  stenosis	  causes	  an	  increase	  in	  pressure	  afterload	  and	  ventricular	  wall	  stress	  that	  stimulates	  
hypertrophy	  of	  the	  left	  ventricular	  myocardium.	  Myocytes	  enlarge	  and	  wall	  thickness	  increases	  in	  a	  
response	  that	  initially	  restores	  wall	  stress	  and	  preserves	  left	  ventricular	  function.52,	  53	  However,	  
evidence	  is	  accumulating	  that	  increasing	  levels	  of	  hypertrophy	  may	  in	  fact	  be	  maladaptive.54	  The	  
landmark	  Framingham	  studies	  first	  linked	  increasing	  hypertrophy	  with	  the	  progression	  to	  heart	  
failure,55	  and	  left	  ventricular	  hypertrophy	  is	  now	  considered	  	  a	  marker	  of	  an	  adverse	  prognosis	  across	  
a	  number	  of	  cardiac	  conditions.56-­‐59	  Furthermore	  animal	  studies	  have	  suggested	  that	  the	  
development	  of	  cardiac	  hypertrophy	  and	  normalization	  of	  wall	  stress	  may	  not	  be	  necessary	  to	  
preserve	  cardiac	  function.60	  
	  	  
In	  aortic	  stenosis,	  patients	  display	  a	  marked	  variation	  in	  the	  magnitude	  of	  their	  hypertrophic	  
response.	  This	  has	  recently	  been	  demonstrated	  to	  be	  of	  prognostic	  importance4	  and	  might	  explain	  
the	  marked	  heterogeneity	  between	  symptom	  onset	  and	  the	  severity	  of	  valve	  narrowing	  that	  is	  
observed.	  	  
	  
VARIATION	  IN	  THE	  DEGREE	  OF	  LEFT	  VENTRICULAR	  HYPERTROPHY	  
It	  is	  perhaps	  surprising	  that	  echocardiographic	  studies	  have	  only	  suggested	  a	  weak	  correlation	  
between	  the	  degree	  of	  left	  ventricular	  hypertrophy	  and	  the	  severity	  of	  valve	  obstruction.54,	  61,	  62	  
Instead	  the	  magnitude	  of	  the	  hypertrophic	  response	  appears	  to	  be	  more	  closely	  associated	  with	  
other	  factors	  such	  as	  advanced	  age,	  male	  sex	  and	  obesity.61,	  63-­‐65	  Genetic	  factors	  modulate	  the	  
degree	  of	  hypertrophy	  in	  response	  to	  a	  wide	  range	  of	  physiological	  and	  pathological	  triggers66-­‐68	  and	  
also	  play	  a	  role	  in	  aortic	  stenosis.	  In	  particular,	  polymorphisms	  of	  the	  ACE	  I/D	  gene	  have	  been	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associated	  with	  different	  degrees	  of	  hypertrophy	  69	  and	  reverse	  remodelling	  after	  valve	  
replacement.70	  
Other	  contributors	  to	  an	  increased	  afterload	  frequently	  co-­‐exist	  in	  patients	  with	  aortic	  stenosis	  and	  
are	  likely	  to	  modulate	  the	  hypertrophic	  response.	  Hypertension	  is	  common	  in	  this	  patient	  group	  and	  
an	  analysis	  of	  participants	  in	  the	  Simvastatin	  and	  Ezetimibe	  in	  Aortic	  Stenosis	  (SEAS)	  trial	  showed	  
that	  co-­‐existent	  hypertension	  was	  associated	  with	  an	  increased	  left	  ventricular	  mass	  and	  higher	  
prevalence	  of	  hypertrophy.71	  Increased	  arterial	  stiffness	  is	  also	  frequently	  observed	  due	  to	  a	  
combination	  of	  advanced	  age,	  co-­‐existent	  atherosclerosis,	  diabetes	  and	  high	  blood	  pressure.	  The	  
resultant	  loss	  of	  arterial	  compliance	  means	  that	  the	  heart	  has	  to	  pump	  even	  harder	  to	  fill	  the	  
vasculature	  with	  blood	  and	  also	  changes	  the	  timing	  of	  the	  pulse	  wave	  reflection	  so	  that	  it	  arrives	  in	  
systole	  rather	  than	  diastole.	  Both	  these	  effects	  result	  in	  an	  increase	  in	  left	  ventricular	  afterload	  and	  
contribute	  to	  the	  development	  of	  left	  ventricular	  dysfunction	  in	  aortic	  stenosis.72	  On	  this	  basis,	  a	  
global	  measure	  of	  afterload,	  ZVA,	  has	  been	  proposed	  that	  is	  derived	  from	  both	  the	  mean	  valve	  
gradient	  and	  the	  systemic	  arterial	  compliance.	  This	  variable	  has	  been	  shown	  to	  predict	  an	  adverse	  
prognosis	  in	  patients	  with	  moderate	  and	  severe	  aortic	  stenosis,	  and	  has	  been	  proposed	  as	  a	  means	  
of	  improving	  risk	  stratification	  and	  clinical	  decision-­‐making.73	  	  
	  
The	  variation	  in	  the	  hypertrophic	  response	  has	  important	  clinical	  consequences.	  In	  a	  study	  of	  218	  
patients	  with	  asymptomatic	  severe	  disease,	  Cioffi	  and	  colleagues	  demonstrated	  that	  subjects	  with	  
inappropriately	  high	  left	  ventricular	  mass	  had	  an	  increased	  mortality	  compared	  to	  patients	  with	  
comparable	  valve	  narrowing	  but	  more	  moderate	  hypertrophy.4	  The	  mechanism	  for	  this	  adverse	  
prognosis	  is	  likely	  to	  relate	  to	  premature	  decompensation	  of	  the	  hypertrophic	  process.	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FROM	  HYPERTROPHY	  TO	  HEART	  FAILURE	  
The	  transition	  from	  hypertrophy	  to	  heart	  failure	  marks	  the	  tipping	  point	  where	  the	  left	  ventricle	  fails	  
in	  the	  face	  of	  an	  increased	  pressure	  afterload	  and	  is	  no	  longer	  able	  to	  maintain	  forward	  flow	  through	  
the	  valve.	  This	  heralds	  the	  onset	  of	  symptoms,	  adverse	  events	  and	  a	  poor	  prognosis.	  Hein	  and	  
colleagues	  established	  that	  this	  key	  progression	  is	  associated	  with	  increased	  myocyte	  apoptosis	  and	  
fibrosis,	  and	  postulated	  that	  these	  two	  processes	  were	  responsible	  for	  the	  transition	  (Figure	  1.3).74	  
	  
Myocyte	  Apoptosis	  
The	  rate	  of	  apoptosis	  in	  the	  hypertrophied	  myocardium	  has	  been	  estimated	  at	  5-­‐10%	  of	  myocytes	  
per	  year.75	  Apoptosis	  is	  usually	  balanced	  by	  myocyte	  regeneration	  but	  in	  hypertrophy	  there	  appears	  
to	  be	  a	  net	  loss	  of	  cells.	  Increased	  apoptotic	  rates	  may	  simply	  be	  a	  response	  to	  the	  direct	  mechanical	  
forces	  associated	  with	  an	  increased	  afterload.76,	  77	  However,	  angiotensin	  II	  has	  also	  been	  implicated	  
and	  angiotensin	  receptor	  blockers	  reduce	  apoptosis	  in	  patients	  with	  hypertension,	  even	  at	  doses	  that	  
do	  not	  reduce	  blood	  pressure.78,	  79	  Ischemia	  may	  also	  be	  important.	  In	  aortic	  stenosis,	  myocardial	  
oxygen	  demand	  is	  increased	  by	  a	  combination	  of	  the	  elevated	  myocardial	  mass	  and	  increased	  
afterload.	  In	  contrast	  to	  physiological	  hypertrophy,	  the	  density	  of	  the	  coronary	  capillary	  network	  
does	  not	  expand	  sufficiently	  to	  meet	  this	  demand	  and	  coronary	  flow	  reserve	  is	  impaired	  (Figure	  
1.3).80	  Galiuto	  and	  colleagues	  demonstrated	  impaired	  myocardial	  perfusion	  in	  patients	  with	  severe	  
aortic	  stenosis	  and	  normal	  coronary	  arteries,	  and	  that	  this	  was	  associated	  with	  increased	  
cardiomyocyte	  apoptosis.81	  Impaired	  coronary	  flow	  reserved	  in	  aortic	  stenosis	  has	  also	  been	  
confirmed	  in	  two	  more	  recent	  studies.82,	  83	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Figure	  1.3.	  The	  development	  and	  subsequent	  decompensation	  of	  left	  ventricular	  hypertrophy	  in	  
response	  to	  aortic	  stenosis	  
	  
Progression	  of	  the	  left	  ventricular	  adaptive	  response	  is	  illustrated	  in	  cartoon	  format	  and	  using	  short-­‐axis	  
cardiovascular	  magnetic	  resonance	  images	  of	  the	  left	  ventricle	  in	  end-­‐diastole.	  Aortic	  valve	  narrowing	  imposes	  an	  
increased	  afterload	  and	  wall	  stress	  on	  the	  left	  ventricle.	  This	  stimulates	  a	  hypertrophic	  response,	  which	  initially	  
restores	  wall	  stress	  and	  maintains	  cardiac	  performance.	  However	  this	  process	  ultimately	  becomes	  decompensated.	  
Myocyte	  apoptosis	  is	  triggered	  by	  a	  combination	  of	  myocardial	  ischemia,	  direct	  mechanical	  forces	  and	  the	  actions	  of	  
angiotensin.	  This	  triggers	  a	  fibrotic	  response	  in	  the	  myocardium	  under	  the	  influence	  of	  pro-­‐fibrotic	  mediators	  such	  
as	  angiotensin	  and	  TGF-­‐β,	  which	  can	  be	  visualized	  using	  the	  late	  gadolinium	  enhancement	  technique	  (red	  arrows	  
show	  regions	  of	  mid-­‐wall	  fibrosis	  in	  the	  lateral	  wall	  of	  the	  ventricle).	  Increasing	  myocardial	  fibrosis	  leads	  to	  
progressive	  systolic	  and	  diastolic	  impairment	  and	  the	  progression	  to	  heart	  failure.	  Symptoms	  and	  adverse	  events	  
ensue	  perhaps	  in	  part	  due	  to	  an	  increased	  tendency	  to	  arrhythmia.	  	  
	  
	   	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   27	  
Fibrosis	  
Histopathological	  studies	  have	  confirmed	  fibrosis	  to	  be	  an	  integral	  part	  of	  the	  hypertrophic	  
process.84,	  85	  Myofibroblasts	  infiltrate	  the	  myocardium	  and	  secrete	  extracellular	  matrix	  proteins	  
including	  collagen	  types	  I	  and	  III.86	  Areas	  of	  fibrosis	  are	  observed	  to	  co-­‐localize	  with	  areas	  of	  myocyte	  
apoptosis	  87	  and	  it	  has	  been	  suggested	  that	  fibrosis	  occurs	  as	  a	  form	  of	  scarring	  after	  myocyte	  death	  
and	  injury.	  As	  with	  fibrosis	  in	  the	  valve,	  the	  renin-­‐angiotensin	  system,	  TGF-­‐beta	  and	  an	  imbalance	  in	  
MMP/TIMP	  activity	  have	  all	  been	  implicated	  in	  this	  process	  (Figure	  1.3).88,	  89-­‐90	  	  
	  
1.4	  SIMILARITIES	  BETWEEN	  AORTIC	  STENOSIS	  AND	  ATHEROSCLEROSIS	  
	  
Atherosclerosis	  and	  aortic	  stenosis	  share	  many	  common	  risk	   factors	  and	  are	  both	  characterized	  by	  
endothelial	   damage,	   lipid	   deposition,	   angioneogenesis,	   calcification	   and	   inflammation	   (Table	   1.1).	  
Both	  are	  prevalent	  in	  an	  elderly	  population	  and	  frequently	  co-­‐exist.	  This	  provides	  the	  opportunity	  to	  
study	  coronary	  pathology	  alongside	  valve	  disease	  in	  a	  population	  of	  patients	  with	  aortic	  stenosis.	  In	  
addition	   the	   similarities	   in	   pathophysiology	   led	   to	   the	   hypothesis	   that	   statins	   might	   delay	   the	  
progressive	   valve	   narrowing	   observed	   in	   aortic	   stenosis.	   However	   this	   strategy	   has	   proven	  
disappointing	  with	   three	  major	  prospective	   randomized	  control	   trials	  having	   failed	   to	  demonstrate	  
any	  impact	  on	  disease	  progression	  or	  clinical	  outcome.91-­‐93	  These	  results	  probably	  reflect	  important	  
pathophysiological	   differences	   between	   the	   development	   and	   progression	   of	   aortic	   stenosis	   and	  
atherosclerosis	  (Table	  1.1).	  In	  atherosclerosis,	  inflammation	  and	  lipid	  deposition	  are	  key	  components	  
in	   both	   the	   development	   of	   arterial	   plaque	   and	   its	   stability.	   Adverse	   events	   are	   predominantly	  
related	  to	  plaque	  rupture	  and	  much	  of	  the	  benefit	  from	  statin	  therapy	  is	  due	  to	  plaque	  stabilization	  
and	   a	   thickening	   of	   the	   fibrous	   cap.	   By	   contrast	   in	   aortic	   stenosis,	   adverse	   events	   are	   related	   to	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progressive	  narrowing	  of	  the	  aortic	  valve.	  This	  is	  predominantly	  driven	  by	  increasing	  calcification,	  a	  
process	   that	   statins	   have	   consistently	   failed	   to	   impact	   on,	   even	   in	   the	   context	   of	   coronary	  
atherosclerosis.94-­‐96	  	  
	  
Table	  1.1	  Comparisons	  between	  the	  pathological	  processes	  underlying	  aortic	  stenosis	  and	  
atherosclerosis	  
	   AORTIC	  STENOSIS	   ATHEROSCLEROSIS	  
Initiating	  event	   Increased	  mechanical	  stress	  and	  
reduced	  shear	  stress	  causing	  
endothelial	  damage	  
	  
Increased	  mechanical	  stress	  and	  reduced	  
shear	  stress	  causing	  endothelial	  damage.	  
Predominant	  Cell	  Types	   Macrophages	  and	  T	  helper	  cells	  




Macrophages	  and	  T	  helper	  cells	  
Foam	  cells	  
Vascular	  smooth	  muscle	  cells	  
Early	  pathology	  
	  
Oxidized	  lipid	  deposition,	  
inflammation	  
Oxidized	  lipid	  deposition,	  inflammation,	  
foam	  cells	  
Later	  pathology	   Calcification	  and	  fibrosis	  predominate	  
Neovascularization	  and	  hemorrhage	  
Lipid	  deposition	  and	  pools,	  Inflammation	  
and	  calcification	  	  
Neovascularization	  and	  hemorrhage	  
	  
Disease	  Progression	   Fibrosis,	  calcification	  and	  hemorrhage	   Lipid	  deposition	  and	  pools,	  inflammation	  
plaque	  rupture	  and	  thrombosis	  
Mechanism	  of	  adverse	  
events	  
Progressive	  valve	  rigidity	  due	  to	  
calcification	  and	  fibrosis	  
Decompensation	  of	  the	  hypertrophic	  
response	  
Plaque	  rupture	  due	  to	  lipid	  rich	  pool,	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1.5	  Positron	  Emission	  Tomography	  
Physics	  
Positron	  Emission	  Tomography	  is	  a	  non-­‐invasive	  imaging	  technique,	  which	  provides	  information	  
regarding	  the	  activity	  of	  specific	  biochemical	  processes	  within	  the	  body.	  The	  positron	  or	  anti-­‐electron	  
is	  the	  antiparticle	  of	  the	  electron,	  having	  the	  same	  mass	  but	  a	  positive	  electric	  charge.	  PET	  tracers	  
consist	  of	  a	  positron	  emitter,	  such	  as	  18F-­‐fluoride,	  15O-­‐oxygen	  or	  11C-­‐carbon,	  attached	  to	  a	  
molecular	  vehicle	  that	  targets	  the	  biochemical	  process	  of	  interest.	  97	  
	  
18F-­‐Fluoride	  is	  the	  most	  commonly	  used	  positron	  emitter	  because	  its	  relatively	  long	  half-­‐life	  allows	  for	  
commercial	  production	  and	  distribution.	  In	  the	  nuclei	  of	  these	  molecules,	  protons	  decay	  to	  neutrons	  
(beta	  decay)	  resulting	  in	  emission	  of	  a	  positron	  and	  a	  neutrino.	  After	  a	  time,	  collision	  between	  the	  
positron	  and	  an	  electron	  results	  in	  annihilation	  of	  both	  particles	  and	  the	  release	  of	  two	  photons,	  with	  a	  	  	  
specific	  energy	  (511keV),	  at	  180	  degrees	  to	  one	  another.	  Detection	  of	  these	  photons	  provides	  the	  basis	  
for	  PET	  scanning.	  
	  
PET	  imaging	  uses	  a	  dedicated	  PET	  camera	  system,	  which	  involves	  multiple	  rings	  of	  detectors	  
completely	  surrounding	  the	  patient.	  These	  detectors	  are	  made	  up	  of	  scintillation	  crystals	  (bismuth	  
gernmanium	  oxide	  (BGO)	  gadolinium	  oxyorthosilicate	  (GSO)	  or	  lutetium	  oxyorthosilicate)	  coupled	  
with	  photomultiplier	  tubes.	  When	  photons	  hit	  the	  scintillator	  an	  energetic	  electron	  is	  produced.	  This	  
excites	  other	  surrounding	  electrons,	  which	  release	  light	  as	  they	  decay	  back	  to	  the	  ground	  state.	  This	  
light	  is	  then	  detected	  by	  a	  photomultiplier	  tube	  and	  converted	  in	  to	  an	  electrical	  signal.	  PET	  imaging	  
utilises	  the	  concept	  that	  two	  511keV	  photons	  detected	  in	  close	  temporal	  proximity	  (6-­‐12	  
nanoseconds)	  by	  two	  opposed	  detectors	  in	  the	  ring	  are	  likely	  to	  have	  originated	  from	  a	  single	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annihilation	  event	  in	  the	  body	  somewhere	  in	  a	  line	  between	  them	  (the	  line	  of	  response).	  	  Such	  
simultaneous	  detections	  are	  termed	  coincidences	  and	  these	  events	  are	  used	  to	  build	  up	  the	  PET	  
image	  of	  activity	  and	  the	  sites	  where	  tracer	  accumulation	  has	  occurred.	  97	  	  
	  
The	  resultant	  images	  provide	  detailed	  functional	  data	  regarding	  the	  biochemical	  process	  being	  
studied,	  however	  PET	  scans	  are	  limited	  by	  a	  lack	  of	  spatial	  resolution.	  Recently	  this	  issue	  has	  
addressed	  using	  combined	  positron	  emission	  tomography	  and	  computed	  tomography,	  which	  
combines	  the	  functional	  PET	  data	  with	  the	  high-­‐resolution	  data	  provided	  by	  CT	  scanning.	  PET/CT	  
scanners	  incorporate	  both	  PET	  and	  CT	  within	  the	  same	  gantry.	  Patients	  lie	  in	  the	  same	  position	  for	  
both	  scans,	  which	  allows	  the	  PET	  and	  CT	  scans	  to	  be	  superimposed	  upon	  one	  another.	  This	  serves	  
two	  purposes:	  firstly	  the	  CT	  can	  be	  used	  to	  perform	  accurate	  attenuation	  correction	  of	  the	  PET	  
image;	  and	  secondly	  co-­‐registration	  allows	  precise	  localisation	  of	  tracer	  uptake	  within	  small	  
structures	  such	  as	  the	  aortic	  valve.	  	  
	  
18F-­‐Flurodeoxyglucose	  
Tracer	  development	  has	  largely	  been	  driven	  by	  oncology	  studies,	  in	  which	  PET	  has	  become	  a	  widely	  
available	  clinical	  tool.	  The	  most	  commonly	  used	  tracer	  is	  18F-­‐flurodeoxyglucose	  (18F-­‐FDG),	  which	  is	  a	  
glucose	  analogue	  that	  is	  taken	  up	  into	  cells	  by	  glucose	  transport	  proteins	  and	  enters	  the	  glycolytic	  
metabolic	  pathway.	  Following	  the	  initial	  hexokinase	  step,	  18F-­‐FDG-­‐6-­‐phosphate	  cannot	  be	  
metabolized	  further	  and	  becomes	  trapped	  within	  cells	  that	  have	  high	  metabolic	  requirements.	  
Increased	  uptake	  is	  therefore	  observed	  in	  malignant	  cells	  but	  also	  by	  arterial	  macrophages,	  which	  
have	  increased	  metabolic	  requirements	  compared	  to	  other	  cells	  in	  the	  vasculature.	  This	  has	  been	  the	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basis	  for	  vascular	  PET	  imaging	  using	  18F-­‐FDG,	  which	  has	  become	  an	  established	  means	  of	  quantifying	  
vascular	  inflammation	  in	  both	  the	  aorta	  and	  carotid	  arteries.98,	  99	  	  
	  
Rudd	  and	  colleagues	  first	  established	  that	  18F-­‐FDG	  uptake	  was	  increased	  in	  symptomatic	  carotid	  
plaque	  following	  TIA	  compared	  to	  contralateral	  lesions.99	  	  	  Subsequently	  the	  level	  of	  18F-­‐FDG	  activity	  
has	  been	  shown	  to	  correlate	  with	  plaque	  macrophage	  burden100	  although	  preclinical	  studies	  have	  
suggested	  that	  uptake	  may	  also	  relate	  to	  plaque	  hypoxia.	  101	  Arterial	  uptake	  of	  18F-­‐FDG	  has	  now	  
been	  extended	  to	  the	  aorta,	  femoral	  and	  iliac	  vessels	  displaying	  excellent	  reproducibility102,103	  as	  well	  
as	  the	  aortic	  valve	  in	  a	  small	  observational	  study	  of	  oncology	  patients.20	  It	  is	  hoped	  that	  vascular	  18-­‐
FDG	  scanning	  may	  provide	  useful	  prognostic	  information.	  Several	  small	  observational	  studies	  have	  
linked	  increased	  uptake	  to	  an	  increased	  incidence	  of	  cardiovascular	  events	  104,	  105	  although	  the	  results	  
of	  a	  large-­‐scale	  prospective	  study,	  The	  High	  Risk	  Plaque	  Initiative,	  are	  still	  awaited.	  In	  this	  study	  
prognostic	  information	  from	  non-­‐invasive	  cardiac	  imaging,	  including	  FDG-­‐PET,	  will	  be	  compared	  
against	  traditional	  risk	  factors.	  	  
	  
Finally	  FDG	  PET	  holds	  promise	  as	  means	  of	  assessing	  novel	  anti-­‐inflammatory	  atherosclerotic	  agents.	  
Tahara	  and	  colleagues	  demonstrated	  that	  simvastatin	  significantly	  reduced	  carotid	  18F-­‐FDG	  uptake	  
after	  3	  months	  of	  treatment.	  More	  recently	  18F-­‐FDG	  has	  been	  used	  to	  study	  a	  novel	  cholesteryl	  ester	  
transfer	  protein	  (CETP)	  inhibitor,	  Dalcetrapib,	  that	  appeared	  to	  result	  in	  a	  reduction	  in	  the	  carotid	  
plaque	  signal.19	  	  
	  
Advances	  in	  our	  knowledge	  regarding	  18F-­‐FDG	  uptake	  in	  the	  major	  arteries	  of	  the	  body	  has	  led	  to	  
hope	  that	  this	  technique	  might	  also	  be	  applicable	  to	  the	  coronary	  arteries.	  Acute	  plaque	  rupture	  is	  
the	  most	  common	  cause	  of	  acute	  coronary	  syndromes	  and	  a	  major	  cause	  of	  morbidity	  and	  mortality.	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Such	  events	  are	  related	  to	  increased	  plaque	  inflammation	  leading	  to	  the	  hope	  that	  18F-­‐FDG	  might	  be	  
able	  to	  identify	  vulnerable	  coronary	  plaque.	  Whilst	  several	  reports	  have	  shown	  some	  promise,106	  this	  
technique	  has	  been	  hampered	  by	  the	  problems	  caused	  by	  cardiac	  motion	  and	  myocardial	  uptake.	  
However	  potential	  solutions	  to	  these	  problems	  exist	  in	  the	  form	  of	  ECG/respiratory	  gating	  and	  the	  
use	  a	  high	  fat,	  low	  carbohydrate	  diet	  prior	  to	  the	  scan	  (aimed	  at	  switching	  the	  myocardium	  from	  a	  
glucose	  to	  fat-­‐based	  metabolism).107,	  108	  	  
	  
18F-­‐	  Sodium	  Fluoride	  (18F-­‐NaF)	  
18F-­‐sodium	  fluoride	  (18	  F-­‐NaF)	  is	  an	  alternative	  PET	  tracer	  that	  is	  thought	  to	  detect	  areas	  of	  novel	  
calcification	  and	  regions	  of	  calcium	  remodelling.	  It	  is	  used	  clinically	  for	  the	  detection	  of	  primary	  
osteoblastic	  tumours,	  bone	  metastases	  and	  conditions	  associated	  with	  high	  bone	  turnover	  such	  as	  
Paget’s	  disease.109,	  110	  More	  recently	  studies	  have	  described	  18F-­‐NaF	  uptake	  as	  a	  marker	  of	  
calcification	  within	  carotid	  and	  aortic	  atheroma,111,	  112	  and	  demonstrated	  an	  association	  between	  
activity	  and	  cardiovascular	  risk	  factors.112	  However	  to	  date	  this	  tracer	  has	  not	  been	  used	  to	  study	  
patients	  with	  aortic	  stenosis	  nor	  coronary	  atheroma.	  	  
	  
18F-­‐sodium	  fluoride	  is	  thought	  to	  directly	  incorporate	  in	  to	  bone	  crystals	  via	  an	  exchange	  with	  
hydroxyl	  groups	  in	  the	  hydroxyapatite	  crystal	  of	  bone	  (Ca10(PO4)6OH2)	  to	  form	  fluoroapatite	  
(Ca10(PO4)6F2).	  This	  process	  can	  be	  divided	  into	  four	  stages	  as	  originally	  described	  by	  Blau	  and	  
colleagues.113	  In	  steps	  1	  and	  2,	  fluoride	  moves	  from	  the	  blood	  through	  the	  extracellular	  space	  to	  the	  
shell	  of	  bound	  water	  around	  exposed	  crystals,	  a	  process	  which	  occurs	  within	  minutes	  of	  exposure.	  
Step	  3	  is	  travelling	  of	  the	  tracer	  on	  to	  the	  crystal	  surface	  and	  probably	  occurs	  in	  hours,	  whilst	  in	  step	  4	  
Fluoride	  is	  incorporated	  into	  the	  bone	  crystal,	  which	  takes	  days	  or	  weeks.	  Uptake	  in	  bone	  is	  therefore	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thought	  to	  reflect	  two	  processes:	  firstly	  increased	  blood	  flow	  and	  secondly	  processes	  that	  increase	  
the	  exposed	  bone	  crystal	  surface.	  The	  former	  should	  be	  broadly	  constant	  within	  aortic	  valve	  tissue	  
whilst	  the	  latter	  has	  been	  shown	  to	  correlate	  with	  osteoblast	  and	  osteoclast	  activity,113-­‐115	  which	  
increase	  the	  surface	  area	  to	  which	  18F-­‐NaF	  can	  bind.116	  	  
	  
Limitations	  to	  PET	  
The	  primary	  limitations	  to	  this	  technique	  related	  to	  its	  cost	  (£1,000	  per	  scan	  in	  our	  centre),	  and	  it's	  
relative	  lack	  of	  availability,	  although	  with	  the	  growing	  role	  of	  PET	  in	  the	  assessment	  of	  oncology	  
patients	  this	  is	  becoming	  less	  of	  an	  issue.	  Furthermore	  there	  is	  a	  relative	  lack	  of	  clinically	  approved	  
radiotracers	  so	  that	  only	  a	  limited	  number	  of	  pathological	  processes	  can	  be	  studied	  at	  this	  time.	  
However	  in	  principle	  a	  tracer	  can	  be	  designed	  to	  any	  biochemical	  process	  so	  that	  this	  technique	  holds	  
great	  future	  promise	  as	  a	  means	  of	  studying	  cardiovascular	  pathology.	  Finally	  the	  scans	  are	  
associated	  with	  a	  dose	  of	  radiation.	  This	  is	  generally	  small	  (about	  5mSv	  for	  each	  PET	  scan	  in	  our	  
centre)	  which	  equates	  roughly	  to	  a	  CT	  coronary	  angiogram.	  	  However	  this	  needs	  to	  taken	  in	  to	  
consideration	  especially	  in	  young	  patients	  and	  those	  likely	  to	  undergo	  multiple	  investigations	  which	  
themselves	  involve	  ionising	  radiation.	  Furthermore	  it	  limits	  the	  role	  of	  PET	  in	  longitudinal	  studies	  
requiring	  scans	  at	  multiple	  time	  points.	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1.6	  Cardiovascular	  Magnetic	  Resonance	  
Magnetic	  Resonance	  Imaging	  (MRI)	  uses	  the	  body’s	  natural	  magnetic	  properties	  to	  provide	  detailed	  
anatomical	  and	  functional	  images	  of	  the	  body.	  Clinical	  scans	  use	  the	  hydrogen	  nucleus	  (a	  single	  
proton),	  which	  is	  found	  in	  abundance	  in	  both	  fat	  and	  water.	  Each	  of	  the	  many	  protons	  present	  within	  
each	  cell	  has	  a	  positive	  charge	  and	  is	  spinning	  in	  a	  random	  manner	  that	  creates	  multiple	  tiny	  and	  
opposing	  magnetic	  fields.	  When	  a	  patient	  is	  placed	  within	  a	  high-­‐field	  magnet,	  these	  magnetic	  forces	  
align	  along	  the	  magnet’s	  long-­‐axis.	  The	  MRI	  scanner	  then	  sends	  a	  radiofrequency	  excitation	  pulse	  
into	  the	  patient	  at	  the	  same	  frequency	  as	  the	  precessing	  hydrogen	  nucleus.	  This	  energy	  excites	  the	  
protons	  causing	  a	  deflection	  in	  the	  orientation	  of	  their	  magnetic	  field.	  Protons	  are	  unstable	  at	  this	  
higher	  energy	  state	  and	  will	  ultimately	  relax	  and	  return	  to	  their	  stable	  baseline	  position.	  In	  so	  doing,	  
they	  will	  release	  energy	  back	  in	  the	  form	  of	  a	  radiowave,	  which	  can	  be	  detected	  by	  the	  scanners	  
body	  surface	  coils.	  Different	  tissues	  have	  different	  proton	  densities	  and	  different	  molecular	  
configurations,	  which	  result	  in	  variable	  relaxation	  properties	  (T1	  reflecting	  the	  exchange	  of	  energy	  
from	  protons	  to	  their	  local	  surrounding	  environment;	  and	  T2	  reflecting	  exchange	  of	  energy	  from	  one	  
nucleus	  to	  another).	  They	  will	  therefore	  result	  in	  the	  emission	  of	  different	  radiowaves	  during	  
relaxation	  that	  allows	  the	  MRI	  scanner	  to	  generate	  an	  image	  of	  the	  body’s	  internal	  structures.117	  	  
	  
MRI	  was	  first	  developed	  in	  in	  the	  1950’s	  but	  was	  not	  immediately	  applicable	  with	  respect	  to	  the	  
heart	  due	  to	  problems	  related	  to	  cardiac	  and	  respiratory	  motion.	  	  However,	  with	  the	  development	  of	  
rapid	  sequence	  imaging	  and	  ECG-­‐gating,	  cardiovascular	  magnetic	  resonance	  (CMR)	  has	  become	  a	  
widely	  adopted	  research	  and	  clinical	  tool.	  CMR	  images	  provide	  excellent	  contrast	  between	  the	  
myocardium	  and	  the	  blood	  pool	  and	  affords	  more	  detailed	  assessment	  of	  left	  ventricular	  structure.	  It	  
has	  therefore	  become	  the	  gold-­‐standard	  method	  for	  the	  assessment	  of	  left	  ventricular	  volume,	  mass	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   35	  
and	  ejection	  fraction.118	  In	  addition	  the	  late	  gadolinium	  enhancement	  technique	  allows	  for	  the	  non-­‐
invasive	  visualization	  of	  replacement	  fibrosis	  and	  scar	  tissue	  within	  the	  myocardium.	  	  
	  
Late	  Gadolinium	  Enhancement	  
Gadolinium	  is	  a	  paramagnetic	  contrast	  agent,	  which	  reduces	  the	  T1	  relaxation	  time	  in	  regions	  of	  
uptake.	  	  In	  its	  free	  ion	  form,	  gadolinium	  is	  highly	  toxic	  but	  safe	  when	  chelated	  to	  cyclic	  carrier	  
molecules	  such	  as	  Diethylentriamene	  pentaacetate	  (DTPA).	  	  After	  chelation,	  gadolinium	  contrast	  
agents	  have	  a	  large	  molecular	  size	  that	  prevents	  them	  from	  crossing	  cell	  membranes,	  and	  causes	  
them	  to	  accumulate	  in	  areas	  of	  increased	  extracellular	  water	  or	  within	  cells	  that	  have	  lost	  their	  
membrane	  integrity.	  Regions	  of	  fibrosis	  display	  marked	  expansion	  of	  the	  extracellular	  compartment	  
and	  therefore	  accumulate	  gadolinium	  readily.	  Similarly	  gadolinium	  is	  able	  to	  penetrate	  necrotic	  
myocytes	  within	  regions	  of	  myocardial	  infarction.	  Indeed	  differences	  in	  gadolinium	  pharmacokinetics	  
between	  different	  types	  of	  myocardial	  tissue	  form	  the	  basis	  of	  the	  late	  gadolinium	  enhancement	  
technique	  (Figure	  1.4).	  
	  
In	  regions	  of	  normal	  myocardium	  gadolinium	  washes	  rapidly	  in	  and	  out	  of	  the	  tissue	  due	  to	  an	  
uncompromised	  blood	  supply	  and	  a	  low	  volume	  of	  distribution	  respectively.	  In	  areas	  of	  ischaemic	  
myocardium,	  gadolinium	  moves	  in	  slowly	  due	  to	  restricted	  blood	  flow	  (providing	  the	  basis	  for	  CMR	  
perfusion	  imaging)	  but	  again	  washes	  out	  rapidly.	  Finally	  in	  infarcted	  myocardium	  there	  is	  once	  more	  
a	  delay	  in	  gadolinium	  entering	  these	  regions,	  however	  once	  it	  has	  arrived	  gadolinium	  will	  persist	  in	  
this	  tissue	  and	  washout	  slowly	  due	  to	  the	  high	  volume	  of	  distribution.	  Consequently	  between	  10	  and	  
20	  minutes	  after	  administration	  of	  gadolinium,	  a	  concentration	  gradient	  exists	  between	  regions	  of	  
normal	  and	  fibrotic	  or	  infarcted	  myocardium	  that	  provides	  the	  basis	  for	  late	  gadolinium	  
enhancement.	  Inversion	  recovery	  sequences	  are	  used	  to	  excite	  the	  protons,	  which	  then	  decay	  to	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their	  baseline	  state	  after	  passing	  through	  the	  null	  point.	  Decay	  is	  dependent	  on	  their	  T1	  relaxation	  
times	  and	  therefore	  the	  concentration	  of	  gadolinium	  within	  the	  tissue.	  The	  time	  to	  inversion	  (TI)	  
reflects	  the	  time	  between	  excitation	  and	  imaging	  and	  can	  be	  manipulated	  so	  that	  the	  normal	  
myocardium	  is	  nulled	  and	  appears	  black,	  whilst	  tissue	  containing	  gadolinium	  contrast	  will	  provide	  
comparatively	  infinite	  signal	  and	  appear	  bright.117	  	  	  	  	  	  	  
	  




Gadolinium	  concentrations	  within	  different	  tissues	  following	  its	  bolus	  administration	  are	  shown	  against	  time.	  Blood	  
washes	  quickly	  in	  and	  out	  of	  the	  myocardium	  and	  normal	  cardiac	  tissue.	  Gadolinium	  is	  slow	  to	  wash	  into	  areas	  of	  infarct	  
due	  to	  a	  compromised	  blood	  supply.	  This	  can	  be	  detected	  as	  a	  difference	  in	  first	  pass	  perfusion	  immediately	  following	  
gadolinium	  administration.	  In	  addition	  washout	  is	  slower	  in	  regions	  of	  infarct	  than	  in	  normal	  tissue	  because	  of	  an	  
increased	  volume	  of	  distribution.	  Therefore	  between	  10	  and	  20	  minutes	  after	  administration	  a	  differential	  concentration	  
of	  gadolinium	  exists	  in	  these	  issues,	  which	  can	  be	  detected	  using	  the	  late	  gadolinium	  enhancement	  technique.	  	  	  
Based	  on	  an	  image	  provided	  by	  the	  Royal	  Brompton	  Hospital,	  CMR	  course.	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CMR	  Studies	  in	  Aortic	  Stenosis	  
Cardiovascular	  Magnetic	  Resonance	  has	  been	  used	  in	  previous	  studies	  to	  assess	  patients	  with	  aortic	  
stenosis.	  In	  addition	  to	  accurate	  measurement	  of	  wall	  thickness,	  left	  ventricular	  mass,	  volumes	  and	  
ejection	  fraction	  accurate	  planimetry	  of	  the	  aortic	  valve	  area	  is	  possible.	  Short	  axis	  cine	  images	  can	  
be	  obtained	  at	  the	  level	  of	  the	  tips	  of	  the	  aortic	  valve.	  The	  aortic	  valve	  area	  can	  then	  be	  planimetered	  
during	  systole,	  a	  technique	  that	  has	  demonstrated	  good	  correlation	  with	  measurements	  made	  during	  
transoesophageal	  echocardiography.119	  	  	  	  
	  
Recent	  studies	  have	  demonstrated	  a	  mid-­‐wall	  pattern	  of	  enhancement	  in	  patients	  with	  aortic	  
stenosis	  in	  the	  absence	  of	  coronary	  artery	  disease.120,	  121	  Its	  presence	  has	  been	  shown	  to	  predict	  less	  
symptomatic	  benefit	  following	  surgery122	  and	  has	  been	  associated	  with	  low-­‐gradient,	  severe	  aortic	  
stenosis.123	  However	  whilst	  the	  presence	  of	  LGE	  is	  associated	  with	  an	  adverse	  prognosis	  in	  other	  
cardiac	  conditions,124-­‐128	  this	  has	  not	  been	  assessed	  in	  aortic	  stenosis.	  	  
	  
Limitation	  to	  CMR	  
Whilst	  CMR	  has	  the	  considerable	  advantage	  of	  not	  involving	  ionizing	  radiation	  there	  are	  several	  
limitations.	  Firstly	  there	  is	  the	  cost	  (roughly	  £500	  per	  scan),	  which	  makes	  clinical	  research	  studies	  
expensive.	  Secondly	  there	  is	  availability	  of	  the	  technique:	  acquiring	  interpretable	  pictures	  requires	  
considerable	  training	  and	  experience,	  which	  is	  not	  widely	  available.	  Thirdly	  not	  all	  patients	  can	  
undergo	  CMR,	  for	  example	  patients	  with	  permanent	  pacemakers	  and	  ICDs,	  which	  limits	  the	  use	  of	  
this	  modality	  in	  this	  important	  group	  of	  cardiovascular	  patients.	  The	  issue	  of	  nephrogenic	  systemic	  
fibrosis	  has	  received	  much	  attention	  but	  is	  now	  only	  considered	  a	  problem	  in	  patients	  with	  renal	  
failure	  of	  on	  dialysis,	  in	  whom	  CMR	  is	  generally	  contraindicated.	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1.7	  Aims	  	  
Our	  aim	  was	  to	  investigate	  the	  pathophysiology	  of	  aortic	  stenosis	  using	  modern	  non-­‐invasive	  imaging	  
techniques.	  Specifically	  we	  sought	  to	  assess	  the	  role	  of	  calcification	  and	  inflammation	  in	  progressive	  
valve	  narrowing	  using	  PET/CT	  and	  to	  investigate	  the	  LV	  hypertrophic	  response	  including	  the	  role	  of	  
myocardial	  fibrosis	  using	  CMR.	  	  
	  
Positron	  Emission	  Tomography	  
1)	  To	  examine	  the	  feasibility	  of	  assessing	  aortic	  valve	  inflammation	  with	  18F-­‐FDG	  and	  calcification	  
with	  18F-­‐NaF	  using	  PET/CT.	  	  
	  
2)	  To	  examine	  the	  reproducibility	  of	  this	  approach.	  
	  
3)	  To	  use	  this	  technique	  to	  assess	  the	  relative	  importance	  of	  inflammation	  and	  calcification	  at	  
different	  stages	  of	  the	  disease.	  	  	  
	  
4)	  To	  assess	  uptake	  of	  18F-­‐FDG	  and	  18F-­‐NaF	  in	  the	  coronary	  arteries	  of	  our	  aortic	  stenosis	  patients	  
undergoing	  PET/CT	  scanning.	  
	  
Cardiovascular	  Magnetic	  Resonance	  
1)	  To	  establish	  the	  prevalence	  of	  infarct	  and	  mid-­‐wall	  patterns	  of	  late	  gadolinium	  enhancement	  in	  
patients	  with	  moderate	  and	  severe	  aortic	  stenosis	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2)	  To	  establish	  the	  prognostic	  significance	  of	  mid-­‐wall	  and	  infarct	  patterns	  of	  late	  gadolinium	  
enhancement	  in	  patients	  with	  moderate	  and	  severe	  aortic	  stenosis	  both	  in	  terms	  of	  all	  cause	  and	  
cardiac	  mortality.	  
	  
3)	  To	  establish	  the	  relationship	  between	  aortic	  stenosis	  severity	  and	  the	  degree	  of	  hypertrophy	  using	  
CMR.	  
	  
4)	  To	  investigate	  and	  categorise	  the	  different	  patterns	  of	  remodelling	  and	  hypertrophy	  that	  occur	  in	  
response	  to	  aortic	  stenosis	  using	  CMR	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1.8	  Hypotheses	  
	  
Positron	  Emission	  Tomography	  
We	  hypothesized	  the	  following:	  	  	  
	  
1)	  PET/CT	  using	  18F-­‐FDG	  and	  18F-­‐NaF	  would	  prove	  to	  be	  both	  a	  feasible	  and	  repeatable	  approach	  to	  
the	  assessment	  of	  inflammation	  and	  calcification	  within	  the	  aortic	  valve	  (Chapter	  3).	  	  
	  
2)	  Both	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake	  in	  the	  aortic	  valve	  would	  be	  higher	  in	  patients	  with	  aortic	  
sclerosis	  and	  stenosis	  than	  in	  control	  subjects	  and	  increase	  with	  increasing	  disease	  severity	  (Chapter	  
3).	  	  
	  
3)	  That	  uptake	  of	  18F-­‐NaF	  in	  the	  aortic	  valve	  would	  exceed	  that	  of	  18F-­‐FDG	  reflecting	  the	  relative	  
importance	  of	  calcification	  and	  inflammation	  in	  the	  pathogenesis	  of	  aortic	  stenosis	  (Chapter	  3).	  	  
	  
4)	  That	  uptake	  of	  18F-­‐NaF	  and	  18F-­‐FDG	  might	  be	  feasible	  in	  the	  coronary	  arteries	  and	  demonstrate	  
high	  risk	  plaque	  by	  identifying	  microcalcification	  and	  inflammation	  respectively.	  (Chapter	  4).	  	  
	  
Cardiovascular	  Magnetic	  Resonance	  
We	  hypothesized	  the	  following:	  	  
1)	  That	  mid-­‐wall	  and	  infarct	  patterns	  of	  late	  gadolinium	  enhancement	  would	  be	  prevalent	  in	  patients	  
with	  moderate	  and	  severe	  aortic	  stenosis	  (Chapter	  5).	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2)	  That	  mid-­‐wall	  patterns	  and	  infarct	  patterns	  of	  late	  enhancement	  would	  be	  associated	  with	  an	  
increase	  in	  all-­‐cause	  and	  cardiac	  mortality	  compared	  to	  patients	  with	  no	  late	  gadolinium	  
enhancement	  (Chapter	  5).	  	  
	  
3)	  The	  degree	  of	  left	  ventricular	  hypertrophy	  would	  be	  poorly	  related	  to	  the	  severity	  of	  valve	  
narrowing	  in	  aortic	  stenosis	  (Chapter	  6).	  	  
	  
4)	  That	  CMR	  could	  be	  used	  to	  categorise	  the	  patterns	  of	  left	  ventricular	  remodelling	  and	  hypertrophy	  
observed	  in	  aortic	  stenosis	  (Chapter	  6).	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Methods	  
2.1	  Patient	  Populations	  
	  
This	  thesis	  was	  based	  upon	  the	  study	  of	  two	  populations	  with	  aortic	  stenosis.	  Positron-­‐emission	  
tomography	  studies	  were	  conducted	  in	  a	  prospective	  cohort	  of	  patients	  recruited	  from	  the	  Royal	  
Infirmary	  of	  Edinburgh.	  Cardiovascular	  magnetic	  resonance	  studies	  were	  based	  upon	  a	  registry	  of	  
patients	  who	  underwent	  clinical	  CMR	  scans	  at	  the	  Royal	  Brompton	  Hospital	  London.	  	  
	  
Positron	  Emission	  Tomography	  Studies	  
	  
Consecutive	  patients	  over	  50	  years	  of	  age	  with	  aortic	  sclerosis	  and	  mild,	  moderate	  and	  severe	  aortic	  
stenosis	  attending	  the	  outpatient	  department	  of	  the	  Royal	  Infirmary	  of	  Edinburgh	  were	  considered	  
for	  participation	  in	  this	  study.	  Exclusion	  criteria	  included	  insulin-­‐dependent	  diabetes	  mellitus,	  blood	  
glucose	  >200	  mg/dL,	  planned	  aortic	  valve	  surgery	  (and	  therefore	  symptoms	  attributed	  by	  their	  
physician	  to	  their	  valve	  disease)	  and	  inability	  to	  undergo	  PET/CT	  scanning.	  Patients	  were	  not	  
approached	  if	  they	  fulfilled	  any	  of	  the	  exclusion	  criteria	  or	  if	  their	  clinician	  felt	  participation	  was	  not	  
appropriate.	  Of	  the	  patients	  approached,	  52%	  agreed	  to	  take	  part	  in	  the	  trial.	  	  These	  patients	  were	  
then	  compared	  to	  age-­‐	  and	  sex-­‐matched	  control	  subjects	  with	  a	  normal	  aortic	  valve	  and	  a	  similar	  
range	  of	  co-­‐morbidity.	  The	  studies	  were	  conducted	  with	  the	  written	  informed	  consent	  of	  all	  patients.	  	  
	  
Cardiovascular	  Magnetic	  Resonance	  Imaging	  
Consecutive	  patients	  with	  moderate	  and	  severe	  aortic	  stenosis	  (based	  upon	  Doppler	  
echocardiographic	  demonstration	  of	  peak	  aortic	  valve	  pressure	  gradient	  >36	  mmHg	  and	  peak	  trans-­‐
valvular	  velocity	  >3	  m/s,	  according	  to	  American	  Heart	  Association/American	  College	  of	  Cardiology	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criteria	  129)	  who	  attended	  the	  Royal	  Brompton	  Hospital	  between	  January	  2003	  and	  October	  2009	  for	  
CMR	  were	  recruited	  in	  to	  a	  registry	  prospectively.	  Ethical	  approval	  was	  granted	  in	  2003.	  	  Royal	  
Brompton	  Hospital	  guidelines	  recommend	  CMR	  for	  all	  patients	  with	  severe	  aortic	  stenosis.	  Other	  
reasons	  for	  referral	  included	  diagnostic	  evaluation,	  clarification	  of	  disease	  severity,	  pre-­‐operative	  
evaluation,	  and	  assessment	  of	  the	  hypertrophic	  response.	  	  
	  
Patients	  who	  received	  gadolinium	  contrast	  were	  followed	  up	  in	  order	  to	  determine	  the	  prognostic	  
role	  of	  late	  gadolinium	  enhancement.	  Exclusion	  criteria	  for	  this	  part	  of	  the	  study	  were	  disseminated	  
malignancy;	  moderate	  or	  severe	  aortic	  regurgitation,	  mitral	  regurgitation	  or	  mitral	  stenosis;	  
contraindications	  to	  CMR	  including	  pacemaker	  and	  defibrillator	  implantation;	  and	  an	  estimated	  
glomerular	  filtration	  rate	  (Cockcroft-­‐Gault	  equation)	  of	  <30	  mL/min.	  Clinical	  and	  follow	  up	  data	  was	  
assimilated	  at	  the	  end	  of	  the	  study	  in	  2009.	  	  
	  
	  
For	  the	  studies	  examining	  the	  patterns	  of	  remodelling	  and	  hypertrophy	  the	  same	  registry	  of	  aortic	  
stenosis	  patients	  were	  used	  but	  different	  inclusion	  and	  exclusion	  criteria	  employed.	  Firstly	  it	  was	  not	  
necessary	  for	  patients	  to	  have	  been	  administered	  gadolinium	  during	  their	  CMR	  scan,	  therefore	  
patients	  who	  had	  only	  had	  cine	  imaging	  of	  their	  ventricle	  were	  also	  included.	  Secondly	  in	  order	  to	  
study	  the	  effects	  of	  aortic	  stenosis	  on	  the	  ventricle	  in	  isolation	  the	  patient	  group	  was	  carefully	  
selected	  to	  avoid	  those	  with	  confounding	  drivers	  of	  left	  ventricular	  remodelling.	  Exclusion	  criteria	  
therefore	  included	  those	  with	  prior	  myocardial	  infarction,	  severe	  hypertension	  >180/120,	  significant	  
valve	  disease	  other	  than	  aortic	  stenosis	  (moderate	  or	  severe	  mitral,	  tricuspid	  or	  pulmonary	  valve	  
disease	  and	  moderate	  or	  severe	  aortic	  regurgitation),	  a	  clinical	  diagnosis	  of	  co-­‐existent	  
cardiomyopathy	  including	  hypertrophic	  cardiomyopathy,	  amyloidosis,	  disseminated	  malignancy	  and	  
severe	  renal	  failure	  (estimated	  glomerular	  filtration	  rate	  <30	  mL/min).	  Given	  the	  prevalence	  of	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hypertension	  in	  elderly	  patients	  we	  were	  not	  able	  to	  exclude	  all	  patients	  with	  this	  condition.	  However	  
hypertension	  also	  increases	  the	  LV	  afterload	  and	  so	  can	  be	  expected	  to	  have	  similar	  effects	  on	  the	  
left	  ventricle.	  	  Coronary	  artery	  disease	  was	  excluded	  by	  invasive	  coronary	  angiography	  (84%	  of	  the	  
cohort),	  computed	  tomography	  coronary	  angiography	  (8%)	  or	  stress	  perfusion	  imaging	  (2%).	  In	  
patients	  under	  40	  years,	  it	  was	  excluded	  in	  the	  absence	  of	  symptoms	  or	  risk	  factors	  (6%).	  	  	  
2.2	  Ethical	  Considerations	  
All	  studies	  gained	  ethical	  approval	  from	  the	  South	  East	  Scotland	  Research	  Ethics	  Committee,	  and	  local	  
research	  ethics	  committee	  of	  the	  Royal	  Brompton	  Hospital	  and	  were	  conducted	  in	  accordance	  with	  the	  
Declaration	  of	  Helsinki	  of	  the	  World	  Medical	  Association.	  The	  studies	  were	  registered	  on	  
www.clinicaltrials.gov	  (reference	  numbers	  NCT01358513	  and	  NCT00930735).	  For	  the	  PET	  study	  written	  
informed	  consent	  was	  obtained	  for	  all	  patients.	  This	  was	  not	  required	  under	  the	  ethical	  approval	  for	  
the	  MRI	  studies.	  	  
	  
2.3	  Positron	  Emission	  Tomography	  and	  Computed	  Tomography	  
For	  each	  patient	  enrolled	  in	  to	  the	  PET/CT	  studies	  combined	  PET/CT	  scans	  of	  the	  aortic	  valve	  were	  
performed	  on	  two	  occasions	  in	  close	  succession	  using	  a	  hybrid	  scanner	  (Biograph	  mCT,	  Siemens	  
Medical	  Systems,	  Erlangen,	  Germany).	  	  	  
	  
Upon	  arrival	  the	  patients	  height	  and	  weight	  were	  measured	  on	  a	  consistent	  set	  of	  scales,	  calibrated	  
to	  the	  PET	  scanner.	  Blood	  pressure	  and	  pulse	  rates	  were	  recorded	  and	  an	  intravenous	  cannula	  
inserted.	  Thirty	  mls	  of	  blood	  was	  then	  taken.	  A	  12-­‐lead	  electrocardiogram	  was	  performed	  and	  bloods	  
were	  sent	  for	  measurement	  of	  the	  full	  blood	  count,	  urea	  and	  electrolytes,	  serum	  calcium,	  phosphate	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and	  alkaline	  phosphatase.	  The	  remainder	  was	  centrifuged	  at	  room	  temperature	  (10	  minutes,	  
3000rpm)	  to	  provide	  serum	  samples,	  which	  were	  stored	  in	  case	  of	  future	  use	  at	  -­‐70	  degrees	  Celsius.	  
Patients	  were	  then	  transferred	  to	  the	  lead	  lined	  uptake	  room.	  This	  is	  monitored	  using	  video	  
surveillance,	  patients	  rested	  on	  a	  couch.	  A	  toilet	  with	  restricted	  access	  to	  the	  general	  public	  and	  
other	  staff	  members	  was	  in	  close	  proximity	  and	  patients	  were	  encouraged	  to	  bring	  reading	  material	  
with	  them.	  	  	  
	  
18F-­‐NaF	  had	  been	  ordered	  from	  a	  commercial	  producer	  the	  day	  before	  the	  scans	  (Erigal	  Ltd,	  Keele)	  
pre-­‐specifying	  the	  amount	  of	  activity	  required	  for	  injection	  of	  patients	  at	  specific	  times.	  This	  
information	  allowed	  the	  supplier	  to	  calculate	  the	  amount	  of	  tracer	  that	  needed	  to	  be	  made	  that	  
same	  morning	  based	  upon	  its	  decay	  characteristics.	  Three	  scans	  were	  performed	  in	  an	  afternoon	  in	  
order	  to	  maximize	  the	  cost	  effectiveness	  with	  regard	  to	  delivery	  charges.	  On	  the	  first	  occasion	  we	  
aimed	  to	  administer	  a	  target	  dose	  of	  125	  MBq	  18F-­‐NaF.	  Activity	  was	  drawn	  up	  in	  to	  a	  syringe	  using	  a	  
semi-­‐automatic	  system	  in	  order	  to	  minimize	  radiation	  exposure	  to	  the	  operator.	  The	  activity	  of	  the	  
tracer	  drawn	  up	  in	  to	  the	  syringe	  was	  then	  measured	  and	  the	  time	  of	  measurement	  recorded.	  
Adjustments	  were	  made	  as	  necessary	  in	  order	  to	  ensure	  the	  target	  dose	  would	  be	  achieved.	  The	  
tracer	  was	  then	  injected	  in	  to	  the	  patient	  via	  the	  cannula	  and	  flushed	  with	  10mls	  of	  saline.	  The	  time	  
of	  injection	  was	  recorded.	  The	  intravenous	  cannula	  was	  then	  removed.	  Activity	  in	  the	  empty	  syringe	  
that	  had	  contained	  the	  18F-­‐NaF	  was	  then	  measured	  to	  ensure	  that	  there	  was	  no	  significant	  residual	  
and	  in	  order	  to	  calculate	  the	  exact	  activity	  that	  had	  been	  injected.	  	  Patients	  subsequently	  rested	  in	  
the	  quiet	  environment	  of	  the	  uptake	  room	  for	  60-­‐minutes.	  After	  this	  time	  patients	  were	  transferred	  
on	  to	  the	  PET	  scanner.	  Patients	  lay	  on	  their	  back	  with	  their	  hands	  above	  their	  head	  and	  were	  
connected	  to	  a	  3-­‐lead	  ECG	  monitor,	  which	  allowed	  ECG	  gating	  of	  the	  subsequent	  CT	  calcium	  score.	  
Patients	  then	  moved	  in	  to	  the	  scanner	  feet	  first.	  An	  attenuation	  correction	  CT	  scan	  (non-­‐enhanced	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low-­‐dose	  120	  kV	  and	  50	  mAs,	  pitch	  0.8,	  field	  of	  view	  780mm,	  5mm	  slice	  thickness,	  3mm	  increment,	  
B19f	  LowDose	  kernel,	  standard	  filtered	  back	  projection	  reconstruction	  algorithm)	  was	  then	  
performed	  followed	  by	  PET	  imaging	  covering	  two	  bed	  positions	  centred	  over	  the	  valve	  in	  3-­‐
dimensional	  mode	  for	  10	  min.	  Finally	  an	  ECG-­‐gated,	  breath-­‐hold	  CT	  scan	  (non	  enhanced,	  40	  mAs/rot	  
[CareDose],	  100	  kV,	  Pitch	  0.24,	  field	  of	  view	  210mm,	  3mm	  slice	  thickness,	  1.5mm	  increment,	  B35f	  
kernel,	  standard	  filtered	  back	  projection	  reconstruction	  algorithm)	  was	  performed	  of	  the	  aortic	  valve	  
immediately	  after	  the	  18F-­‐NaF	  PET/CT	  scan	  for	  calculation	  of	  the	  aortic	  valve	  and	  coronary	  calcium	  
scores.	  	  Patients	  were	  then	  removed	  from	  the	  scanner	  and	  allowed	  to	  leave	  the	  department	  with	  
instructions	  not	  to	  have	  close	  physical	  contact	  with	  babies	  or	  pregnant	  females	  for	  the	  rest	  of	  the	  
day.	  	  
	  
On	  the	  second	  occasion,	  18F-­‐FDG	  was	  ordered	  and	  the	  patients	  were	  prepared	  in	  a	  similar	  manner	  as	  
for	  the	  18F-­‐NaF	  scan.	  A	  target	  dose	  of	  200	  MBq	  18F-­‐FDG	  was	  injected.	  Patients	  rested	  in	  the	  uptake	  
room	  for	  90	  min.	  They	  were	  asked	  to	  refrain	  from	  significant	  physical	  activity	  in	  order	  to	  reduce	  
muscle	  uptake	  of	  18F-­‐FDG.	  Towards	  the	  end	  of	  the	  uptake	  time	  they	  were	  asked	  to	  urinate	  in	  order	  
to	  expel	  the	  tracer	  (which	  is	  renally	  excreted)	  from	  the	  bladder.	  Patients	  were	  then	  transferred	  on	  to	  
the	  PET	  scanner.	  They	  again	  lay	  flat	  on	  the	  scanner	  but	  because	  this	  scan	  did	  not	  require	  ECG	  gating,	  
they	  were	  moved	  in	  to	  the	  scanner	  head	  first.	  Combined	  PET/CT	  imaging	  was	  then	  performed	  as	  
described	  for	  the	  18F-­‐NaF	  scan	  but	  using	  a	  15-­‐min	  bed	  time.	  Tracer	  circulation	  times	  for	  the	  two	  
tracers	  were	  based	  on	  previous	  studies	  using	  18F-­‐FDG	  and	  18F-­‐NaF	  in	  atherosclerosis99,	  111,	  112	  and	  
aimed	  to	  allow	  for	  optimal	  contrast	  between	  the	  aortic	  wall,	  aortic	  valve	  and	  the	  blood	  pool.	  	  
	  
The	  PET	  data	  were	  reconstructed	  using	  the	  Siemens	  Ultra-­‐HD	  (time	  of	  flight	  +True	  X)	  reconstruction	  
algorithm.	  Corrections	  were	  applied	  for	  attenuation,	  dead	  time,	  scatter	  and	  random	  coincidences.	  	  All	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image	  analysis	  was	  performed	  on	  fused	  PET/CT	  data	  sets.	  Field	  of	  view	  was	  780mm	  and	  a	  512	  matrix	  
size	  was	  used	  for	  reconstructions	  so	  the	  voxel	  size	  was	  1.5	  ×	  1.5	  ×	  3.0mm.	  	  	  	  
	  
Dietary	  Restrictions	  
Intense	  uptake	  of	  18F-­‐FDG	  by	  the	  left	  ventricle	  leads	  to	  difficulties	  in	  discriminating	  between	  activity	  
in	  the	  aortic	  valve	  and	  the	  myocardium.	  All	  patients	  in	  the	  PET	  cohort	  were	  asked	  to	  observe	  a	  
carbohydrate-­‐free	  diet	  for	  24	  h	  prior	  to	  their	  18F-­‐FDG	  scan	  because	  this	  suppresses	  myocardial	  
uptake	  as	  the	  heart	  switches	  from	  a	  glucose	  to	  free-­‐fatty	  acid	  metabolism.107,	  108,	  130	  Patients	  were	  
provided	  with	  a	  list	  of	  food	  and	  drink	  to	  avoid	  (milk,	  bread,	  pasta,	  rice,	  potatoes,	  chips,	  crisps,	  
chocolate,	  sugar,	  fruit,	  fruit	  juice,	  alcohol)	  and	  reminded	  of	  these	  restrictions	  the	  day	  before	  their	  
scan	  by	  means	  of	  a	  telephone	  call.	  Clear	  fluids	  including	  black	  tea	  and	  coffee	  were	  acceptable	  and	  
patients	  were	  encouraged	  to	  consume	  steak	  and	  a	  salad	  the	  night	  before,	  and	  to	  have	  bacon,	  eggs,	  
sausages,	  black	  pudding	  for	  breakfast	  the	  morning	  of	  the	  scan.	  	  Dietary	  diaries	  were	  recorded	  and	  
patients	  were	  categorized	  into	  dietary	  compliance	  or	  non-­‐compliance.	  Myocardial	  tracer	  uptake	  was	  
assessed	  by	  recording	  the	  maximum	  standardized	  uptake	  value	  (SUV)	  in	  the	  left	  ventricular	  septal	  
myocardium.	  	  The	  SUV	  is	  the	  decay-­‐corrected	  tissue	  uptake	  divided	  by	  the	  injected	  dose	  per	  body	  
weight	  and	  is	  a	  semiquantitative	  dimensionless	  unit	  that	  is	  a	  widely	  used	  and	  validated	  measure	  of	  
tissue	  18F-­‐FDG	  and	  18F-­‐NaF	  uptake.99,	  111,	  131	  High	  myocardial	  18F-­‐FDG	  uptake	  was	  pre-­‐specified	  as	  an	  
SUV	  value	  ≥5.0	  whilst	  low	  uptake,	  indicating	  successful	  myocardial	  suppression,	  was	  defined	  by	  
measurements	  <5.0.108	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2.4	  Cardiovascular	  Magnetic	  Resonance	  	  
For	  each	  patient	  enrolled	  in	  to	  the	  CMR	  study,	  CMR	  was	  performed	  using	  a	  1.5T	  scanner	  (Magnetom	  
Sonata	  or	  Avanto,	  Siemens,	  Erlangen,	  Germany)	  at	  the	  Royal	  Brompton	  Hospital.	  Upon	  arrival	  
patients	  were	  changed	  in	  to	  a	  gown.	  They	  were	  asked	  to	  complete	  an	  MRI	  safety	  questionnaire	  to	  
ensure	  that	  they	  had	  no	  contraindication	  to	  MRI	  (presence	  of	  a	  permanent	  cardiac	  pacemaker,	  
severe	  claustrophobia,	  intracardiac	  defibrillator,	  cerebral	  aneurysm	  clip,	  cochlear	  implant,	  
ventriculoperitoneal	  shunt	  or	  metal	  fragments	  in	  the	  eye).	  Orbital	  x-­‐rays	  were	  preformed	  in	  patients	  
who	  had	  worked	  with	  metalwork	  in	  whom	  there	  was	  a	  concern	  that	  fragments	  may	  have	  entered	  the	  
eye.	  Their	  height	  and	  weight	  were	  recorded	  using	  a	  standard	  set	  of	  scales	  calibrated	  to	  the	  MRI	  
machine.	  Blood	  pressure	  measurements	  were	  recorded	  and	  the	  patient’s	  most	  recent	  eGFR	  checked	  
to	  ensure	  that	  it	  was	  >30mls/min	  (to	  allow	  for	  the	  administration	  of	  gadolinium	  contrast,	  which	  is	  
relatively	  contraindicated	  below	  this	  cut	  off	  due	  to	  the	  risk	  of	  nephrogenic	  systemic	  fibrosis).	  After	  
checking	  that	  they	  did	  not	  have	  metal	  on	  their	  person	  (including	  dentures,	  dental	  plates,	  hearing	  aids,	  
wigs,	  piercings)	  and	  that	  they	  were	  not	  wearing	  analgesic,	  human	  replacement	  therapy	  or	  nicotine	  
patches,	  patients	  were	  transferred	  to	  the	  MRI	  scanner.	  Patients	  lay	  supine	  with	  their	  arms	  lying	  
comfortably	  by	  their	  side.	  They	  were	  attached	  to	  an	  MRI	  compatible	  infusion	  pump	  (containing	  the	  
gadolinium	  contrast).	  Earphones	  were	  placed	  to	  reduce	  the	  noise	  made	  by	  the	  scanner	  and	  a	  body	  
coil	  positioned	  on	  the	  patient’s	  chest.	  Patients	  were	  then	  put	  in	  to	  the	  centre	  of	  the	  MRI	  scanner	  and	  
given	  an	  emergency	  buzzer	  in	  case	  of	  problems.	  	  Communication	  between	  the	  radiographer	  and	  
patient	  was	  possible	  at	  all	  times	  via	  the	  headphones.	  	  
	  
A	   standardised	   imaging	   protocol	   with	   stable	   study	   parameters	   was	   then	   followed.	   Localiser	   scans	  
were	  performed	  to	  ascertain	  the	  position	  of	  the	  heart,	  followed	  by	  HASTE	  black	  blood	  imaging	  in	  the	  
form	  of	  an	  axial	  and	  coronal	  stack	  (in	  addition	  to	  a	  sagittal	  oblique	  stack	  if	  aortic	  assessment	  was	  also	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required	  on	  clinical	  grounds).	  These	  stacks	  were	  used	  to	  plan	  long-­‐axis	  steady	  state	  free	  precession	  
(SSFP)	   cine	   views	   of	   the	   heart	   as	   follows.	   The	   two	   chamber	   view	  was	   obtained	   by	   positioning	   the	  
imaging	  slice	  through	  the	  anterior	  and	  inferior	  walls	  of	  the	  left	  ventricle	  on	  scout	  short-­‐axis	  views	  and	  
also	  through	  the	  apex	  of	   the	   left	  ventricle	  and	  the	   left	  atrium.	  The	  four-­‐chamber	  view	  of	  the	  heart	  
was	  planned	  on	  a	   scout	   short-­‐axis	   view	   through	   the	   left	   and	   right	   ventricles,	   the	   LV	  apex,	   left	   and	  
right	   atria,	   whilst	   missing	   the	   left	   ventricular	   outflow	   tract	   (LVOT).	   	   Three-­‐chamber	   views	   were	  
planned	  through	  the	  LVOT,	  apex	  of	   the	   left	  ventricle	  and	  the	   left	  atrium.	  Finally	  an	  LVOT	  view	  was	  
performed	  by	  placing	  the	   imaging	  position	  through	  the	  aortic	  vale	  and	  aortic	  root	  perpendicular	  to	  
the	   3=chamber	   view.	   Subsequently	   a	   short-­‐axis	   cine	   stack	   of	   the	   left	   and	   right	   ventricles	   was	  
performed	  from	  the	  mitral	  valve	  down	  to	  the	  left	  ventricular	  apex.	  Starting	  basally	  on	  the	  atrial	  side	  
of	   the	   mitral	   valve	   the	   plane	   of	   imaging	   was	   placed	   across	   the	   left	   and	   right	   ventricle	   on	   the	   4-­‐
chamber	   view,	   perpendicular	   to	   the	   septum.	   Eight	   mm	   short-­‐axis	   slices	   were	   then	   acquired	   from	  
bases	   to	   apex	   with	   2mm	   gaps	   so	   that	   each	   slice	   was	   10mm	   further	   towards	   the	   apex	   than	   its	  
predecessor.	  Temporal	  resolution	  was	  less	  than	  45ms	  between	  phases	  and	  parallel	  imaging	  was	  used	  
as	  available.	  	  
	  
SSFP	   cine	   imaging	   of	   the	   vale	  was	   performed	   next.	   Short-­‐axis	   views	  were	   obtained	   by	   placing	   the	  
imaging	  slice	  perpendicular	  to	  the	  aortic	  root	  and	  left	  ventricular	  outflow	  tract	  on	  the	  3-­‐chamber	  and	  
LVOT	  views	  at	   the	   level	  of	   the	  tips	  of	   the	  valve	  during	  systole.	  The	   imaging	  position	  was	  altered	  as	  
necessary	  based	  on	  this	  initial	  image	  to	  ensure	  that	  the	  minimum	  aortic	  valve	  area	  was	  obtained.	  	  
This	  was	  followed	  by	  an	  assessment	  of	  the	  peak	  velocity	  through	  the	  aortic	  valve.	  Flow	  images	  were	  
obtained	  in	  the	  3-­‐chamber	  view,	  with	  the	  velocity	  encoding	  parameter	  adjusted	  to	  prevent	  aliasing.	  
The	  resulting	  image	  was	  used	  to	  generate	  further	  velocity	  maps	  perpendicular	  to	  the	  aortic	  jet	  at	  the	  
level	  of	  the	  peak	  velocity	  seen	  on	  the	  3-­‐chamber	  velocity	  flow	  map.	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After	  cine	  imaging	  a	  proportion	  of	  patients	  received	  Gadolinium	  contrast	  so	  that	  the	  late	  gadolinium	  
enhancement	  technique	  could	  be	  performed	  as	  an	  assessment	  of	  myocardial	  infarction	  and	  fibrosis.	  
An	  injection	  of	  0.1mmol/kg	  gadolinium	  contrast	  agent	  (Gd-­‐DTPA;	  Schering,	  Germany)	  was	  
administered	  using	  an	  MR–compatible	  pump	  injector	  at	  3mls/second,	  followed	  by	  a	  20ml	  flush	  of	  
saline	  at	  the	  same	  injection	  rate.	  Prior	  to	  2007	  a	  dose	  of	  0.2mmol/kg	  was	  used	  because	  this	  was	  the	  
dose	  used	  in	  initial	  validation	  studies.	  However	  concern	  regarding	  the	  risk	  of	  nephrogenic	  systemic	  
fibrosis	  led	  to	  calls	  for	  the	  reduced	  dose	  of	  0.1mmol/kg	  to	  be	  used	  from	  that	  time	  on.	  Patients	  were	  
then	  left	  to	  rest	  inside	  the	  scanner.	  Ten	  to	  fifteen	  minutes	  following	  the	  injection	  inversion-­‐recovery	  
prepared	  spoiled	  gradient	  echo	  images	  were	  acquired	  in	  the	  same	  the	  4-­‐chamber,	  2-­‐chamber	  and	  
short-­‐axis	  views	  used	  for	  cine	  imaging	  to	  detect	  areas	  of	  late	  gadolinium	  enhancement.	  This	  
technique	  relies	  on	  the	  successful	  nulling	  of	  the	  left	  ventricular	  myocardium.	  This	  requires	  continuous	  
alteration	  of	  the	  inversion	  time	  (the	  Ti)	  so	  that	  the	  myocardium	  has	  no	  T1	  signal	  and	  appears	  black.	  
By	  contrast	  regions	  of	  fibrosis	  that	  have	  accumulated	  gadolinium	  contrast	  will	  have	  comparatively	  
infinite	  signal	  and	  will	  appear	  bright.125	  The	  operator	  did	  not	  move	  on	  to	  the	  next	  image	  until	  the	  
optimal	  Ti	  had	  been	  achieved.	  	  
	  
All	  images	  were	  repeated	  in	  two	  separate	  phase-­‐encoding	  directions	  to	  exclude	  artifact	  (artifacts	  
usually	  move	  in	  the	  direction	  of	  the	  phase	  encoding	  direction	  and	  so	  will	  be	  shifted	  by	  changing	  its	  
orientation).	  In	  those	  cases	  where	  great	  difficulty	  was	  had	  in	  nulling	  the	  myocardium	  phase	  sensitive	  
inversion	  recovery	  (PSIR)	  sequences	  were	  used	  which	  are	  less	  sensitive	  to	  variations	  in	  the	  inversion	  
time.	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2.5	  Echocardiography	  
Each	  patient	  participating	  in	  the	  PET/CT	  study	  underwent	  echocardiography	  on	  the	  day	  of	  one	  of	  
their	  PET/CT	  scans.	  This	  was	  performed	  by	  a	  dedicated	  research	  sonographer	  using	  a	  standardised	  
protocol.	  	  
	  
On	  arrival	  patients	  were	  asked	  to	  remove	  clothing	  from	  the	  waist	  up	  and	  if	  necessary	  asked	  to	  put	  on	  
a	  gown.	  ECG	  electrodes	  were	  placed	  on	  the	  chest	  and	  the	  patients	  connected	  to	  the	  dedicated	  echo	  
machine	  (Phillips	  Medical	  Systems,	  Best,	  the	  Netherlands).	  Echocardiograms	  were	  performed	  by	  a	  
single	  dedicated	  research	  ultrasonographer	  in	  the	  same	  room	  on	  the	  same	  bed	  to	  ensure	  consistency	  
of	  conditions.	  A	  formal	  protocol	  was	  employed30,	  92	  using	  an	  S51	  pure	  wave	  transducer	  (Phillips	  
Medical	  Systems,	  Best,	  the	  Netherlands)	  for	  2-­‐dimensional,	  M-­‐mode,	  and	  pulsed	  and	  continuous	  
wave	  Doppler	  studies.	  	  
	  
Patients	  were	  placed	  in	  the	  left	  lateral	  position.	  Two-­‐dimensional	  images	  were	  obtained	  in	  the	  
parasternal	  position	  to	  provide	  long	  and	  short-­‐axis	  view	  views	  of	  the	  heart.	  Switching	  to	  the	  apical	  
position,	  4-­‐chamber,	  5-­‐chamber	  and	  2-­‐chamber	  views	  were	  obtained.	  These	  images	  allowed	  for	  
assessment	  of	  left	  ventricular	  systolic	  function	  and	  valve	  function.	  In	  the	  5-­‐chamber	  view	  pulsed	  
wave	  Doppler	  was	  used	  to	  obtain	  pre-­‐valve	  velocities	  in	  the	  left	  ventricular	  out	  flow	  tract	  just	  below	  
the	  level	  of	  the	  valve.	  Continuous	  wave	  Doppler	  was	  then	  used	  to	  calculate	  the	  peak	  post	  valve	  
velocity.	  This	  was	  confirmed	  using	  a	  D2	  CWC	  transducer	  (Phillips,	  Netherlands)	  from	  the	  apex,	  right	  
sternal	  edge	  and	  supra-­‐sternal	  notch.	  Measurements	  were	  determined	  on	  line	  and	  averaged	  from	  
three	  cardiac	  cycles	  or	  five	  if	  the	  patient	  was	  in	  atrial	  fibrillation.	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Aortic	  sclerosis	  was	  defined	  as	  a	  thickened	  aortic	  valve	  on	  echocardiography	  in	  the	  absence	  of	  
accelerated	  flow	  though	  the	  valve	  (peak	  jet	  velocity	  <2	  m/s).	  The	  severity	  of	  aortic	  stenosis	  was	  
graded	  according	  to	  American	  Heart	  Association	  and	  American	  College	  of	  Cardiology	  criteria	  using	  the	  
peak	  transvalvular	  aortic	  valve	  velocity,	  and	  the	  mean	  and	  maximum	  aortic	  valve	  pressure	  gradients,	  
the	  time	  velocity	  integral	  (TVI),	  the	  dimensionless	  index	  and	  the	  aortic	  valve	  area,	  calculated	  using	  
the	  continuity	  equation.129	  Mild	  aortic	  stenosis	  was	  defined	  as	  a	  peak	  velocity	  of	  2-­‐3m/s,	  a	  mean	  
gradient	  of	  less	  than	  25mmHg	  and	  an	  aortic	  valve	  area	  >1.5cm2:	  moderate	  aortic	  stenosis,	  peak	  
velocity	  of	  3-­‐4m/s,	  a	  mean	  gradient	  of	  25-­‐40mmHg,	  aortic	  valve	  area	  1.0-­‐1.5cm2:	  severe	  aortic	  
stenosis,	  peak	  velocity	  >4m/s,	  mean	  gradient	  >40mmHg,	  aortic	  valve	  area	  <1.0cm2.	  In	  our	  clinical	  
laboratory,	  we	  have	  previously	  demonstrated	  a	  co-­‐efficient	  of	  reproducibility	  of	  0.32	  m/s	  for	  the	  
Doppler	  measurement	  of	  peak	  aortic	  valve	  velocity	  in	  patients	  with	  aortic	  stenosis.30	  	  
	  
For	  patients	  participating	  in	  the	  CMR	  studies	  the	  results	  of	  echocardiograms	  performed	  within	  6	  
months	  of	  their	  CMR	  scan	  were	  identified.	  These	  were	  conducted	  at	  a	  variety	  of	  different	  hospital	  
however	  standard	  assessments	  of	  aortic	  stenosis	  severity	  were	  employed	  at	  all	  sites	  according	  to	  
British	  Society	  of	  Echocardiography	  guidelines	  (http://www.bsecho.org/education/guidelines-­‐and-­‐
protocols/).	  Furthermore	  the	  presence	  and	  severity	  of	  aortic	  regurgitation,	  mitral	  vale	  disease	  and	  
tricuspid	  valve	  disease	  was	  assessed	  according	  to	  those	  same	  guidelines.	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2.7	  Image	  Analysis	  
	  
Positron	  Emission	  Tomography	  
Regions	  of	  interest	  were	  drawn	  around	  the	  aortic	  valve,	  and	  the	  ascending	  and	  descending	  aortae	  on	  
adjacent	  slices	  until	  their	  entire	  volume	  of	  each	  structure	  had	  been	  covered	  (Figure	  2.1).	  Exact	  
methods	  are	  discussed	  below.	  Mean	  and	  maximum	  SUV	  values	  were	  calculated	  for	  each	  slice	  and	  
then	  for	  the	  tissue	  as	  a	  whole	  after	  averaging	  these	  values.	  However,	  SUV	  measurements	  in	  vascular	  
structures	  are	  influenced	  by	  variation	  in	  18F-­‐FDG	  and	  18F-­‐NaF	  activity	  in	  the	  blood-­‐pool.	  Therefore	  
SUV	  measurements	  were	  divided	  by	  an	  averaged	  mean	  SUV	  value	  derived	  from	  5	  circular	  ROIs	  drawn	  
in	  the	  central	  blood-­‐pool	  of	  the	  superior	  vena	  cava.	  This	  provided	  mean	  and	  maximum	  tissue-­‐to-­‐
background	  ratios	  (TBRs).100,	  103	  Regions	  of	  interest	  were	  also	  drawn	  in	  the	  left	  main	  stem	  and	  the	  
proximal	  portions	  of	  the	  left	  anterior	  descending,	  circumflex	  and	  right	  coronary	  arteries	  and	  
maximum	  SUV	  and	  TBR	  values	  recorded.	  	  
	  
Quantification	  of	  tracer	  uptake	  in	  the	  aortic	  valve	  
PET	  image	  quantification	  is	  usually	  performed	  in	  the	  axial,	  coronal	  or	  sagittal	  planes.	  However,	  the	  
aortic	  valve	  is	  a	  complex	  3-­‐dimensional	  structure	  that	  does	  not	  align	  perfectly	  with	  any	  of	  these	  
orthogonal	  planes,	  making	  accurate	  identification	  of	  the	  boundaries	  of	  the	  valve	  difficult	  using	  
standard	  techniques.	  To	  try	  to	  overcome	  this,	  the	  PET	  and	  CT	  images	  were	  fused	  and	  analysed	  using	  a	  
workstation	  (OsiriX	  version	  3.5.1	  64-­‐bit;	  OsiriX	  Imaging	  Software,	  Geneva,	  Switzerland)	  that	  allows	  for	  
rotation	  of	  the	  plane	  of	  view	  into	  the	  true	  axis	  of	  the	  valve.	  This	  is	  the	  first	  time	  such	  a	  technique	  has	  
been	  described	  and	  it	  facilitated	  the	  more	  accurate	  delineation	  of	  regions	  of	  interest	  (ROI)	  around	  
the	  valve	  as	  described	  below.	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18F-­‐NaF	  Analysis	  
The	  fused	  PET/CT	  image	  was	  rotated	  in	  a	  3-­‐dimensional	  multi-­‐planar	  reconstruction	  (MPR)	  mode	  to	  
provide	  a	  co-­‐axial	  short-­‐axis	  view	  of	  the	  aortic	  valve	  (Figure	  2.1).	  Starting	  superiorly,	  a	  circular	  region	  
of	  interest	  (ROI)	  was	  drawn	  around	  the	  aortic	  valve	  on	  3-­‐mm	  slices	  guided	  by	  anatomical	  information	  
provided	  by	  CT	  and	  any	  obvious	  valvular	  calcification	  (Figure	  2.2).	  	  Further	  ROIs	  were	  drawn	  on	  





The	  co-­‐axial	  short-­‐axis	  method	  was	  performed	  for	  18F-­‐FDG	  as	  described	  above.	  Whilst	  the	  pre-­‐scan	  
dietary	  restrictions	  aimed	  to	  minimize	  the	  difficulties	  cause	  by	  myocardial	  18F-­‐FDG	  uptake,	  we	  also	  
explored	  two	  further	  image	  analysis	  approaches	  to	  define	  better	  and	  to	  assess	  more	  specifically	  the	  
valvular	  uptake	  (Figure	  2.1).	  In	  the	  long-­‐axis	  technique,	  images	  were	  reoriented	  into	  a	  modified	  
coronal	  view	  where	  it	  was	  hoped	  the	  boundaries	  of	  myocardial	  uptake	  would	  be	  more	  clearly	  
observed	  and	  therefore	  avoided.	  In	  the	  center-­‐valve	  technique,	  ROIs	  were	  again	  drawn	  on	  the	  co-­‐
axial	  short-­‐axis	  view	  but	  in	  the	  center	  of	  the	  valve,	  thereby	  excluding	  the	  base	  of	  the	  valve	  leaflets	  
and	  any	  potential	  incorporation	  of	  myocardial	  or	  aortic	  wall	  uptake.132	  For	  all	  techniques,	  
measurements	  were	  taken	  on	  adjacent	  3-­‐mm	  slices,	  and	  mean	  and	  maximum	  SUV	  and	  TBR	  values	  
calculated	  for	  the	  valve.	  
	  
	  
Quantification	  of	  tracer	  uptake	  in	  the	  aorta	  
	  
For	  the	  aorta,	  circular	  ROIs	  were	  drawn	  around	  the	  ascending	  and	  descending	  aorta	  on	  adjacent	  
3-­‐mm	  axial	  slices,	  from	  the	  arch	  down	  to	  the	  right	  pulmonary	  artery	  and	  diaphragm	  
respectively.	  This	  provided	  mean	  and	  maximum	  SUV	  and	  TBR	  values.	  Uptake	  from	  surrounding	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tissue	  spilling	  in	  to	  the	  aorta	  was	  avoided	  (Figure	  2.2).	  Most	  commonly	  this	  was	  in	  the	  form	  
activity	  in	  the	  thoracic	  vertebral	  column	  spilling	  in	  to	  the	  descending	  aorta.	  Uptake	  was	  not	  
quantified	  in	  the	  aortic	  arch	  as	  that	  has	  previously	  been	  shown	  to	  be	  poorly	  reproducible.102	  
	  
Quantification	  of	  tracer	  uptake	  in	  the	  coronary	  arteries	  
For	  18F-­‐NaF	  uptake,	  the	  coronary	  arteries	  were	  visually	  identified	  and	  regions	  of	  interest	  drawn	  
around	  areas	  of	  maximal	  uptake	  in	  the	  left	  main	  stem,	  left	  anterior	  descending	  artery,	  circumflex	  
artery	  and	  the	  right	  coronary	  artery	  (Figure	  2.2).	  The	  maximum	  SUV	  value	  was	  recorded	  from	  these	  
regions.	  It	  was	  not	  possible	  to	  determine	  the	  mean	  SUV	  values	  given	  the	  difficulty	  in	  identifying	  the	  
exact	  borders	  of	  the	  coronary	  arteries	  on	  the	  non-­‐contrast	  enhanced	  scans.	  SUV	  values	  were	  used	  to	  
calculate	  the	  maximum	  TBR.	  Quantification	  of	  18F-­‐FDG	  uptake	  was	  performed	  as	  for	  18F-­‐NaF	  but	  
restricted	  to	  the	  proximal	  and	  mid-­‐portions	  of	  the	  coronary	  vessels.106	  Difficulties	  were	  still	  
encountered	  as	  a	  result	  of	  the	  pervasive	  myocardial	  uptake	  observed	  with	  this	  tracer	  and	  coronary	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Figure	  2.1.	  Method	  for	  the	  quantification	  of	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake	  in	  the	  aortic	  valve.	  	  
	  
18F-­‐NaF	  A.	  Coronal	  view	  (blue	  axis)	  of	  the	  thorax:	  note	  the	  intense	  18F-­‐NaF	  uptake	  (white,	  red	  and	  yellow	  areas)	  in	  
the	  calcified	  aortic	  valve	  as	  well	  as	  in	  the	  ribs,	  clavicles	  and	  arch	  of	  the	  aorta.	  The	  purple	  axis	  has	  been	  rotated	  so	  that	  
it	  lies	  perpendicular	  to	  the	  aorta	  and	  parallel	  to	  the	  aortic	  valve.	  B.	  Modified	  sagittal	  view	  of	  the	  valve	  (yellow	  axis).	  
The	  purple	  axis	  has	  again	  been	  rotated	  so	  that	  it	  lies	  perpendicular	  to	  the	  aorta	  and	  parallel	  to	  the	  aortic	  valve.	  C.	  A	  
co-­‐axial	  short	  axis	  view	  of	  the	  aortic	  valve	  is	  now	  obtained	  along	  the	  purple	  axis.	  White	  areas	  denote	  areas	  of	  existing	  
calcium	  whilst	  yellow/red	  region	  denote	  areas	  of	  increased	  18F-­‐NaF	  uptake.	  A	  region	  of	  interest	  has	  been	  drawn	  
around	  the	  valve	  (green	  lines).	  	  
18F-­‐FDG	  D.	  Short-­‐axis	  technique.	  The	  imaging	  plane	  has	  been	  reorientated	  as	  described	  for	  18F-­‐NaF	  to	  provide	  the	  co-­‐
axial	  short	  axis	  view	  shown.	  This	  patient	  has	  intense	  myocardial	  18F-­‐FDG	  uptake,	  which	  appears	  to	  spill	  in	  to	  the	  aortic	  
valve	  (white	  arrows)	  and	  makes	  appreciation	  of	  the	  less	  intense	  activity	  in	  the	  valve	  difficult.	  In	  the	  short-­‐axis	  
technique	  the	  green	  ROI	  has	  been	  drawn	  to	  include	  as	  much	  of	  the	  valve	  as	  possible	  whilst	  avoiding	  the	  myocardial	  
activity.	  	  
E.	  Centre-­‐valve	  technique.	  In	  the	  same	  patient	  the	  ROI	  has	  been	  drawn	  in	  the	  centre	  of	  the	  valve	  well	  away	  from	  
myocardial	  uptake	  around	  the	  periphery.	  F	  Long-­‐axis	  technique:	  an	  ROI	  has	  been	  drawn	  on	  the	  modified	  coronal	  
images	  attempting	  to	  avoid	  the	  myocardial	  uptake.	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Figure	  2.2.	  Regions	  of	  interest	  in	  different	  tissues	  on	  fused	  PET/CT	  scans	  
A.	  Circular	  regions	  of	  interest	  drawn	  around	  the	  aortic	  valve	  using	  the	  short	  axis	  technique	  for	  the	  
assessment	  of	  18F-­‐NaF	  activity	  
B.	  Regions	  of	  interest	  drawn	  around	  the	  ascending	  and	  descending	  aortae	  and	  the	  left	  anterior	  
descending	  coronary	  artery	  for	  the	  assessment	  of	  18F-­‐NaF	  activity	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Quantification	  of	  Aortic	  Valve	  and	  Coronary	  Calcium	  Scoring	  
Evaluation	  of	  the	  calcium	  score	  was	  performed	  using	  calcium	  score	  analysis	  software	  (VScore,	  Vital	  
Images,	  Minnetonka,	  USA).	  Vessel	  specific	  and	  total	  Agatston	  calcium	  scores	  were	  calculated	  as	  
described	  previously.	  133	  Coronary	  calcium	  was	  defined	  as	  an	  area	  greater	  than	  or	  equal	  to	  1	  mm2	  in	  
the	  axial	  plane	  in	  the	  course	  of	  a	  coronary	  artery	  with	  an	  attenuation	  threshold-­‐value	  of	  greater	  than	  
or	  equal	  to	  130	  Hounsfield	  units.	  Regions	  of	  interest	  were	  defined	  in	  each	  vessel	  (left	  main	  stem,	  left	  
anterior	  descending	  artery,	  circumflex	  artery,	  right	  coronary	  artery)	  on	  each	  slice	  by	  one	  trained	  
observer.	  The	  Agatston	  score	  was	  calculated	  in	  Agatston	  units	  (AU)	  by	  multiplying	  the	  area	  of	  a	  
region	  of	  interest	  by	  a	  weighting	  factor	  selected	  dependent	  on	  the	  peak	  signal	  within	  the	  region	  of	  
interest.	  Vessel	  and	  total	  scores	  were	  obtained	  by	  summing	  the	  weighted	  scores.	  	  
	  
For	  the	  aortic	  valve	  regions	  of	  interest	  were	  drawn	  around	  areas	  of	  calcification	  in	  the	  valve	  on	  
adjacent	  slices.	  Care	  was	  taken	  to	  avoid	  calcium	  in	  the	  aorta	  and	  mitral	  valve	  annulus.	  Agatston	  
scores	  were	  calculated	  as	  above	  for	  the	  valve	  as	  a	  whole	  on	  the	  basis	  of	  these	  regions.	  	  
	  
Cardiovascular	  Magnetic	  Resonance	  	  
For	  quantification	  of	  LV	  function	  and	  volumes,	  the	  endocardial	  and	  epicardial	  contours	  were	  semi-­‐
automatically	  applied	  in	  end-­‐systole	  and	  end-­‐diastole	  using	  dedicated	  software	  (CMR	  Tools,	  
Cardiovascular	  Imaging	  Solutions,	  London).	  LV	  mass	  was	  calculated	  from	  the	  total	  end-­‐diastolic	  
myocardial	  volume	  multiplied	  by	  the	  specific	  gravity	  of	  the	  myocardium	  (1.05	  g/mL).	  LV	  mass	  and	  
volumes	  were	  indexed	  to	  body	  surface	  area,	  age	  and	  gender,	  and	  were	  considered	  abnormal	  if	  they	  
were	  outside	  the	  95thpercentile	  of	  the	  normal	  range	  published	  by	  Maceira	  and	  colleagues.134	  Ejection	  
fractions	  were	  calculated	  and	  considered	  impaired	  if	  below	  the	  95th	  percentile	  of	  the	  normal	  range	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published	  by	  Maceira	  et	  al.134	  This	  quantification	  was	  performed	  by	  multiple	  different	  experienced	  
operators	  over	  the	  course	  of	  the	  six	  years	  that	  the	  scans	  were	  performed.	  However	  all	  operators	  
underwent	  a	  standardized	  period	  of	  training	  and	  used	  the	  same	  analysis	  technique.	  Each	  operator	  
underwent	  an	  initial	  period	  of	  validation	  before	  analyzing	  scans	  independently.	  We	  did	  not	  examine	  
our	  inter-­‐scan	  or	  inter	  observer	  measures	  of	  reproducibility	  or	  validate	  our	  volumes	  against	  other	  
measures	  such	  as	  stroke	  volume	  calculated	  on	  velocity	  mapping.	  This	  is	  a	  limitation	  of	  our	  study.	  	  
	  
Maximal	  wall	  thickness	  was	  measured	  by	  observers	  from	  short-­‐axis	  views	  of	  the	  LV	  in	  end	  diastole,	  
and	  its	  position	  with	  reference	  to	  the	  17-­‐segment	  model	  of	  the	  LV	  recorded.135	  Measurements	  were	  
made	  so	  that	  they	  were	  perpendicular	  to	  the	  compacted	  myocardium	  with	  right	  and	  left	  ventricular	  
trabeculations	  excluded	  from	  the	  measurements.	  Aortic	  stenosis	  severity	  was	  assessed	  using	  CMR-­‐
derived	  planimetry	  of	  aortic	  valve	  area	  by	  one	  experienced	  operator	  (MD).	  This	  technique	  has	  been	  
validated	  against	  echocardiographic	  measures	  of	  aortic	  stenosis	  severity.136	  In	  accordance	  with	  
American	  Heart	  Association/American	  College	  of	  Cardiology	  guidelines,	  aortic	  stenosis	  was	  graded	  
using	  the	  aortic	  valve	  area	  as	  follows:	  mild,	  >1.5	  cm2;	  moderate,	  1.5-­‐1.0	  cm2;	  and	  severe,	  <1.0	  cm.129	  	  
	  
The	  presence	  and	  pattern	  of	  LGE	  was	  assessed	  by	  two	  independent	  observers	  (Francisco	  
Alpendurado	  and	  Raad	  Mohiaddin)	  who	  were	  blinded	  to	  the	  clinical	  data	  including	  valve	  severity,	  
coronary	  anatomy	  and	  outcomes.	  A	  third	  blinded	  observer	  adjudicated	  where	  there	  was	  a	  disparity	  
between	  the	  initial	  two	  observers	  (Sanjay	  Prasad).	  Patients	  with	  a	  mixed	  pattern	  of	  LGE	  were	  
categorized	  according	  to	  the	  predominant	  pattern	  of	  fibrosis.	  LGE	  mass	  was	  calculated	  semi-­‐
automatically	  by	  a	  single	  operator	  using	  MRI-­‐mass	  software	  (Qmass	  ,Medis,	  Leiden	  Netherlands).	  The	  
endocardial	  and	  epicardial	  borders	  were	  traced	  for	  each	  short-­‐axis	  slice.	  A	  region	  of	  interest	  
averaging	  50	  mm2	  was	  defined	  within	  normal	  remote	  myocardium	  in	  an	  area	  with	  uniform	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myocardial	  suppression	  free	  of	  artifacts.	  A	  multi-­‐pass	  region-­‐growing	  algorithm	  was	  used	  to	  identify	  
the	  fibrotic	  boundaries	  based	  on	  the	  “full	  width	  half	  maximum”	  technique	  and	  fibrosis	  was	  expressed	  
as	  present	  or	  absent,	  and	  its	  extent	  was	  quantified	  as	  a	  percentage	  of	  total	  LV	  mass	  (%	  LGE	  mass).	  It	  
has	  been	  pointed	  out	  that	  the	  algorithm	  used	  by	  the	  Medis	  software	  may	  not	  actually	  represent	  the	  
full	  width	  half	  maximum	  technique	  as	  it	  is	  also	  based	  on	  the	  signal	  in	  the	  nulled	  myocardium.	  
Nevertheless	  the	  same	  software	  was	  used	  for	  all	  studies	  to	  ensure	  consistency	  in	  this	  measurement.	  
2.6	  Statistics	  	  
Continuous	  variables	  were	  expressed	  as	  mean	  ±	  SD	  and	  compared	  using	  unpaired	  Student’s	  t-­‐test	  or	  
one-­‐way	  analysis	  of	  variance	  where	  appropriate.	  	  Categorical	  variables	  were	  expressed	  as	  
percentages	  and	  analyzed	  using	  the	  χ2-­‐test.	  Correlations	  between	  normally	  distributed	  data	  were	  
performed	  using	  Pearson’s	  correlation,	  whilst	  Spearman’s	  correlation	  was	  used	  for	  non-­‐parametric	  
data.	  A	  two-­‐sided	  P<0.05	  was	  regarded	  as	  statistically	  significant.	  
Reproducibility	  Studies	  
Measures	  of	  reproducibility	  for	  the	  PET	  studies	  in	  this	  thesis	  are	  based	  on	  the	  operators	  analyzing	  the	  
same	  scans	  on	  different	  occasions.	  They	  effectively	  represent	  inter	  and	  intra	  observer	  variation	  in	  
conducting	  the	  measurements.	  	  PET	  scans	  were	  not	  themselves	  repeated	  so	  we	  have	  not	  assessed	  
the	  test/retest	  repeatability.	  Reproducibility	  measures	  are	  not	  presented	  for	  the	  CMR	  studies.	  The	  
95%	  normal	  range	  for	  differences	  between	  sets	  of	  SUV	  and	  TBR	  measurements	  (the	  limits	  of	  
agreement)	  were	  estimated	  by	  multiplying	  the	  standard	  deviation	  of	  the	  mean	  difference	  by	  1.96.137	  
Intra-­‐class	  correlation	  coefficients	  with	  95%	  confidence	  intervals	  were	  calculated	  for	  intra-­‐observer	  
and	  inter-­‐observer	  variation.	  Statistical	  analysis	  was	  performed	  using	  SPSS	  version	  18	  (SPSS	  Inc,	  
Chicago,	  Illinois)	  unless	  stated.	  A	  two-­‐sided	  P<0.05	  was	  regarded	  as	  statistically	  significant.	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3.1	  Summary	  
	  
Background.	   	  
The	  pathophysiology	  of	  aortic	  stenosis	  is	  incompletely	  understood	  and	  the	  relative	  contributions	  of	  
valvular	  calcification	  and	  inflammation	  to	  disease	  progression	  are	  unknown.	  	  	  
	  
	  
Methods.	  	   	  
Patients	  with	  aortic	  sclerosis	  and	  mild,	  moderate	  and	  severe	  stenosis	  were	  prospectively	  compared	  
to	  age	  and	  sex-­‐matched	  control	  subjects.	  Aortic	  valve	  severity	  was	  determined	  by	  echocardiography.	  
Calcification	  and	  inflammation	  in	  the	  aortic	  valve	  were	  assessed	  by	  sodium	  18-­‐fluoride	  (18F-­‐NaF)	  and	  
18-­‐fluorodeoxyglucose	  (18F-­‐FDG)	  uptake	  using	  positron	  emission	  tomography.	  
	  
Results.	  
One	  hundred	  and	  twenty	  one	  subjects	  (20	  controls;	  20	  aortic	  sclerosis;	  25	  mild,	  33	  moderate	  and	  23	  
severe	  aortic	  stenosis)	  were	  administered	  both	  18F-­‐NaF	  and	  18F-­‐FDG.	  Quantification	  of	  tracer	  uptake	  
within	  the	  valve	  demonstrated	  excellent	  inter-­‐observer	  reproducibility	  with	  no	  fixed	  or	  proportional	  
biases	  and	  limits	  of	  agreement	  of	  ±0.21	  (18F-­‐NaF)	  and	  ±0.13	  (18F-­‐FDG)	  for	  maximum	  tissue-­‐to-­‐
background	  ratios	  (TBR).	  Activity	  of	  both	  tracers	  was	  higher	  in	  patients	  with	  aortic	  stenosis	  than	  
control	  subjects	  (18F-­‐NaF:	  2.87±0.82	  vs	  1.55±0.17;	  18F-­‐FDG:	  1.58±0.21	  vs	  1.30±0.13;	  both	  P<0.001).	  
18F-­‐NaF	  uptake	  displayed	  a	  progressive	  rise	  with	  valve	  severity	  (r2=0.540,	  P<0.001)	  with	  a	  more	  
modest	  increase	  observed	  for	  18F-­‐FDG	  (r2=0.218;	  P<0.001).	  Amongst	  patients	  with	  aortic	  stenosis,	  
91%	  had	  increased	  18F-­‐NaF	  (>1.97)	  and	  35%	  increased	  18F-­‐FDG	  (>1.63)	  uptake.	  A	  weak	  correlation	  
between	  the	  activities	  of	  these	  tracers	  was	  observed	  (r2=	  0.174,	  P<0.001).	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Conclusions.	  
Positron	  emission	  tomography	  is	  a	  novel,	  feasible	  and	  repeatable	  approach	  to	  the	  evaluation	  of	  
valvular	  calcification	  and	  inflammation	  in	  patients	  with	  aortic	  stenosis.	  The	  frequency	  and	  magnitude	  
of	  increased	  tracer	  activity	  correlates	  with	  disease	  severity,	  and	  is	  strongest	  for	  18F-­‐NaF.	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3.2	  Introduction	  
Calcific	  aortic	  stenosis	  is	  the	  commonest	  form	  of	  valvular	  heart	  disease	  in	  the	  western	  world	  and	  
represents	  a	  major	  healthcare	  burden	  that	  is	  projected	  to	  increase	  with	  an	  ageing	  population.131	  
However,	  the	  underlying	  pathophysiology	  remains	  incompletely	  defined,	  and	  there	  are	  currently	  no	  
effective	  medical	  treatments	  capable	  of	  altering	  its	  course.2	  Unfortunately	  histological	  studies	  are	  
limited	  by	  the	  availability	  of	  valve	  tissue	  from	  patients	  with	  advanced	  disease	  and	  do	  not	  lend	  
themselves	  to	  the	  longitudinal	  study	  of	  disease	  progression.	  	  Alternative	  techniques	  are	  therefore	  
required	  to	  investigate	  the	  pathogenesis	  and	  progression	  of	  this	  condition.	  
	  
Positron	  emission	  tomography	  (PET)	  combined	  with	  computed	  tomography	  (CT)	  is	  a	  non-­‐invasive	  
imaging	  technique	  that	  allows	  the	  identification	  and	  quantification	  of	  specific	  biochemical	  processes	  
within	  small	  anatomic	  structures,	  such	  as	  the	  aortic	  valve.	  Furthermore	  two	  common	  PET	  tracers	  
target	  calcification	  and	  inflammation,	  which	  are	  believed	  to	  play	  a	  key	  role	  in	  the	  development	  of	  the	  
disease.	  PET/CT	  therefore	  holds	  considerable	  promise	  as	  a	  means	  of	  investigating	  the	  
pathophysiology	  of	  aortic	  stenosis.	  	  	  
	  
18F-­‐Flurodeoxyglucose	  (18F-­‐FDG)	  is	  a	  glucose	  analogue	  that	  is	  taken	  up	  into	  cells	  by	  glucose	  
transport	  proteins	  and	  enters	  the	  glycolytic	  metabolic	  pathway.	  Following	  the	  initial	  hexokinase	  step,	  
18F-­‐FDG-­‐6-­‐phosphate	  cannot	  be	  metabolized	  further	  and	  becomes	  trapped	  within	  cells	  that	  have	  
high	  metabolic	  requirements,	  such	  as	  macrophages.	  PET	  imaging	  using	  18F-­‐FDG	  has	  become	  an	  
established	  means	  of	  quantifying	  vascular	  inflammation	  in	  both	  the	  aorta	  and	  carotid	  arteries,98,	  99	  
correlating	  with	  plaque	  macrophage	  burden,100	  and	  symptomatic	  status.99	  18F-­‐sodium	  fluoride	  (18	  F-­‐
NaF)	  is	  an	  alternative	  PET	  tracer	  that	  is	  directly	  incorporated	  into	  exposed	  bone	  crystal	  
(hydroxyapatite)	  via	  an	  exchange	  mechanism	  with	  hydroxyl	  groups.113	  It	  is	  therefore	  thought	  to	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detect	  areas	  of	  novel	  calcification	  and	  regions	  of	  calcium	  remodelling,	  and	  is	  used	  clinically	  for	  the	  
detection	  of	  primary	  osteoblastic	  tumours	  and	  bone	  metastases.110	  More	  recently	  studies	  have	  
described	  18F-­‐NaF	  uptake	  as	  a	  marker	  of	  calcification	  within	  atherosclerotic	  plaque,111,	  112	  however	  to	  
date	  this	  tracer	  has	  not	  been	  used	  to	  study	  patients	  with	  aortic	  stenosis.	  
	  
In	  this	  PET	  study	  we	  investigated	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake	  in	  the	  valves	  of	  patients	  with	  aortic	  
stenosis,	  with	  three	  major	  aims:	  to	  examine	  the	  feasibility	  of	  this	  approach,	  to	  establish	  its	  
reproducibility,	  and	  to	  assess	  the	  relative	  importance	  of	  inflammation	  and	  calcification	  at	  different	  
stages	  of	  the	  disease.	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3.3	  Methods	  
As	  described	  in	  Chapter	  2	  patients	  over	  50	  years	  of	  age	  with	  aortic	  sclerosis	  and	  mild,	  moderate	  and	  
severe	  aortic	  stenosis	  were	  recruited	  prospectively	  from	  the	  outpatient	  department	  of	  the	  Royal	  
Infirmary	  of	  Edinburgh	  and	  compared	  to	  age-­‐	  and	  sex-­‐matched	  control	  subjects	  with	  a	  normal	  aortic	  
valve	  and	  similar	  range	  of	  co-­‐morbidity.	  	  
	  
Echocardiography	  
Valve	  disease	  severity	  was	  assessed	  using	  echocardiography	  in	  all	  patients	  by	  a	  single	  dedicated	  
research	  ultrasonographer	  on	  a	  dedicated	  machine	  as	  described	  in	  Chapter	  2.	  Aortic	  sclerosis	  was	  
defined	  as	  a	  thickened	  aortic	  valve	  on	  echocardiography	  in	  the	  absence	  of	  accelerated	  flow	  though	  
the	  valve	  (peak	  jet	  velocity	  <2	  m/s).	  The	  severity	  of	  aortic	  stenosis	  was	  graded	  according	  to	  American	  
Heart	  Association	  and	  American	  College	  of	  Cardiology	  criteria	  using	  the	  peak	  transvalvular	  aortic	  
valve	  velocity,	  and	  the	  mean	  and	  maximum	  aortic	  valve	  pressure	  gradients.129	  Aortic	  stenosis	  severity	  
was	  also	  assessed	  using	  the	  time	  velocity	  integral	  (TVI),	  the	  dimensionless	  index	  and	  the	  aortic	  valve	  
area,	  calculated	  using	  the	  continuity	  equation.	  
	  
Positron	  Emission	  Tomography	  and	  Computed	  Tomography	  
As	  described	  in	  Chapter	  2	  combined	  PET/CT	  scans	  of	  the	  aortic	  valve	  were	  performed	  using	  18F-­‐FDG	  
and	  18F-­‐NaF	  on	  two	  occasions	  in	  close	  succession	  using	  a	  hybrid	  scanner.	  Dietary	  restrictions	  were	  
applied	  prior	  to	  the	  18F-­‐FDG	  scan	  and	  myocardial	  uptake	  measured.	  Patients	  were	  then	  categorised	  
in	  to	  dietary	  compliance	  and	  non-­‐compliance	  and	  to	  high	  and	  low	  myocardial	  18F-­‐FDG	  uptake	  
(Chapter	  2).	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Quantification	  of	  tracer	  uptake	  in	  the	  aortic	  valve	  
PET	  image	  quantification	  was	  performed	  as	  described	  in	  Chapter	  2.	  Breifly	  the	  short-­‐axis	  method	  was	  
used	  for	  18F-­‐NaF	  and	  18F-­‐FDG.	  	  Whilst	  the	  pre-­‐scan	  dietary	  restrictions	  aimed	  to	  minimize	  the	  
difficulties	  cause	  by	  myocardial	  18F-­‐FDG	  uptake,	  we	  also	  explored	  two	  further	  image	  analysis	  
approaches	  to	  define	  better	  and	  to	  assess	  more	  specifically	  the	  valvular	  uptake:	  the	  long	  axis	  and	  
centre-­‐valve	  techniqes	  (Chapter	  2,	  Figure	  2.1).	  For	  all	  techniques,	  measurements	  were	  taken	  on	  
adjacent	  3-­‐mm	  slices,	  and	  mean	  and	  maximum	  SUV	  and	  TBR	  values	  calculated	  for	  the	  valve.	  
	  
Reproducibility	  studies	  	  
Twenty-­‐five	  patients	  with	  a	  range	  of	  aortic	  valve	  disease	  were	  selected	  at	  random	  from	  the	  cohort.	  
Having	  established	  the	  aortic	  valve	  image	  analysis	  methodology,	  all	  scans	  from	  these	  patients	  were	  
analyzed	  independently	  by	  two	  trained	  observers	  (MD,	  CJ).	  For	  each	  technique,	  this	  provided	  
measures	  of	  inter-­‐observer	  reproducibility	  for	  mean	  and	  maximum	  SUV	  and	  TBR	  values.	  	  In	  order	  to	  
assess	  intra-­‐observer	  variation,	  both	  observers	  repeated	  the	  analyses	  at	  least	  two	  weeks	  later	  to	  
minimize	  recall	  bias.	  	  
	  
Ex-­‐vivo	  studies	  
One	  patient	  underwent	  an	  aortic	  valve	  replacement	  3	  months	  after	  their	  PET	  scans.	  The	  valve	  was	  
harvested	  and	  incubated	  with	  18F-­‐FDG,	  Dulbecco’s	  modified	  eagle	  medium	  (Invitrogen,	  Paisley,	  UK)	  
and	  10%	  fetal	  calf	  serum	  for	  90	  min	  before	  PET/CT	  imaging	  using	  the	  same	  protocol	  as	  the	  in	  vivo	  
clinical	  scans.	  The	  next	  day,	  PET/CT	  imaging	  was	  repeated	  after	  incubation	  with	  18F-­‐NaF	  for	  60	  min.	  
Finally	  the	  valve	  was	  fixed	  in	  formalin	  and	  decalcified	  using	  ethylene	  diamine	  tetracetic	  acid	  before	  
immunohistochemistry	  was	  performed	  to	  examine	  for	  macrophage	  accumulation	  (CD68)	  and	  active	  
calcification	  (osteocalcin).	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Statistical	  Methods	  
Continuous	  variables	  were	  expressed	  as	  mean	  ±	  standard	  deviation	  (SD)	  and	  compared	  using	  
unpaired	  Student’s	  t	  -­‐test	  or	  one-­‐way	  analysis	  of	  variance	  where	  appropriate.	  All	  continuous	  variables	  
were	  tested	  for	  normal	  distribution	  using	  the	  Shapiro-­‐Wilk	  test.	  Where	  data	  were	  not	  normally	  
distributed,	  they	  were	  presented	  as	  the	  median	  ±	  interquartile	  range.	  Categorical	  variables	  were	  
expressed	  as	  percentages	  and	  analyzed	  using	  the	  χ2-­‐test.	  Correlations	  between	  normally	  distributed	  
data	  were	  performed	  using	  Pearson’s	  correlation,	  and	  presented	  as	  r	  2	  values.	  Spearman’s	  correlation	  
was	  used	  for	  non-­‐parametric	  data.	  Differences	  between	  sets	  of	  SUV	  and	  TBR	  measurements	  were	  
calculated	  along	  with	  limits	  of	  agreement	  and	  Intra-­‐class	  correlation	  coefficients	  to	  provide	  measures	  
of	  intra	  and	  inter-­‐observer	  variation.	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3.4	  Results	  
Patient	  Population	  	  
A	  total	  of	  121	  patients	  were	  recruited	  (age	  72±8	  years,	  69%	  male,	  peak	  aortic	  valve	  velocity	  2.8±1.2	  
m/s)	  and	  had	  both	  18F-­‐NaF	  (66±7	  min	  after	  124±10	  MBq)	  and	  18F-­‐FDG	  (94±7	  min	  after	  197±14	  MBq)	  
scans	  of	  their	  aortic	  valve	  less	  than	  one	  month	  apart.	  	  This	  cohort	  comprised	  20	  control	  subjects,	  20	  
patients	  with	  aortic	  sclerosis,	  and	  25	  patients	  with	  mild,	  33	  with	  moderate	  and	  23	  with	  severe	  aortic	  
stenosis.	  Patients	  were	  well-­‐matched	  for	  age,	  sex	  and	  co-­‐morbidity	  (Table	  3.1).	  	  	  
	  
Dietary	  Restrictions	  &	  Blood	  Pool	  Uptake	  
Average	  myocardial	  SUV	  across	  the	  entire	  cohort	  was	  4.6±3.6	  and	  dietary	  restrictions	  effectively	  
suppressed	  18F-­‐FDG	  myocardial	  uptake	  (SUV<5)	  in	  67%	  of	  patients,	  similar	  to	  that	  observed	  in	  
previous	  studies.106	  Based	  on	  dietary	  diaries,	  61%	  of	  patients	  complied	  with	  the	  dietary	  restrictions	  
and	  had	  lower	  myocardial	  18F-­‐FDG	  uptake	  than	  non-­‐compliers	  (SUV	  3.2±2.3	  vs	  6.7±4.2;	  P<0.001).	  
Across	  the	  cohort	  blood-­‐pool	  uptake	  in	  the	  SVC	  was	  0.99±0.18	  for	  18F-­‐NaF	  and	  1.26±0.20	  for	  18F-­‐
FDG.	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Table	  3.1.	  Baseline	  subject	  characteristics.	  
	  
Mean	  ±SD.	  BUN-­‐	  Blood	  urea	  nitrogen,	  AU-­‐	  Agatston	  unit,	  LDL-­‐	  low	  density	  lipoprotein,	  HDL-­‐	  high	  density	  lipoprotein,	  ACE-­‐	  
angiotensin	  converting	  enzyme.	  	  	  
*There	  was	  no	  correlation	  between	  peak	  aortic	  valve	  velocity	  and	  either	  serum	  total	  cholesterol	  (Pearson’s	  correlation,	  r2=	  
0.000;	  p=	  0.976)	  or	  LDL	  cholesterol	  (r2	  =	  0.007,	  p=	  0.36)	  concentrations.	  
	  




Aortic	  Stenosis	   P	  Value	  
	  Mild	   Moderate	   Severe	  
Number	   20	   20	   25	   33	   23	   -­‐	  
Age	  (years)	   70	  ±8	   71	  ±9	   73	  ±8	   72	  ±7	   73	  ±11	   0.726	  
Male	  Sex	  (%)	   65	   75	   60	   76	   65	   0.687	  
Body	  Mass	  Index	  (kg/m2)	   26	  ±3	   29	  ±6	   27	  ±3	   29	  ±5	   28	  ±4	   0.051	  
Ischemic	  Heart	  Disease	  (%)	   35	   40	   48	   36	   22	   0.445	  
Cardiovascular	  Disease	  (%)	   35	   45	   48	   39	   22	   0.373	  
Smoking	  (%)	   50	   35	   48	   52	   61	   0.566	  
Diabetes	  Mellitus	  (%)	   10	   15	   20	   13	   17	   0.886	  
Hypertension	  (%)	   40	   55	   64	   73	   61	   0.203	  
Chronic	  kidney	  disease	  Stage	  3	  
and	  above	  (%)	  
20	   20	   20	   24	   30	   0.927	  
Creatinine	  (mg/dL)	   0.91	  ±0.20	   0.99	  ±0.26	   0.97	  ±0.32	   1.05	  ±0.26	   1.09	  ±0.41	   0.314	  
Urea	  (BUN)	  (mg/dL)	   20.2	  ±5.1	   19.0	  ±6.8	   20.5	  ±10.4	   21.0	  ±4.6	   22.3	  ±7.8	   0.651	  
Calcium	  (mg/dL)	   9.2	  ±0.2	   9.2	  ±0.7	   9.2	  ±0.5	   9.3	  ±0.4	   9.5	  ±0.9	   0.228	  
Phosphate	  (mg/dL)	   3.7	  ±0.5	   3.6	  ±0.6	   3.6	  ±0.5	   3.6	  ±1.5	   3.6	  ±0.4	   0.973	  
Alkaline	  Phosphatase	  (U/L)	   75	  ±19	   85	  ±30	   79	  ±21	   82	  ±22	   102	  ±89	   0.314	  
Total	  Cholesterol	  (mg/dL)	   191	  ±42	   194	  ±53	   210	  ±59	   171	  ±41	   203	  ±52	   0.040*	  
LDL	  Cholesterol	  (mg/dL)	   98	  ±44	   101	  ±41	   121	  ±47	   89	  ±37	   119	  	  ±48	   0.036*	  
HDL	  Cholesterol	  (mg/dL)	   58	  ±15	   60	  ±35	   57	  ±19	   49	  ±11	   49	  	  ±13	   0.165	  
Triglycerides	  (mg/dL)	   63	  ±35	   72	  ±33	   69	  ±41	   77	  	  ±52	   82	  	  ±45	   0.613	  
Statin	  therapy	  (%)	   35	   50	   52	   67	   57	   0.262	  
ACE	  inhibitor	  therapy	  (%)	   35	   40	   52	   36	   30	   0.604	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Amongst	  the	  25	  patients	  selected	  (age	  74±10	  years,	  64%	  male,	  aortic	  valve	  peak	  velocity	  3.8±1.1	  
m/s),	  aortic	  valve	  18F-­‐NaF	  uptake	  showed	  excellent	  inter-­‐observer	  reproducibility	  for	  the	  mean	  and	  
maximum	  SUV	  and	  TBR	  values.	  There	  were	  no	  fixed	  or	  proportional	  biases,	  and	  the	  majority	  of	  data	  
fell	  within	  narrow	  limits	  of	  agreement:	  ±0.20	  for	  mean	  and	  ±0.21	  for	  maximum	  TBR	  measurements	  
(Table	  3.2,	  Figure	  3.1).	  	  Limits	  of	  agreement	  for	  intra-­‐observer	  measurements	  were	  similarly	  good	  
whilst	  intra-­‐class	  coefficients	  for	  inter	  and	  intra-­‐observer	  reproducibility	  were	  all	  >0.95	  indicating	  
excellent	  agreement	  (Table	  4).	  	  	  
	  
18F-­‐Fluorodeoxyglucose	  
Avoiding	  myocardial	  uptake	  was	  difficult	  using	  the	  short	  and	  long-­‐axis	  techniques,	  particularly	  for	  the	  
latter.	  Reproducibility	  statistics	  reflected	  this	  and	  demonstrated	  that	  the	  variability	  was	  much	  greater	  
than	  for	  18F-­‐NaF.	  The	  inter-­‐observer	  limits	  of	  agreement	  for	  the	  short-­‐axis	  technique	  were	  ±0.28	  and	  
±0.72	  for	  the	  mean	  and	  maximum	  TBR	  values	  respectively,	  and	  were	  	  ±0.78	  and	  ±1.18	  using	  the	  long-­‐
axis	  approach	  (Table	  3.2,	  Figure	  3.1).	  The	  intra-­‐class	  coefficients	  for	  the	  short-­‐axis	  technique	  were	  
0.76	  and	  0.59	  for	  the	  mean	  and	  maximum	  TBR	  values	  respectively,	  and	  were	  0.39	  and	  0.52	  using	  the	  
long-­‐axis	  approach	  (Table	  3.3).	  Intra-­‐observer	  reproducibility	  measures	  were	  similarly	  poor.	  The	  
reason	  for	  better	  measures	  on	  reproducibility	  for	  CJ	  than	  MD	  using	  the	  long-­‐axis	  technique	  is	  not	  
clear.	  	  
	  
The	  centre-­‐valve	  analysis	  was	  more	  reproducible.	  There	  were	  no	  fixed	  or	  proportional	  biases	  in	  the	  
differences	  between	  inter-­‐observer	  measurements	  and	  the	  data	  fell	  within	  narrow	  limits	  of	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agreement:	  	  ±0.11	  for	  mean	  and	  ±0.13	  for	  maximum	  TBR	  values	  (Table	  3.2,	  Figure	  3.1).	  Intra-­‐observer	  
reproducibility	  was	  similarly	  good	  whilst	  intra-­‐class	  coefficients	  were	  all	  >0.90	  indicating	  excellent	  
agreement	  (Tables	  3.2	  &	  3.3).	  
	  
There	  were	  concerns	  that	  the	  centre-­‐valve	  technique	  might	  underestimate	  18F-­‐FDG	  activity	  in	  the	  
valve	  by	  excluding	  the	  valve	  ring.	  However,	  there	  was	  no	  difference	  between	  mean	  uptake	  values	  
calculated	  using	  the	  centre-­‐valve	  technique	  and	  the	  short-­‐axis	  method	  (centre-­‐valve	  TBR:	  1.43±0.17;	  
short-­‐axis:	  1.47±0.45;	  P=0.473).	  Maximum	  TBR	  values	  were	  lower	  using	  the	  former	  approach	  (centre-­‐
valve:	  1.60±0.20	  vs	  short-­‐axis:	  1.80±0.45;	  P=0.041).	  However,	  this	  difference	  was	  no	  longer	  apparent	  
when	  patients	  with	  high	  myocardial	  uptake	  (n=11)	  were	  excluded	  from	  the	  analysis	  	  (centre-­‐valve	  
1.56±0.18	  vs	  short-­‐axis	  1.64±0.20;	  P=0.245)	  reflecting	  the	  wide	  limits	  of	  agreement	  (±1.05)	  for	  the	  
short-­‐axis	  technique	  when	  myocardial	  suppression	  was	  poor.	  By	  contrast,	  limits	  of	  agreement	  for	  the	  
centre-­‐valve	  technique	  were	  equally	  good	  in	  patients	  with	  low	  and	  high	  myocardial	  uptake	  (±0.13	  vs	  
±0.14	  respectively;	  P=0.919).	  Given	  this	  and	  other	  advantages,	  subsequent	  analysis	  of	  the	  entire	  
cohort	  was	  performed	  using	  the	  centre-­‐valve	  method	  for	  18F-­‐FDG.	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Table	  3.2	  Inter	  and	  intra-­‐observer	  reproducibility	  statistics	  for	  18F-­‐NaF	  and	  18F-­‐FDG	  quantification	  
in	  the	  aortic	  valve	  	  
	  
	   Mean	  Difference	  between	  Aortic	  Valve	  SUV	  &	  TBR	  measurements	  
	   Inter-­‐observer	   Intra-­‐observer	  
(MD)	   (CJ)	  
Mean	  SUV	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.04	  (-­‐0.12	  to	  0.20)	   0.02	  (-­‐0.10	  to	  0.14)	   0.05	  (-­‐0.14	  to	  0.24)	  
	   18F-­‐FDG	  short-­‐axis	   0.02	  (-­‐0.18	  to	  0.20)	   -­‐0.01	  (-­‐0.10	  to	  0.12)	   -­‐0.02	  (-­‐0.19	  to	  0.15)	  
	   18F-­‐FDG	  long-­‐axis	   0.05	  (-­‐0.57	  to	  0.67)	   0.05	  (-­‐0.37	  to	  0.47)	   0.00	  (-­‐0.14	  to	  0.14)	  
	   18F-­‐FDG	  centre-­‐valve	   0.01	  (-­‐0.05	  to	  0.07)	   0.01	  (-­‐0.05	  to	  0.07)	   -­‐0.02	  (-­‐0.16	  to	  0.12)	  
Maximum	  SUV	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.02	  (-­‐0.16	  to	  0.20)	   0.04	  (-­‐0.11	  to	  0.19)	   0.00	  (-­‐0.19	  to	  0.19)	  
	   18F-­‐FDG	  short-­‐axis	   0.02	  (-­‐0.80	  to	  0.84)	   -­‐0.11	  (-­‐0.64	  to	  0.42)	   -­‐0.09	  (-­‐0.89	  to	  0.72)	  
	   18F-­‐FDG	  long-­‐axis	   -­‐0.03	  (-­‐1.06	  to	  1.00)	   0.12	  (-­‐0.44	  to	  0.68)	   0.10	  (-­‐0.41	  to	  0.61)	  
	   18F-­‐FDG	  centre-­‐valve	   0.03	  (-­‐0.07	  to	  0.13)	   0.02	  (-­‐0.13	  to	  0.17)	   -­‐0.06	  (-­‐0.26	  to	  0.14)	  
Mean	  TBR	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.07	  (-­‐0.13	  to	  0.27)	   -­‐0.01	  (-­‐0.15	  to	  0.17)	   0.05	  (-­‐0.17	  to	  0.27)	  
	   18F-­‐FDG	  short-­‐axis	  
18F-­‐FDG	  long-­‐axis	  
0.06	  (-­‐0.22	  to	  0.34)	  
0.06	  (-­‐0.72	  to	  0.84)	  
0.00	  (-­‐0.15	  to	  0.15)	  
0.07	  (-­‐0.50	  to	  0.64)	  
0.01	  (-­‐0.12	  to	  0.14)	  
0.02	  (-­‐0.22	  to	  0.26)	  
18F-­‐FDG	  centre-­‐valve	   -­‐0.01	  (-­‐0.12	  to	  0.10)	   0.02	  (-­‐0.06	  to	  0.10)	   -­‐0.01	  (-­‐0.07	  to	  0.05)	  
Maximum	  TBR	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.02	  (-­‐0.19	  to	  0.23)	   -­‐0.04	  (-­‐0.16	  to	  0.24)	   0.00	  (-­‐0.21	  to	  0.21)	  
	   18F-­‐FDG	  short-­‐axis	   0.06	  (-­‐0.66	  to	  0.78)	   -­‐0.09	  (-­‐0.39	  to	  0.57)	   0.07	  (-­‐0.06	  to	  0.20)	  
	   18F-­‐FDG	  long-­‐axis	   0.01	  (-­‐1.17	  to	  1.19)	   0.12	  (-­‐0.50	  to	  0.74)	   0.06	  (-­‐0.33	  to	  0.39)	  
	   18F-­‐FDG	  centre-­‐valve	   -­‐0.02	  (-­‐0.15	  to	  0.11)	   0.02	  (-­‐0.11	  to	  0.15)	   -­‐0.05	  (-­‐0.14	  to	  0.04)	  
Mean	  difference	  between	  standard	  uptake	  value	  (SUV)	  and	  tissue-­‐to-­‐background	  ratio	  (TBR)	  measurements	  for	  18F-­‐NaF	  valve	  
uptake	  using	  the	  short-­‐axis	  technique	  and	  18F-­‐FDG	  uptake	  using	  the	  short-­‐axis,	  centre-­‐valve	  and	  long-­‐axis	  techniques	  (95%	  
confidence	  intervals	  in	  brackets).	  The	  short-­‐axis	  technique	  for	  18F-­‐NaF	  and	  the	  centre-­‐valve	  technique	  for	  18F-­‐FDG	  display	  no	  
fixed	  proportional	  bias	  with	  narrow	  limits	  of	  agreement.	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Table	  3.3.	  Intra-­‐class	  coefficient	  values	  for	  18F-­‐NaF	  and	  18F-­‐FDG	  quantification	  in	  the	  aortic	  valve	  
	   ICC	  Values	  comparing	  Aortic	  Valve	  SUV	  and	  TBR	  measurements	  
	   Inter-­‐observer	   Intra-­‐observer	  
MD	   CJ	  
Mean	  SUV	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.98	  (0.96-­‐0.99)	   0.99	  (0.98-­‐1.00)	   0.98	  (0.94-­‐0.99)	  
	   18F-­‐FDG	  short-­‐axis	   0.95	  (0.88-­‐0.98)	   0.98	  (0.96-­‐0.99)	   0.96	  (0.91-­‐0.98)	  
	   18F-­‐FDG	  long-­‐axis	   0.58	  (0.24-­‐0.79)	   0.68	  (0.39-­‐0.84)	   0.96	  (0.91-­‐0.98)	  
	   18F-­‐FDG	  centre-­‐valve	   0.99	  (0.97-­‐0.99)	   1.00	  (0.99-­‐1.00)	   0.99	  (0.98-­‐1.00)	  
Maximum	  SUV	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.99	  (0.99-­‐1.00)	   1.00	  (0.99-­‐1.00)	   0.99	  (0.98-­‐1.00)	  
	   18F-­‐FDG	  short-­‐axis	   0.62	  (0.30-­‐0.81)	   0.88	  (0.75-­‐0.95)	   0.58	  (0.24-­‐0.79)	  
	   18F-­‐FDG	  long-­‐axis	   0.53	  (0.18-­‐0.76)	   0.77	  (0.54-­‐0.89)	   0.80	  (0.60-­‐0.91)	  
	   18F-­‐FDG	  centre-­‐valve	   0.98	  (0.94-­‐0.99)	   0.98	  (0.95-­‐0.99)	   0.96	  (0.90-­‐0.98)	  
Mean	  TBR	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.98	  (0.96-­‐0.99)	   0.99	  (0.97-­‐0.99)	   0.97	  (0.93-­‐0.99)	  








18F-­‐FDG	  centre-­‐valve	   0.96	  (0.90-­‐0.98)	   0.97	  (0.93-­‐0.99)	   0.84	  (0.66-­‐0.92)	  
Maximum	  TBR	   	   	   	  
	   18F-­‐NaF	  short-­‐axis	   0.99	  (0.99-­‐1.00)	   0.99	  (0.99-­‐1.00)	   0.99	  (0.99-­‐1.00)	  
	   18F-­‐FDG	  short-­‐axis	   0.59	  (0.26-­‐0.80)	   0.89	  (0.76-­‐0.95)	   0.71	  (0.44-­‐0.86)	  
	   18F-­‐FDG	  long-­‐axis	   0.52	  (0.17-­‐0.76)	   0.85	  (0.69-­‐0.93)	   0.92	  (0.83-­‐0.97)	  
	   18F-­‐FDG	  centre-­‐valve	   0.92	  (0.83-­‐0.97)	   0.94	  (0.87-­‐0.97)	   0.91	  (0.80-­‐0.96)	  
Intra-­‐class	  correlation	  coefficient	  (ICC)	  values	  (95%	  confidence	  intervals	  in	  parentheses)	  for	  the	  short-­‐axis	  18F-­‐NaF	  technique	  and	  
the	  centre-­‐valve	  18F-­‐FDG	  method.	  SUV,	  standard	  uptake	  value;	  TBR,	  tissue-­‐to-­‐background	  ratio.	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Figure	  3.1	  Bland-­‐Altman	  plots	  of	  inter-­‐observer	  variability	  
	  	  
A)	  Maximum	  18F-­‐NaF	  tissue-­‐to-­‐background	  ratio	  (TBR)	  values	  using	  the	  short-­‐axis	  technique.	  The	  central	  line	  is	  the	  mean	  
difference	  between	  the	  two	  analyses,	  which	  does	  not	  show	  any	  fixed	  or	  proportional	  biases.	  The	  dotted	  lines	  show	  the	  
limits	  of	  agreement	  (mean	  of	  the	  differences	  ±	  1.96	  ×	  SD),	  which	  are	  narrow.	  	  
Maximum	  18F-­‐FDG	  values	  using	  the	  short-­‐axis	  (B),	  long-­‐axis	  (C)	  and	  centre-­‐valve	  techniques	  (D).	  Note	  the	  wide	  limits	  of	  
agreement	  for	  the	  short-­‐axis	  and	  long	  axis	  18F-­‐FDG	  techniques	  but	  the	  excellent	  measures	  of	  reproducibility	  for	  the	  
centre-­‐valve	  technique.	  Also	  note	  there	  is	  a	  single	  outlier	  not	  plotted	  on	  the	  long-­‐axis	  graph	  (C):	  the	  mean	  difference	  for	  
this	  patient	  is	  given	  in	  brackets.	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Aortic	  Valve	  Uptake	  
Sodium	  18Fluoride	  
Focal	  18F-­‐NaF	  uptake	  was	  observed	  in	  the	  valves	  of	  patients	  with	  calcific	  aortic	  valve	  disease	  in	  areas	  
overlying,	  adjacent	  to	  and	  remote	  from	  existing	  calcification.	  Areas	  of	  established	  calcium	  were	  also	  
frequently	  observed	  in	  the	  absence	  of	  increased	  18F-­‐NaF	  activity	  (Figure	  3.2).	  Compared	  to	  control	  
subjects,	  valvular	  18F-­‐NaF	  uptake	  was	  higher	  in	  patients	  with	  both	  aortic	  sclerosis	  (max	  TBR:	  
1.55±0.17	  vs	  1.92±0.31;	  p<0.001)	  and	  aortic	  stenosis	  (max	  TBR:	  1.55±0.17	  vs	  2.87±0.82;	  P<0.001).	  The	  
highest	  maximum	  TBR	  value	  in	  the	  control	  group	  was	  1.97,	  which	  was	  used	  to	  divide	  patients	  with	  
aortic	  valve	  disease	  into	  those	  with	  increased	  18F-­‐NaF	  uptake	  (>1.97)	  and	  those	  without	  (≤1.97).	  
Overall	  45%	  of	  patients	  with	  aortic	  sclerosis	  and	  91%	  of	  those	  with	  aortic	  stenosis	  had	  increased	  
uptake.	  The	  proportion	  of	  patients	  with	  increased	  activity	  rose	  sharply	  with	  increasing	  disease	  
severity	  such	  that	  100%	  of	  patients	  with	  severe	  disease	  had	  increased	  uptake	  (Table	  3.4).	  	  
	  
All	  measures	  of	  18F-­‐NaF	  uptake	  displayed	  a	  progressive	  rise	  with	  increasing	  aortic	  jet	  velocity	  (max	  
TBR:	  r2=0.540,	  P<0.001;	  Table	  3.4,	  Figure	  3.3),	  the	  aortic	  valve	  calcium	  score	  (r2=	  0.641,	  P<0.001)	  and	  
other	  echocardiographic	  measures	  of	  aortic	  stenosis	  severity	  (time-­‐velocity	  integral:	  r2=	  0.546,	  
p<0.001;	  aortic	  valve	  area:	  r2=	  0.387,	  p<0.001;	  dimensionless	  index:	  r2=0.527,	  p<0.001).	  	  	  
	  
18Fluorodeoxyglucose	  	  
18F-­‐FDG	  showed	  a	  more	  diffuse	  pattern	  of	  activity	  within	  the	  valve	  (Figure	  3.2)	  and	  compared	  to	  
control	  subjects,	  uptake	  was	  increased	  in	  patients	  with	  aortic	  sclerosis	  (max	  TBR:	  1.30±0.13	  vs	  
1.47±0.15;	  P<0.001)	  and	  aortic	  stenosis	  (max	  TBR:	  1.30±0.13	  vs	  1.58±0.21;	  P<0.001).	  	  The	  highest	  
maximum	  TBR	  value	  in	  the	  control	  group	  was	  1.63,	  which	  was	  used	  to	  divide	  patients	  with	  aortic	  
valve	  disease	  into	  those	  with	  increased	  18F-­‐FDG	  uptake	  (>1.63)	  and	  those	  without	  (≤1.63).	  Overall	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20%	  of	  patients	  with	  aortic	  sclerosis	  and	  35%	  of	  patients	  with	  aortic	  stenosis	  had	  increased	  uptake.	  
The	  proportion	  of	  patients	  with	  increased	  activity	  in	  the	  valve	  again	  rose	  with	  increasing	  aortic	  valve	  
disease,	  however	  this	  rise	  was	  more	  gradual	  than	  for	  18F-­‐NaF	  with	  only	  52%	  of	  patients	  with	  severe	  
disease	  demonstrating	  increased	  activity	  (Table	  3.4).	  	  
	  
All	  measures	  of	  18F-­‐FDG	  activity	  displayed	  a	  progressive	  rise	  with	  increasing	  aortic	  jet	  velocity	  (max	  
TBR:	  r2=0.218,	  P<0.001;	  Table	  3.4,	  Figure	  3.3),	  the	  aortic	  valve	  Agatston	  score	  (r2=	  0.138,	  p<0.001)	  
and	  other	  echocardiographic	  measures	  of	  aortic	  stenosis	  (time-­‐velocity	  integral:	  r2=	  0.246,	  p<0.001;	  
aortic	  valve	  area:	  r2=	  0.184,	  p<0.001;	  dimensionless	  index:	  r2=	  0.229;	  p<0.001).	  	  These	  correlations	  
were	  weaker	  and	  more	  modest	  than	  for	  18F-­‐NaF.	  A	  modest	  correlation	  was	  also	  observed	  between	  
valvular	  18F-­‐NaF	  and	  18F-­‐FDG	  activities	  (max	  TBR:	  r2=	  0.174,	  P<0.001).	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Figure	  3.2	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake	  in	  patients	  with	  aortic	  stenosis.	  
	  
	  
18F-­‐NaF.	  Fused	  PET/CT	  scans	  demonstrating	  uptake	  of	  18F-­‐NaF	  on	  co-­‐axial	  short	  axis	  views	  of	  the	  aortic	  valve	  in	  
patients	  with	  a	  normal	  aortic	  valve	  (A),	  aortic	  sclerosis	  (B),	  and	  mild	  (C),	  moderate	  (D)	  and	  severe	  aortic	  stenosis	  
(E	  &	  F).	  	  White	  areas	  show	  regions	  of	  existing	  calcium	  whilst	  yellow	  and	  red	  areas	  show	  areas	  of	  18F-­‐NaF	  uptake.	  
Focal	  areas	  of	  uptake	  are	  observed	  in	  areas	  overlying	  existing	  calcium	  as	  well	  as	  in	  areas	  remote	  from	  it.	  
Furthermore	  areas	  of	  existing	  calcification	  are	  observed	  in	  the	  absence	  of	  overlying	  18F-­‐NaF	  uptake.	  Note	  the	  
increased	  activity	  with	  increasing	  severity	  of	  valve	  disease.	  Regions	  of	  interest	  have	  been	  drawn	  around	  the	  
periphery	  of	  the	  valve	  (white	  lines)	  using	  the	  short-­‐axis	  technique.	  	  
18F-­‐FDG	  Fused	  PET/CT	  scans	  demonstrating	  uptake	  of	  18F-­‐FDG	  on	  co-­‐axial	  short	  axis	  views	  of	  the	  aortic	  valve	  in	  
patients	  with	  a	  normal	  aortic	  valve	  (G),	  mild	  aortic	  stenosis	  (H),	  and	  severe	  aortic	  stenosis	  (I).	  	  Patients	  all	  have	  
excellent	  myocardial	  suppression	  allowing	  uptake	  to	  be	  visualized	  in	  the	  patients	  with	  aortic	  valve	  disease.	  
Regions	  of	  interest	  have	  been	  drawn	  using	  both	  the	  short-­‐axis	  and	  centre-­‐valve	  techniques	  (green	  lines).	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Box-­‐plots	  show	  the	  median	  and	  interquartile	  ranges	  of	  the	  tissue-­‐to-­‐background	  ratios	  (TBR)	  for	  18F-­‐NaF	  (white	  boxes)	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18F-NaF
18F-FDG
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Table	  3.4.	  Correlation	  between	  aortic	  stenosis	  severity	  and	  radiotracer	  uptake	  
SUV,	  standard	  uptake	  value;	  TBR,	  tissue-­‐to-­‐background	  ratio.	  Median	  ±interquartile	  range.	  Pearson’s	  correlation.	  	  
	   	  




Aortic	  Stenosis	   Correlation	  with	  
peak	  
aortic-­‐jet	  velocity	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   Moderate	   Severe	  
r2	  value	   P	  value	  
18F-­‐NaF	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Ex-­‐vivo	  studies	  
18F-­‐NaF	  uptake	  was	  consistent	  on	  both	  the	  in	  vivo	  and	  ex	  vivo	  PET/CT	  scans.	  Furthermore	  uptake	  co-­‐
localized	  with	  the	  distribution	  of	  osteocalcin	  staining	  on	  histology,	  extending	  beyond	  the	  boundaries	  
of	  existing	  macroscopic	  calcification	  (Figure	  3.4).	  The	  pattern	  of	  valvular	  18F-­‐FDG	  uptake	  was	  again	  
consistent	  between	  in-­‐vivo	  and	  ex-­‐vivo	  PET/CT	  scans.	  Furthermore	  activity	  mapped	  closely	  to	  areas	  of	  
increased	  macrophage	  density	  on	  immunohistochemistry	  (Figure	  3.5).	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Figure	  3.4	  
	  
A	  Excised	  portion	  of	  a	  stenotic	  bicuspid	  aortic	  valve	  removed	  at	  the	  time	  of	  an	  aortic	  valve	  and	  root	  replacement.	  
The	  aortic	  side	  of	  one	  of	  the	  valve	  leaflets	  is	  shown.	  	  
B	  Immunohistochemistry	  of	  the	  valve	  for	  osteocalcin	  in	  a	  region	  of	  the	  valve	  adjacent	  to	  a	  calcific	  nodule.	  
Osteocalcin	  is	  incorporated	  in	  to	  the	  bone	  matrix	  where	  it	  binds	  to	  hydroxyapatite	  during	  active	  mineralization.	  
Osteocalcin	  immunoreactivity	  can	  be	  seen	  at	  the	  periphery	  of	  the	  existing	  calcified	  nodule.	  Inset	  (black	  border)	  
shows	  cytoplasmic	  staining	  of	  cells	  adjacent	  to	  this.	  C.	  Immunohistochemistry	  in	  a	  region	  remote	  from	  existing	  
calcification	  with	  no	  staining	  present.	  This	  focal	  distribution	  of	  staining	  matches	  the	  pattern	  of	  18F-­‐NaF	  activity	  in	  
the	  valve	  on	  both	  the	  in	  vivo	  and	  ex	  vivo	  scans	  described	  below.	  	  
D.	  In	  vivo	  18F-­‐NaF	  PET/CT	  scan	  performed	  3	  months	  prior	  to	  the	  operation.	  	  Note	  the	  focal	  areas	  of	  uptake	  overlying	  
the	  area	  of	  calcification	  at	  the	  bottom	  left	  of	  the	  valve	  and	  adjacent	  to	  the	  smaller	  area	  of	  calcification	  in	  the	  top	  
right.	  This	  closely	  matches	  the	  pattern	  of	  uptake	  observed	  on	  the	  ex	  vivo	  PET/CT	  scan	  performed	  on	  the	  excised	  
valve	  (E).	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Figure	  3.5	  
	  	  
A.	  Excised	  portion	  of	  the	  same	  aortic	  valve	  as	  in	  Figure	  1.	  	  
B.	  Immunohistochemistry	  for	  CD	  68	  in	  a	  region	  of	  the	  valve	  adjacent	  to	  a	  calcific	  nodule	  demonstrating	  the	  presence	  of	  
macrophages	  around	  the	  lesion	  in	  the	  fibrosa	  of	  the	  valve	  leaflet.	  C.	  Immunohistochemistry	  in	  a	  region	  remote	  from	  
existing	  calcification,	  which	  again	  displays	  staining	  for	  macrophages.	  	  D.	  In	  vivo	  18F-­‐FDG	  PET/CT	  of	  the	  valve	  shows	  a	  more	  
diffuse	  pattern	  of	  uptake	  than	  for	  18F-­‐NaF	  matching	  the	  distribution	  of	  macrophages	  as	  well	  as	  the	  pattern	  of	  uptake	  
observed	  in	  the	  ex	  vivo	  PET/CT	  scan	  of	  the	  excised	  valve	  tissue	  (E).	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3.5	  Discussion	  
	  
In	  this	  PET	  study,	  we	  have	  established	  the	  feasibility	  of	  evaluating	  18F-­‐NaF	  and	  18F-­‐FDG	  activity	  in	  
patients	  with	  aortic	  stenosis.	  Moreover	  we	  have	  demonstrated	  excellent	  reproducibility	  for	  the	  
quantification	  of	  these	  tracers	  in	  the	  valve	  as	  measures	  of	  calcification	  and	  inflammation	  respectively.	  	  
18F-­‐NaF	  and	  18F-­‐FDG	  activity	  was	  increased	  in	  patients	  with	  both	  aortic	  sclerosis	  and	  stenosis,	  
displaying	  a	  progressive	  rise	  in	  uptake	  with	  increasing	  disease	  severity.	  However,	  calcification	  rather	  
than	  inflammation	  appears	  to	  be	  the	  predominant	  process	  affecting	  the	  valve	  particularly	  in	  the	  
latter	  stages	  of	  the	  disease	  where	  a	  more	  marked	  progression	  in	  18F-­‐NaF	  activity	  was	  observed	  that	  
was	  disproportionate	  to	  18F-­‐FDG.	  	  
	  
Valve	  calcification	  plays	  a	  key	  role	  in	  the	  development	  of	  aortic	  stenosis.	  Hydroxyapatite	  becomes	  
deposited	  on	  a	  bone-­‐like	  matrix	  containing	  collagen,	  osteopontin	  and	  other	  bone	  matrix	  proteins45,	  46,	  
51	  to	  form	  nodules	  that	  progress	  until,	  by	  the	  end	  stage	  of	  the	  disease,	  lamellar	  bone,	  microfractures	  
and	  haemopoeitic	  tissue	  can	  all	  be	  identified.46	  This	  appears	  to	  occur	  as	  part	  of	  a	  highly	  regulated	  
process,	  coordinated	  by	  increased	  osteoblast	  activity43,	  44	  and	  the	  local	  production	  of	  osteopontin,	  
osteocalcin,	  bone	  sialoprotein	  and	  bone	  morphogenic	  protein	  2	  (BMP-­‐2),	  all	  of	  which	  are	  more	  
commonly	  associated	  with	  skeletal	  bone	  formation.44-­‐47	  Established	  aortic	  valve	  calcium	  can	  be	  
measured	  accurately	  using	  CT30	  but	  measurement	  of	  18F-­‐NaF	  uptake	  offers,	  for	  the	  first	  time,	  the	  
possibility	  of	  detecting	  areas	  of	  developing	  	  calcification	  within	  the	  valve.	  In	  this	  study,	  18F-­‐NaF	  
uptake	  was	  observed	  in	  regions	  adjacent	  to,	  and	  remote	  from,	  existing	  calcium	  suggesting	  expansion	  
of	  the	  calcific	  process	  to	  new	  areas	  of	  the	  valve.	  In	  addition,	  uptake	  was	  observed	  in	  regions	  
overlapping	  with	  that	  of	  established	  calcium,	  and	  in	  these	  areas,	  activity	  is	  likely	  to	  represent	  calcium	  
remodelling	  and	  maturation	  of	  the	  calcific	  process.	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18F-­‐NaF	  activity	  was	  increased	  in	  the	  valves	  of	  patients	  with	  aortic	  sclerosis	  and	  stenosis	  compared	  to	  
control	  subjects	  and	  demonstrated	  a	  marked	  progressive	  rise	  with	  increasing	  disease	  severity	  
accounting	  for	  more	  than	  50%	  of	  the	  variance	  associated	  with	  valve	  stenosis.	  Moreover,	  increased	  
valvular	  18F-­‐NaF	  activity	  was	  observed	  in	  45%	  of	  patients	  with	  aortic	  sclerosis,	  91%	  of	  patients	  with	  
aortic	  stenosis	  and	  all	  patients	  with	  severe	  stenosis.	  Calcium	  accumulation	  is	  the	  predominant	  
mechanism	  by	  which	  valve	  cusp	  rigidity	  increases	  and	  aortic	  stenosis	  advances.	  As	  such,	  this	  
technique	  offers	  considerable	  promise	  as	  a	  biomarker	  of	  disease	  activity	  and	  as	  a	  means	  of	  predicting	  
disease	  progression.	  Longitudinal	  studies	  are	  now	  required	  to	  determine	  whether	  calcification	  
activity	  quantified	  by	  18F-­‐NaF	  uptake	  is	  an	  accurate	  predictor	  of	  disease	  progression	  and	  superior	  to	  
baseline	  measures	  of	  valve	  severity	  and	  calcium	  scores.	  If	  confirmed,	  these	  studies	  would	  pave	  the	  
way	  for	  mechanistic	  studies	  of	  medical	  interventions	  to	  interrupt	  progressive	  calcific	  disease	  using	  
18F-­‐NaF	  activity	  as	  a	  surrogate	  biomarker	  and	  end-­‐point.	  Interscan	  repeatability	  will	  however	  first	  
need	  to	  be	  established	  in	  order	  to	  power	  these	  studies.	  	  
	  
In	  the	  early	  stages	  of	  aortic	  stenosis,	  endothelial	  damage	  secondary	  to	  mechanical	  stress	  and	  lipid	  
deposition	  triggers	  an	  inflammatory	  response	  within	  the	  valve.	  This	  is	  characterized	  by	  increased	  
macrophage13	  and	  T-­‐cell	  activity	  within	  the	  valve	  leaflets,	  and	  the	  expression	  of	  a	  range	  of	  pro-­‐
inflammatory	  cytokines	  including	  TGF-­‐β1,14	  TNF-­‐α	  and	  interleukin-­‐1β.15	  The	  inflammatory	  response	  is	  
thought	  to	  trigger	  the	  fibrotic	  and	  calcific	  processes	  that	  subsequently	  drive	  valve	  orifice	  narrowing.	  
Thus,	  identifying	  and	  quantifying	  valvular	  inflammation	  with	  18F-­‐FDG	  has	  the	  potential	  to	  be	  critical	  
in	  the	  evaluation	  of	  aortic	  stenosis.	  In	  the	  present	  study,	  18F-­‐FDG	  uptake	  was	  higher	  in	  patients	  with	  
aortic	  sclerosis	  and	  stenosis	  compared	  to	  control	  subjects,	  and	  activity	  again	  rose	  with	  increasing	  
valve	  severity.	  However,	  this	  association	  was	  weaker	  and	  the	  increase	  in	  activity	  more	  modest	  than	  
for	  18F-­‐NaF.	  Indeed	  increased	  valvular	  18F-­‐FDG	  activity	  was	  only	  observed	  in	  20%	  of	  patients	  with	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aortic	  sclerosis,	  35%	  of	  patients	  with	  aortic	  stenosis	  and	  52%	  of	  patients	  with	  severe	  stenosis.	  Whilst	  
this	  may	  reflect	  the	  high	  cut-­‐off	  used	  for	  increased	  activity	  or	  an	  insensitivity	  of	  18F-­‐FDG	  in	  detecting	  
inflammation,	  these	  data	  would	  suggest	  that	  calcification	  is	  the	  predominant	  pathogenic	  process	  in	  
aortic	  stenosis	  and	  a	  better	  target	  for	  novel	  therapeutic	  strategies.	  It	  might	  also	  explain	  the	  
disappointing	  results	  of	  statin	  therapy	  in	  this	  condition,	  which	  has	  consistently	  failed	  to	  modify	  
vascular	  calcification	  even	  in	  the	  coronary	  circulation	  despite	  reducing	  systemic	  markers	  of	  
inflammation.91-­‐93	  94	  	  	  
	  
A	  recent	  retrospective	  study	  has	  described	  increased	  18F-­‐FDG	  uptake	  in	  the	  valves	  of	  42	  patients	  
with	  cancer	  who	  were	  co-­‐incidentally	  found	  to	  have	  aortic	  stenosis.132	  However	  in	  contrast	  to	  our	  
study,	  a	  reduction	  in	  activity	  was	  observed	  in	  patients	  with	  severe	  compared	  to	  moderate	  disease.	  
This	  difference	  is	  likely	  to	  reflect	  the	  small	  number	  of	  subjects	  in	  the	  severe	  subgroup	  (n=8),	  the	  
retrospective	  nature	  of	  the	  study	  analysis	  as	  well	  as	  the	  confounding	  effects	  of	  co-­‐existent	  
malignancy.	  In	  contrast,	  we	  have	  prospectively	  recruited	  a	  larger	  well-­‐defined	  cohort	  of	  patients	  with	  
aortic	  stenosis	  who	  are	  more	  likely	  to	  be	  representative	  of	  those	  seen	  in	  cardiology	  practice.	  
Moreover,	  we	  studied	  patients	  following	  dietary	  restriction	  to	  minimize	  effects	  of	  myocardial	  uptake	  
and	  spillover	  into	  the	  valve.	  Our	  data	  are	  in	  keeping	  with	  a	  modest	  yet	  sustained	  and	  progressive	  





By	  excluding	  a	  part	  of	  the	  valve,	  it	  is	  possible	  that	  the	  centre-­‐valve	  technique	  employed	  for	  18F-­‐FDG	  
analysis	  may	  be	  underestimating	  valvular	  inflammation.	  However,	  there	  were	  no	  differences	  in	  mean	  
uptake	  values	  compared	  to	  the	  short-­‐axis	  technique.	  This	  reflects	  the	  diffuse	  nature	  of	  18F-­‐FDG	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activity	  in	  stenotic	  valves	  and	  the	  equal	  distribution	  of	  lesions	  between	  the	  base	  of	  the	  valve	  leaflets	  
(54%),	  and	  the	  mid-­‐portion	  and	  tips	  (46%).7	  	  	  
This	  study	  has	  not	  fully	  validated	  18F-­‐FDG	  and	  18F-­‐NaF	  activity	  against	  histological	  samples.	  Whilst	  
the	  mechanism	  of	  uptake	  for	  both	  tracers	  has	  been	  investigated	  in	  other	  tissues,	  further	  work	  is	  
required	  in	  the	  valve	  to	  address	  this	  issue.	  
	  	  
Conclusion	  
The	  evaluation	  of	  aortic	  stenosis	  using	  PET	  is	  feasible	  and	  highly	  reproducible	  with	  18F-­‐FDG	  and	  in	  
particular	  18F-­‐NaF	  holding	  considerable	  promise	  as	  novel	  biomarkers	  of	  disease	  activity.	  Both	  
calcification	  and	  inflammation	  are	  increased	  in	  patients	  with	  aortic	  valve	  disease	  compared	  to	  control	  
subjects	  and	  the	  activity	  of	  both	  steadily	  rises	  with	  increasing	  disease	  severity.	  However,	  calcification	  
appears	  to	  be	  the	  predominant	  pathological	  process	  particularly	  in	  the	  latter	  stages	  of	  the	  disease	  
and	  would	  therefore	  appear	  to	  be	  a	  better	  target	  for	  future	  potential	  medical	  therapies.	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4.1	  Summary	  
Objective	  	  
Using	   combined	   positron	   emission	   tomography	   (PET)	   and	   computed	   tomography	   (CT),	   we	  
investigated	  coronary	  arterial	  uptake	  of	  18F-­‐sodium	  fluoride	   (18F-­‐NaF)	  and	  18F-­‐fluorodeoxyglucose	  
(18F-­‐FDG)	  as	  markers	  of	  active	  plaque	  calcification	  and	  inflammation	  respectively.	  
	  
Background	  	  
The	   non-­‐invasive	   assessment	   of	   coronary	   artery	   plaque	   biology	   would	   be	   a	   major	   advance	  
particularly	  in	  the	  identification	  of	  vulnerable	  plaques,	  which	  are	  associated	  with	  specific	  pathological	  
characteristics	  including	  micro-­‐calcification	  and	  inflammation.	  
	  
Methods	  	  
We	  prospectively	  recruited	  119	  volunteers	  (age	  72±8,	  68%	  male)	  with	  and	  without	  aortic	  valve	  
disease	  and	  measured	  their	  coronary	  calcium	  score	  and	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake.	  
Patients	  with	  a	  calcium	  score	  of	  0	  were	  used	  as	  controls	  and	  compared	  to	  those	  with	  calcific	  
atherosclerosis	  (ca	  score	  >0).	  
	  
Results	  	  
Inter-­‐observer	  reproducibility	  of	  coronary	  18F-­‐NaF	  uptake	  measurements	  (maximum	  tissue-­‐to-­‐
background	  ratio)	  were	  excellent	  (intra-­‐class	  co-­‐efficient	  0.99).	  Activity	  was	  higher	  in	  patients	  with	  
coronary	  atherosclerosis	  (n=106)	  versus	  controls	  (1.64±0.49	  vs	  1.23±0.24;	  P=0.003)	  and	  correlated	  
with	  the	  calcium	  score	  (r=0.652,	  p<0.001),	  although	  40%	  of	  those	  with	  scores	  >1000	  displayed	  normal	  
uptake.	  Patients	  with	  increased	  coronary	  18F-­‐NaF	  activity	  (n=40)	  had	  higher	  rates	  of	  prior	  
cardiovascular	  events	  (p=0.016)	  and	  angina	  (p=0.023),	  and	  higher	  Framingham	  risk	  scores	  (p=0.011).	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Quantification	  of	  coronary	  18F-­‐FDG	  uptake	  was	  hampered	  by	  myocardial	  activity	  and	  was	  not	  
increased	  in	  patients	  with	  atherosclerosis	  versus	  controls	  (p=0.498).	  	  
	  
Conclusions	  	   	  
18F-­‐NaF	  is	  a	  promising	  new	  approach	  for	  the	  assessment	  of	  coronary	  artery	  plaque	  biology.	  
Prospective	  studies	  with	  clinical	  outcomes	  are	  now	  needed	  to	  assess	  whether	  coronary	  18F-­‐NaF	  
uptake	  represents	  a	  novel	  marker	  of	  plaque	  vulnerability,	  recent	  plaque	  rupture	  and	  future	  
cardiovascular	  risk.	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4.2	  Introduction	  	  
Myocardial	  infarction	  (MI)	  is	  the	  foremost	  cause	  of	  death	  in	  developed	  countries138	  and	  confers	  a	  
major	  economic,	  social	  and	  healthcare	  burden	  worldwide.139	  The	  majority	  of	  myocardial	  infarctions	  
result	  from	  rupture	  of	  atherosclerotic	  plaque	  although	  identifying	  those	  at	  risk	  of	  rupture	  is	  
problematic.	  The	  vast	  majority	  (86%)	  of	  culprit	  atherosclerotic	  lesions	  cause	  non-­‐flow	  limiting	  luminal	  
stenosis140,	  141	  that	  will	  not	  be	  detected	  by	  non-­‐invasive	  stress	  testing.	  New	  methods	  focusing	  on	  
plaque	  pathology	  are	  required	  to	  identify	  high-­‐risk	  lesions	  so	  that	  risk	  of	  clinical	  events	  can	  be	  
reduced	  by	  appropriate	  therapy.	  
	  
Calcification	  is	  a	  key	  feature	  of	  human	  atherosclerosis	  and	  its	  macroscopic	  presence	  in	  the	  coronary	  
arteries	  can	  be	  detected	  by	  cardiac	  computed	  tomography	  (CT).	  Coronary	  artery	  calcium	  scoring	  
(CAC)	  provides	  a	  surrogate	  measure	  of	  the	  atherosclerotic	  burden	  and	  a	  powerful	  predictor	  of	  
cardiovascular	  risk.142	  Risk	  prediction	  can	  be	  improved	  by	  examining	  the	  progression	  of	  coronary	  
calcification143,	  144	  and	  by	  detecting	  spotty	  calcification.145	  However	  CT	  is	  unable	  to	  measure	  active	  
calcification	  directly,	  nor	  can	  it	  reliably	  detect	  microcalcifications	  that	  can	  lead	  to	  microfractures	  and	  
acute	  thrombosis.146-­‐148	  18F-­‐NaF	  is	  an	  established	  PET	  tracer	  that	  detects	  novel	  areas	  of	  bone	  
formation	  and	  remodelling.149	  Uptake	  has	  also	  been	  described	  in	  aortic	  and	  carotid	  atheroma	  where	  
activity	  is	  believed	  to	  signal	  areas	  of	  active	  vascular	  calcification	  although	  this	  is	  hypothetical.111,	  112,	  
150	  To	  date,	  18F-­‐NaF	  uptake	  has	  not	  been	  measured	  in	  the	  coronary	  vasculature.	  	  	  
	  
Inflammation	  is	  thought	  to	  play	  a	  key	  role	  in	  plaque	  rupture.	  Histologically,	  the	  vulnerable	  plaque	  is	  
characterized	  by	  a	  lipid-­‐rich	  pool,	  infiltration	  of	  inflammatory	  cells	  and	  a	  thin	  fibrous	  cap.141	  
Macrophages	  in	  particular	  are	  found	  in	  abundance	  within	  ruptured	  plaques	  and	  are	  thought	  to	  
contribute	  to	  a	  pro-­‐thrombotic	  state	  and	  degradation	  of	  the	  fibrous	  cap	  via	  the	  action	  of	  matrix	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metalloproteinases	  (MMP).151	  Vascular	  inflammation	  can	  be	  assessed	  non-­‐invasively	  in	  the	  carotid	  
arteries,	  aorta,	  iliac	  and	  femoral	  arteries	  using	  uptake	  of	  18F-­‐fluorodeoxyglucose	  (18F-­‐FDG)	  as	  
measured	  by	  combined	  positron	  emission	  tomography	  (PET)	  and	  computed	  tomography	  (CT).98	  18F-­‐
FDG	  uptake	  correlates	  with	  plaque	  macrophage	  burden,100	  symptoms,99	  and	  Framingham	  Risk	  Score	  
152	  and	  can	  be	  lowered	  with	  statin	  and	  other	  therapies.19,	  153	  Recent	  in	  vitro	  and	  ex	  vivo	  data	  have	  also	  
suggested	  that	  18F-­‐FDG	  uptake	  may	  reflect	  plaque	  hypoxia.154	  However,	  measurement	  of	  18F-­‐FDG	  
uptake	  within	  coronary	  atheroma	  is	  challenging	  because	  of	  cardiac	  and	  respiratory	  motion,	  and	  the	  
intense	  myocardial	  18F-­‐FDG	  uptake	  that	  can	  potentially	  swamp	  any	  plaque	  signal.106,	  155	  	  
	  
The	  aim	  of	  this	  study	  was	  to	  investigate	  coronary	  arterial	  uptake	  of	  18F-­‐NaF	  and	  18F-­‐FDG	  as	  markers	  
of	  active	  calcification	  and	  inflammation	  respectively.	  We	  hypothesized	  that	  the	  degree	  of	  uptake	  of	  
both	  tracers	  would	  correlate	  with	  atherosclerotic	  disease	  severity,	  symptoms,	  prior	  cardiovascular	  
events	  and	  predictors	  of	  future	  clinical	  risk.	  Coronary	  atherosclerosis	  and	  aortic	  stenosis	  commonly	  
co-­‐exist	  and	  so	  this	  study	  was	  conducted	  in	  a	  cohort	  of	  patients	  with	  aortic	  valve	  disease	  originally	  
recruited	  to	  study	  PET	  uptake	  in	  the	  valve.	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4.3	  Methods	  
Study	  Population	  
This	  was	  a	  sub-­‐study	  of	  the	  cohort	  of	  the	  121	  patients	  with	  and	  without	  aortic	  stenosis	  described	  in	  
Chapters	  2	  and	  3.156	  Coronary	  calcium	  scoring	  was	  not	  interpretable	  in	  2	  of	  the	  original	  cohort	  who	  
were	  excluded	  for	  the	  purposes	  of	  this	  present	  study.	  	  
	  
Baseline	  Clinical	  Assessment	  
Baseline	  clinical	  assessment	  was	  performed	  on	  the	  day	  of	  the	  initial	  PET/CT	  scan	  and	  included	  current	  
cardiac	  symptoms,	  prior	  coronary	  intervention	  (percutaneous	  coronary	  intervention	  and	  coronary	  
artery	  bypass	  grafting)	  and	  past	  medical	  history	  of	  previous	  major	  adverse	  cardiovascular	  events	  
(MACE;	  myocardial	  infarction,	  cerebrovascular	  accident	  and	  coronary	  revascularization).	  Atherogenic	  
risk	  factors	  such	  as	  age,	  sex,	  smoking	  habit,	  history	  of	  hypertension,	  diabetes	  mellitus,	  
hypercholesterolemia,	  socioeconomic	  status	  and	  family	  history	  of	  cardiovascular	  disease	  were	  
identified.	  Full	  external	  examination	  was	  performed,	  and	  height	  and	  weight	  measured	  to	  determine	  
body	  mass	  index	  (BMI).	  A	  12-­‐lead	  electrocardiogram	  was	  performed	  and	  venous	  blood	  collected	  for	  
measurement	  of	  serum	  creatinine,	  full	  lipid	  profile	  and	  markers	  of	  calcium	  metabolism.	  On	  the	  basis	  
of	  this	  information,	  Framingham	  risk	  scores	  for	  coronary	  heart	  disease	  (CHD),	  CHD	  death,	  
cardiovascular	  disease	  (CVD)	  and	  CVD	  death	  were	  calculated.	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PET/CT	  Image	  Acquisition	  and	  Reconstruction	  
Subjects	  underwent	  combined	  PET/CT	  imaging	  of	  the	  aorta	  and	  coronary	  arteries	  with	  18F-­‐FDG	  and	  
18F-­‐NaF	  as	  described	  in	  Chapter	  2.	  In	  addition	  an	  ECG-­‐gated	  breath-­‐hold	  CT	  scan	  (non-­‐contrast	  
enhanced,	  40	  mAs/rot	  [CareDose],	  100	  kV)	  of	  the	  coronary	  arteries	  was	  performed	  for	  calculation	  of	  
the	  calcium	  score.	  Patients	  observed	  dietary	  restrictions	  prior	  to	  their	  18F-­‐FDG	  scan	  as	  described	  in	  
Chapter	  2.	  
	  
Image	  Analysis:	  Coronary	  arteries	  
Quantification	  of	  coronary	  tracer	  uptake	  is	  described	  in	  Chapter	  2.	  Breifly	  regions	  of	  interest	  drawn	  
around	  areas	  of	  maximal	  uptake	  in	  the	  left	  main	  stem,	  left	  anterior	  descending	  artery,	  circumflex	  
artery	  and	  the	  right	  coronary	  artery.	  The	  maximum	  SUV	  and	  TBR	  values	  were	  recorded	  from	  these	  
regions.	  It	  was	  not	  possible	  to	  determine	  the	  mean	  SUV	  values	  given	  the	  difficulty	  in	  identifying	  the	  
exact	  borders	  of	  the	  coronary	  arteries	  on	  the	  non-­‐contrast	  enhanced	  scans.	  Quantification	  of	  18F-­‐
FDG	  uptake	  was	  performed	  as	  for	  18F-­‐NaF	  but	  restricted	  to	  the	  proximal	  and	  mid-­‐portions	  of	  the	  
coronary	  vessels.106	  Difficulties	  were	  still	  encountered	  as	  a	  result	  of	  the	  pervasive	  myocardial	  uptake	  
observed	  with	  this	  tracer	  and	  coronary	  activity	  was	  only	  quantified	  in	  areas	  where	  myocardial	  uptake	  
could	  be	  confidently	  avoided.	  Quantification	  of	  the	  coronary	  calcium	  score	  is	  described	  in	  Chapter	  2.	  	  
	  
	  
Inter-­‐observer	  reproducibility	  of	  image	  analysis	  	  
Having	  established	  the	  image	  analysis	  methodology,	  PET	  scans	  from	  20	  patients	  were	  selected	  at	  
random	  from	  the	  cohort.	  All	  scans	  from	  these	  patients	  were	  analyzed	  independently	  by	  two	  trained	  
observers	  (MD,	  NJ).	  This	  provided	  measures	  of	  inter-­‐observer	  reproducibility	  for	  maximum	  TBR	  
values.	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Image	  Analysis:	  Aorta	  
The	  uptake	  18F-­‐FDG157	  and	  18F-­‐NaF150	  in	  the	  ascending	  and	  descending	  aorta	  was	  quantified	  as	  




Comparisons	  of	  tracer	  uptake	  were	  initially	  made	  between	  those	  with	  and	  without	  calcific	  
atherosclerosis.	  Patients	  with	  coronary	  artery	  calcium	  scores	  >0	  or	  a	  prior	  history	  of	  ischemic	  heart	  
disease	  were	  considered	  to	  have	  underlying	  calcific	  coronary	  atherosclerosis.	  Patients	  with	  a	  
coronary	  artery	  calcium	  score	  of	  0	  and	  no	  past	  history	  of	  coronary	  heart	  disease	  were	  considered	  not	  
to	  have	  calcific	  atherosclerosis	  and	  designated	  as	  controls.	  Patients	  with	  atherosclerosis	  were	  then	  
divided	  according	  to	  well-­‐established	  cutoffs	  in	  the	  coronary	  calcium	  score	  (0,	  1-­‐100,	  101-­‐400,	  401-­‐
1000,	  >1000)158	  in	  order	  of	  assess	  the	  impact	  of	  disease	  severity	  on	  tracer	  activity.	  Finally	  
comparisons	  were	  made	  between	  subjects	  who	  had	  normal	  and	  increased	  18F-­‐NaF	  uptake.	  The	  
highest	  maximum	  TBR	  value	  in	  the	  control	  group	  was	  used	  as	  the	  cut-­‐off	  value	  above	  which	  18F-­‐NaF	  
was	  deemed	  to	  be	  elevated.	  In	  patients	  with	  underlying	  calcific	  coronary	  atherosclerosis,	  those	  who	  
had	  increased	  18F-­‐NaF	  uptake	  were	  defined	  as	  having	  active	  coronary	  calcification	  whilst	  those	  with	  
normal	  18F-­‐NaF	  uptake	  were	  defined	  as	  having	  inactive	  calcification.	  	  
	  
Continuous	  variables	  were	  expressed	  as	  mean	  ±	  SD	  and	  compared	  using	  unpaired	  Student’s	  t-­‐test	  or	  
one-­‐way	  analysis	  of	  variance	  where	  appropriate.	  	  Categorical	  variables	  were	  expressed	  as	  
percentages	  and	  analyzed	  using	  the	  χ2-­‐test.	  Correlations	  between	  normally	  distributed	  data	  were	  
performed	  using	  Pearson’s	  correlation,	  whilst	  Spearman’s	  correlation	  was	  used	  for	  non-­‐parametric	  
data.	  The	  95%	  confidence	  interval	  for	  differences	  between	  sets	  of	  SUV	  and	  TBR	  measurements	  were	  
calculated	  along	  with	  intra-­‐class	  correlation	  coefficients.	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4.4	  Results	  
Baseline	  Characteristics	  
One	  hundred	  and	  nineteen	  patients	  were	  studied	  (age	  72±8	  years,	  68%	  male;	  66%	  with	  aortic	  
stenosis)	  and	  had	  both	  18F-­‐NaF	  (66±6	  min	  after	  124±10	  MBq)	  and	  18F-­‐FDG	  (94±7	  min	  after	  198±13	  
MBq)	  scans	  of	  their	  thorax	  less	  than	  one	  month	  apart	  (median	  7	  days,	  interquartile	  range	  1	  to	  14	  
days).	  The	  effective	  radiation	  dose	  per	  patient,	  including	  all	  PET	  and	  CT	  scans,	  was	  9.73±1.19	  mSv	  
using	  a	  CT	  conversion	  factor	  of	  0.014	  mSv/mGy/cm.	  	  
	  
Thirteen	  patients	  had	  no	  past	  history	  of	  coronary	  artery	  disease	  or	  evidence	  of	  calcific	  coronary	  
atherosclerosis,	  and	  formed	  the	  control	  group	  (Table	  4.1).	  One	  hundred	  and	  six	  patients	  had	  evidence	  
of	  coronary	  atherosclerosis:	  41	  having	  a	  clinical	  diagnosis	  of	  prior	  coronary	  artery	  disease,	  and	  a	  
further	  65	  having	  calcium	  scores	  above	  zero.	  One	  patient	  had	  experienced	  an	  acute	  coronary	  




Average	  myocardial	  SUV	  across	  the	  entire	  cohort	  was	  4.6±3.6	  and	  dietary	  restrictions	  effectively	  
suppressed	  18F-­‐FDG	  myocardial	  uptake	  (pre-­‐specified	  as	  a	  max	  SUV	  <5	  measured	  in	  the	  maximal	  area	  
of	  uptake	  in	  the	  left	  ventricular	  septum)	  in	  67%	  of	  patients,	  similar	  to	  that	  seen	  in	  previous	  studies.106	  
Based	  on	  dietary	  diaries,	  61%	  of	  patients	  complied	  with	  the	  dietary	  restrictions	  and	  had	  lower	  
myocardial	  18F-­‐FDG	  uptake	  than	  non-­‐compliers	  (SUV	  3.2±2.3	  vs	  6.7±4.2;	  P<0.001).	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Table	  4.1.	  Patient	  Demographics	  
	  
Hypercholesterolemia	  %	   49	   38	   39	   39	   59	   	  	  	  57	  
Aortic	  Stenosis	  %	   66	   54	   58	   61	   78	   73	  
Aortic	  Sclerosis	  %	   17	   23	   11	   22	   11	   19	  
ACEi	  /	  ARB	  %	   49	   15	   21	   39	   56	   76	  
Beta-­‐blockers	  %	   39	   15	   26	   48	   44	   46	  
Statins	  %	   53	   15	   21	   52	   67	   73	  
Total	  Cholesterol	  mg/dL	   193	  ±50	   227	  ±48	   199	  ±41	   204	  ±57	   175	  ±44	   181	  ±49	  
LDL	  Cholesterol	  mg/dL	   104	  ±44	   123	  ±45	   119	  ±37	   112	  ±52	   93	  ±36	   94	  ±42	  
HDL	  Cholesterol	  mg/dL	   54±20	   69	  ±42	   54	  ±12	   52	  ±15	   54	  ±18	   51	  ±12	  
	   TOTAL	   CONTROL	   ATHEROSCLEROSIS	  










Number	   119	   13	   19	   23	   27	   37	  
Age	  (years)	   72	  ±8	   66	  ±7	   69	  ±8	   72	  ±8	   70	  ±9	   76	  ±7	  
Male	  %	   68	   46	   58	   61	   74	   81	  
BMI	   28	  ±4	   28	  ±4	   28	  ±3	   28	  ±4	   28	  ±4	   27	  ±5	  
Coronary	  Heart	  Disease	  %	   34	   0	   0	   17	   48	   65	  
Angina	  %	   24	   0	   0	   13	   37	   43	  
MACE	  %	   40	   0	   0	   32	   44	   75	  
	   Previous	  MI	  %	  	   12	   0	   0	   9	   11	   24	  
	   Previous	  CVA	  /	  TIA	  %	   6	   0	   0	   14	   4	   8	  
	   Previous	  PCI	  %	   15	   0	   0	   9	   22	   27	  
	   Previous	  CABG	  %	   7	   0	   0	   0	   7	   16	  
Smokers	  (ex	  or	  current)	  %	   50	   38	   53	   26	   59	   59	  
Diabetes	  %	   15	   23	   5	   13	   12	   22	  
Hypertension	  %	   60	   38	   42	   65	   52	   57	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   TOTAL	   CONTROL	   ATHEROSLEROSIS	  







	  	  	  	  	  	  	  401-­‐1000	  
Ca	  Score	  
>1000	  
Calcium	  mg/dL	   9.30±0.57	   9.41	  ±0.23	   9.41	  ±0.97	   9.29	  ±0.61	   9.24	  ±0.32	   9.24	  ±0.49	  
Phosphate	  mg/dL	   3.55±0.49	   3.68	  ±0.55	   3.57	  ±0.55	   3.51	  ±0.40	   	  	  	  	  	  	  3.53	  ±0.40	   3.54	  ±0.48	  
Alk	  Phosphatase	  U/L	   84	  ±44	   93	  ±23	   83	  ±25	   79	  ±20	   80	  ±23	   77	  ±27	  












18F-­‐NaF	  SUV	   1.56	  ±0.50	   1.21	  ±0.26	   1.28	  ±0.27	   1.40±0.27	   1.49±0.31	   1.97	  ±0.60	  
18F-­‐NaF	  TBR	  	   1.59	  ±0.48	   1.23	  ±0.22	   1.33	  ±0.32	   1.42	  ±0.27	   1.59	  ±0.29	   1.97	  ±0.58	  
Patients	  with	  increased	  
coronary	  18F-­‐NaF	  %	  
34%	   0%	   5%	   26%	   41%	   59%	  
18F-­‐FDG	  SUV	   1.54	  ±0.24	   1.43	  ±0.30	   1.56	  ±0.19	   1.55	  ±0.27	   1.46	  ±0.24	   1.60	  ±0.22	  
18F-­‐FDG	  TBR	   1.22	  ±0.21	   1.18	  ±0.31	   1.25	  ±0.18	   1.19	  ±0.16	   1.22	  ±0.29	   1.24	  ±0.15	  
10yr	  Framingham	  Risk	  Scores	   	   	   	   	   	   	  
	   CVD	  	   30	  ±13	   25	  ±17	   27	  ±13	   31	  ±10	   27	  ±12	   35	  ±13	  
	   CVD	  Death	  	   14	  ±10	   8	  ±9	   11	  ±8	   14	  ±8	   12	  ±10	   18	  ±11	  
	   CHD	  	   19	  ±12	   16±15	   18	  ±11	   20	  ±10	   18	  ±12	   22	  ±12	  
	   CHD	  Death	  	   6.3	  ±4.7	   4.5	  ±5.4	   5.2	  ±3.9	   6.3	  ±3.6	   5.3	  ±4.4	   8.3	  ±5.1	  
Mean	  ±SD	  unless	  stated.	  *median	  ±	  IQR,	  Ca	  score=Agatston	  Coronary	  Calcium	  Score,	  BMI=Body	  mass	  index,	  MACE=Major	  
Adverse	  Cardiovascular	  Events,	  MI=Myocardial	  Infarction,	  CVA=Cerebrovascular	  accident,	  TIA=Transient	  Ischemic	  Attack,	  
PCI=Percutaneous	   Coronary	   Intervention,	   CABG=Coronary	   artery	   bypass	   graft,	   ACEi=ACE	   inhibitors,	   ARB=Angiotensin	  
Receptor	  Blocker,	  LDL=Low	  Density	  Lipoprotein,	  HDL=High	  Density	  Lipoprotein,	  Alk=Alkaline,	  CVD=Cardiovascular	  Disease,	  
CHD=Coronary	  Heart	  Disease.	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18F-­‐NaF	  Coronary	  Uptake	  
Coronary	  18F-­‐NaF	  uptake	  was	  quantifiable	  in	  96%	  of	  the	  coronary	  territories	  examined.	  It	  was	  not	  
possible	  to	  assess	  the	  left	  main	  stem	  in	  20	  patients	  due	  to	  overspill	  of	  activity	  from	  the	  aortic	  valve	  
secondary	  to	  calcific	  aortic	  stenosis	  (Table	  4.2).	  Reproducibility	  studies	  were	  excellent	  for	  coronary	  
18F-­‐NaF	  quantification	  with	  no	  fixed	  or	  proportional	  biases,	  limits	  of	  agreement	  of	  ±0.14	  for	  
maximum	  TBR	  values	  (Figure	  4.1)	  and	  an	  ICC	  value	  of	  0.99	  (0.98-­‐1.00).	  Limits	  of	  agreement	  for	  18F-­‐
NaF	  were	  in	  the	  order	  ±0.20	  when	  examined	  in	  each	  of	  the	  coronary	  territories	  (Table	  4.2).	  
	  
18F-­‐NaF	  activity	  was	  observed	  in	  areas	  overlying,	  adjacent	  to	  and	  remote	  from	  existing	  coronary	  
calcification.	  Uptake	  was	  focal	  in	  nature	  and	  could	  be	  localized	  to	  individual	  calcified	  coronary	  
plaques.	  Areas	  of	  coronary	  calcification	  with	  no	  18F-­‐NaF	  uptake	  were	  also	  commonly	  observed	  
(Figure	  4.2).	  	  
	  
Coronary	  18F-­‐NaF	  uptake	  was	  higher	  in	  those	  with	  coronary	  atherosclerosis	  compared	  to	  the	  control	  
group	  	  (1.64±0.49	  vs	  1.23±0.24;	  p=0.003).	  The	  highest	  maximum	  TBR	  value	  in	  the	  control	  group	  was	  
1.61,	  which	  was	  used	  to	  divide	  patients	  with	  coronary	  atherosclerosis	  into	  those	  with	  increased	  18F-­‐
NaF	  uptake	  (active	  calcification;	  TBR	  maximum	  	  >1.61;	  n=40)	  and	  those	  without	  (inactive	  calcification;	  
TBR	  maximum	  ≤1.61;	  n=66;	  Figure	  4.2,	  Table	  4.3).	  	  
	  
Patients	  with	  increased	  18F-­‐NaF	  uptake	  were	  older,	  more	  likely	  to	  be	  male,	  and	  had	  higher	  serum	  
high-­‐density	  lipoprotein	  (HDL)	  cholesterol	  concentrations	  than	  those	  without	  increased	  uptake	  (Table	  
4.3).	  Overall	  statin	  use	  was	  similar	  between	  the	  groups	  although	  atorvastatin	  use	  appeared	  to	  be	  
double	  in	  those	  with	  active	  calcification	  (28%	  vs	  14%;	  P=0.077).	  They	  also	  had	  higher	  calcium	  scores,	  
and	  there	  was	  a	  strong	  correlation	  between	  the	  coronary	  artery	  calcium	  score	  and	  18F-­‐NaF	  uptake	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(r=0.652,	  p<0.001).	  However	  extensive	  overlap	  was	  observed,	  with	  some	  patients	  with	  increased	  18F-­‐
NaF	  uptake	  having	  relatively	  little	  coronary	  calcification	  (minimum	  Agatston	  score	  98)	  and	  patients	  
without	  18F-­‐NaF	  uptake	  having	  extensive	  calcium	  	  (maximum	  Agatston	  score	  4636).	  Indeed	  41%	  of	  
patients	  with	  coronary	  artery	  calcium	  scores	  >1000	  had	  no	  significant	  18F-­‐NaF	  uptake	  (Table	  4.1).	  	  
	  
Sites	  of	  increased	  18F-­‐NaF	  uptake	  were	  evenly	  distributed	  across	  the	  coronary	  vasculature	  (Table	  4.2)	  
and	  on	  average	  activity	  was	  50%	  higher	  in	  these	  plaques	  compared	  to	  inactive	  plaques	  in	  the	  same	  
patient	  (2.14±0.42	  vs	  1.43±0.32;	  p<0.001).	  In	  25	  patients,	  significant	  uptake	  was	  observed	  in	  two	  or	  
more	  coronary	  territories.	  	  
	  
Patients	  with	  high	  18F-­‐NaF	  uptake	  were	  more	  likely	  to	  have	  a	  clinical	  diagnosis	  of	  coronary	  artery	  
disease	  (60%	  vs	  26%;	  p<0.001),	  anginal	  symptoms	  (40%	  vs	  20%;	  p=0.023),	  prior	  revascularization	  
(38%	  vs	  11%:	  p=0.001)	  and	  previous	  major	  adverse	  cardiovascular	  events	  (45%	  vs	  23%;	  p<0.016:	  
Table	  4.3).	  	  Furthermore,	  cardiovascular	  risk	  factor	  burden	  was	  increased.	  Framingham	  risk	  prediction	  
scores	  were	  higher	  in	  those	  with	  increased	  18F-­‐NaF	  uptake	  in	  terms	  of	  Framingham	  CVD	  (p=0.043),	  
CVD	  death	  (p=0.011),	  and	  CHD	  death	  (p=0.028,	  Table	  4.4,	  Figure	  4.3).	  An	  apparent	  trend	  was	  
observed	  with	  the	  Framingham	  CHD	  score,	  but	  this	  failed	  to	  reach	  statistical	  significance.	  
Interestingly	  10-­‐year	  Framingham	  risk	  scores	  for	  CVD,	  CVD	  death	  and	  CHD	  death	  all	  displayed	  a	  
correlation	  with	  18F-­‐NaF	  coronary	  uptake	  but	  not	  with	  the	  coronary	  artery	  calcium	  score	  (Table	  4.4).	  
Framingham	  risk	  scores	  are	  not	  designed	  for	  patients	  with	  prior	  cardiovascular	  events.	  If	  these	  
patients	  were	  excluded	  from	  the	  analysis,	  risk	  scores	  were	  higher	  in	  those	  with	  active	  calcification	  for	  
both	  CHD	  (inactive	  calcification	  18.1±1.6	  vs	  active	  calcification	  25.6±2.8;	  p=0.020)	  and	  CVD	  (inactive	  
calcification	  28.8±1.9	  vs	  active	  calcification	  36.8±2.7;	  P=0.017).	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One	  patient	  was	  assessed	  1	  week	  after	  sustaining	  an	  inferior	  non-­‐ST	  elevation	  myocardial	  infarction.	  
Intense	  uptake	  was	  observed	  in	  the	  proximal	  right	  coronary	  artery,	  which	  had	  been	  felt	  clinically	  to	  
be	  the	  culprit	  coronary	  artery	  (based	  on	  dynamic	  changes	  on	  the	  electrocardiogram	  and	  appearances	  
at	  invasive	  coronary	  angiography).	  Despite	  having	  three-­‐vessel	  coronary	  artery	  disease	  and	  extensive	  
coronary	  calcification,	  relatively	  little	  uptake	  was	  observed	  in	  his	  other	  coronary	  territories	  (Figure	  
4.2).	  	  This	  artery	  had	  not	  undergone	  stenting	  prior	  to	  the	  PET	  scan.	  	  
	  	  
18F-­‐FDG	  Coronary	  Uptake	  
18F-­‐FDG	  uptake	  was	  difficult	  to	  quantify,	  particularly	  in	  the	  left	  main	  stem	  and	  circumflex	  artery.	  It	  
was	  not	  possible	  to	  quantify	  accurately	  in	  49%	  of	  the	  vessel	  territories	  examined	  (Table	  4.2).	  This	  was	  
largely	  the	  result	  of	  myocardial	  spill	  over	  into	  the	  coronary	  arteries,	  which	  was	  observed	  despite	  the	  
dietary	  restrictions	  imposed	  in	  the	  study.	  Even	  when	  possible,	  coronary	  18F-­‐FDG	  reproducibility	  was	  
inferior	  to	  that	  for	  18F-­‐NaF,	  with	  a	  fixed	  bias	  of	  0.22,	  limits	  of	  agreement	  of	  ±0.32	  and	  an	  ICC	  value	  of	  
0.67	  (0.31-­‐0.86)	  (Figure	  4.1).	  	  
	  
There	  were	  no	  differences	  in	  18F-­‐FDG	  uptake	  between	  the	  control	  group	  and	  those	  with	  
atherosclerosis	  (1.18±0.31	  vs	  1.23±0.20;	  p=0.498;	  Table	  4.1).	  Nor	  was	  there	  was	  a	  correlation	  
between	  18F-­‐FDG	  activity	  and	  the	  coronary	  artery	  calcium	  score	  whether	  in	  the	  coronary	  vasculature	  
as	  a	  whole	  (r=0.063,	  p=0.538)	  or	  on	  a	  vessel-­‐by-­‐vessel	  basis	  (LAD:	  r=-­‐0.041,	  p=0.705;	  RCA:	  r=0.039,	  
p=0.726).	  18F-­‐FDG	  coronary	  uptake	  was	  not	  associated	  with	  increased	  rates	  of	  coronary	  artery	  
disease,	  anginal	  symptoms,	  prior	  coronary	  revascularization	  or	  previous	  major	  adverse	  cardiovascular	  
events.	  Neither	  was	  there	  a	  significant	  correlation	  with	  any	  of	  the	  risk	  prediction	  scores	  (Table	  4.4).	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Table	  4.2.	  18F-­‐NaF	  and	  18F-­‐FDG	  maximum	  standard	  uptake	  values	  (SUV	  max)	  and	  tissue-­‐to-­‐
background	  ratio	  (TBR	  max)	  values	  in	  the	  coronary	  arteries,	  ascending	  aorta	  and	  descending	  aorta.	  
Inter-­‐observer	  reproducibility	  statistics	  are	  also	  provided	  for	  TBR	  max	  measurements	  in	  each	  of	  the	  
coronary	  territories	  (mean	  difference	  ±	  limits	  of	  agreement)	  
	   Coronary	  Arteries	   Ascending	  
Aorta	  	  
Descending	  
Aorta	  	  LMS	  	   	  	  	  	  LAD	   	  	  	  	  	  	  CX	  	   	  	  	  	  	  RCA	  	   ALL	  VESSELS	  
18F-­‐NaF	   	   	   	   	   	   	   	  
	   %	  interpretable	  
	  
83%	   100%	   99%	   100%	   96%	   100%	   100%	  
	   SUV	  max	  	  
	  
	  




	   TBR	  max	  
	  
	  	  




	   %	  with	  increased	  activity	  
(TBR	  >1.61)	  
	  
13%	   21%	   19%	   16%	   34%	   -­‐	   -­‐	  
	   Interobserver	  limits	  of	  
agreement	  	  
(mean	  difference	  ±	  2SD)	  
	  
0.06	  ±0.17	   0.01	  ±0.20	   0.00	  ±0.21	   0.01	  
±0.21	  
0.03	  ±0.14	   -­‐	   -­‐	  
18F-­‐FDG	   	   	   	   	   	   	   	  
	   %	  interpretable	  
	  
25%	   74%	   33%	   74%	   51%	   100%	   100%	  
	   SUV	  max	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Table	  4.3.	  Baseline	   characteristics	   and	  10-­‐year	   Framingham	   risk	   scores	  of	  patients	  with	   coronary	  
atherosclerosis	  and	  either	  normal	  (SUV≤1.61)	  or	  high	  (SUV>1.61)	  coronary	  18F-­‐NaF	  uptake.	  
	  








Age	  (years)	   71	  ±8	   75	  ±8	   0.015*	  
Male	  %	   65	   80	   0.103	  
BMI	   27	  ±4	   28	  ±5	   0.343	  
Coronary	  Heart	  Disease	  %	   26	   60	   <0.001**	  
Angina	  %	   20	   40	   0.023*	  
Major	  Adverse	  Cardiovascular	  
Events	  %	  
23	   45	   0.016*	  
	   Previous	  MI	  %	   11	   18	   0.324	  
	   Previous	  CVA	  /	  TIA	  %	   8	   5	   0.591	  
	   Previous	  PCI	  %	   9	   30	   0.005**	  
	   Previous	  CABG	  %	   2	   18	   0.003**	  
Smokers	  (ex/current)	  %	   50	   52	   0.803	  
Diabetes	  %	   12	   18	   0.410	  
Hypertension	  %	   59	   68	   0.387	  
Hypercholesterolaemia	  %	   49	   53	   0.745	  
ACEi	  /	  ARB	  %	   50	   58	   0.453	  
Β-­‐blockers	  %	   38	   50	   0.221	  
Statin	  %	   52	   68	   0.107	  
Atorvastatin	  %	   14	   28	   0.077	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Total	  Cholesterol	  mg/dL	   196	  ±48	   174	  ±48	   0.023*	  
LDL	  Cholesterol	  mg/dL	   105	  ±43	   96	  ±43	   0.288	  
HDL	  Cholesterol	  mg/dL	   55	  ±15	   48	  ±11	   0.021*	  
Creatinine	  mg/dL	   0.90	  ±0.14	   0.87	  ±0.11	   0.278	  
Calcium	  mg/dL	   9.21	  ±0.43	   9.39	  ±0.79	   0.125	  
Phosphate	  mg/dL	   3.55	  ±0.52	   3.51	  ±0.43	   0.647	  
Alkaline	  Phosphatase	  U/L	   81	  ±23	   87	  ±69	   0.473	  





Coronary	  18F-­‐NaF	  TBR	  max	   1.34	  ±0.17	   2.14	  ±0.42	   <0.001**	  
Coronary	  18F-­‐FDG	  TBR	  max	   1.23	  ±0.20	   1.23	  ±0.20	   0.875	  
10yr	  Framingham	  Risk	  Scores	   	   	   	  
	   CVD	  	   29	  ±13	   34	  ±12	   0.043*	  
	   CVD	  Death	  	   12	  ±9	   17	  ±11	   0.011*	  
	   CHD	  	   18	  ±11	   23	  ±12	   0.058	  
	   CHD	  Death	  	   5.8	  ±4.4	   7.9	  ±4.6	   0.028*	  
BMI=Body	   mass	   index,	   MACE=Major	   Adverse	   Cardiovascular	   Events,	   MI=Myocardial	   Infarction,	   CVA=Cerebrovascular	  
accident,	   TIA=Transient	   Ischemic	  Attack,	   PCI=Percutaneous	   Coronary	   Intervention,	   CABG=Coronary	   artery	   bypass	   graft,	  
ACEi=ACE	   inhibitors,	   ARB=Angiotensin	   Receptor	   Blocker,	   LDL=Low	   Density	   Lipoprotein,	   HDL=High	   Density	   Lipoprotein,	  
Alk=Alkaline,	   CVD=Cardiovascular	   Disease,	   CHD=Coronary	   Heart	   Disease.	   *p<0.05,	   **p<0.01.	   ☨median	   (interquartile	  
range)	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Table	  4.4.	  Correlation	  of	  10-­‐year	  Framingham	  risk	  scores	  with	  the	  coronary	  calcium	  score	  and	  18F-­‐























CVD=Cardiovascular	   Disease,	   CHD=Coronary	   Heart	   Disease,	   Max	   TBR=Maximum	   Tissue-­‐to-­‐Background	   Ratio.	   *p<0.05,	  
**p<0.01.	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Figure	  4.1.	  Bland	  Altman	  Plot	  of	  Inter-­‐observer	  Reproducibility	  for	  max	  TBR	  values	  for	  A)	  18F-­‐NaF	  
and	  B)	  18F-­‐FDG	  
	  
	  	  
Blue	  line	  shows	  the	  mean	  inter-­‐observer	  difference.	  Grey	  lines	  show	  the	  limits	  of	  agreement	  for	  measurements.	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Figure	  4.2.	  Fused	  PET/CT	  images	  of	  18F-­‐NaF	  activity	  in	  the	  coronary	  arteries	  	  
	  	  
A)	  Patient	  in	  the	  control	  group	  with	  no	  coronary	  calcium	  and	  no	  coronary	  18F-­‐NaF	  uptake.	  Note	  the	  intense	  uptake	  in	  the	  
vertebrae.	  
B)	  Patient	  with	  extensive	  calcification	  in	  the	  left	  anterior	  descending	  artery	  but	  no	  18F-­‐NaF	  uptake	  	  
C)	  Intense	  focal	  18F-­‐NaF	  uptake	  is	  observed	  in	  the	  proximal	  LAD	  overlying	  existing	  coronary	  calcium	  in	  this	  region	  	  
D)	  Increased	  and	  focal	  18F-­‐NaF	  uptake	  is	  observed	  in	  the	  mid-­‐LAD	  adjacent	  to	  an	  area	  of	  existing	  coronary	  calcification.	  	  
E)	  Patient	  who	  suffered	  a	  recent	  inferior	  non-­‐ST	  segment	  elevation	  myocardial	  infarction	  showing	  intense	  focal	  uptake	  of	  
the	  proximal	  right	  coronary	  artery	  with	  sparing	  of	  the	  left	  anterior	  descending	  artery.	  	  The	  proximal	  right	  coronary	  artery	  
was	  felt	  to	  be	  the	  culprit	  artery	  based	  on	  the	  electrocardiogram	  and	  appearances	  on	  coronary	  angiography	  (F),	  which	  
demonstrated	  a	  complex	  ulcerated	  plaque	  with	  in	  situ	  thrombus	  (Supplemental	  movie	  file	  1).	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Figure	  4.3.	  Ten-­‐year	  Framingham	  risk	  scores	  for	  control	  subjects	  and	  patients	  with	  atherosclerosis	  
who	  did	  and	  did	  not	  have	  increased	  18F-­‐NaF	  uptake	  
	  
Error	  bars	  denote	  the	  standard	  deviation	  of	  the	  mean	  
Aortic	  Uptake	  
18F-­‐NaF	  uptake	  in	  the	  aorta	  was	  observed	  in	  a	  focal	  distribution	  most	  commonly	  in	  areas	  overlying	  or	  
adjacent	  to	  existing	  aortic	  calcification	  (Figure	  4.4).	  Less	  frequently	  18F-­‐NaF	  uptake	  occurred	  in	  the	  
absence	  of	  local	  calcium	  (Table	  4.2;	  Figure	  4.4).	  Across	  the	  cohort	  as	  a	  whole,	  18F-­‐NaF	  uptake	  in	  the	  
aorta	  was	  higher	  than	  in	  the	  coronary	  arteries	  (2.01±0.31	  vs	  1.59	  ±0.48;	  p<0.001:	  Table	  4.2).	  Uptake	  
in	  the	  ascending	  aorta	  correlated	  with	  activity	  in	  the	  descending	  aorta	  (r=0.815,	  p<0.001),	  the	  
coronary	  arteries	  (r=0.525,	  p<0.001)	  and	  with	  Framingham	  risk	  scores	  (e.g.	  ascending	  aorta	  vs	  CVD:	  
r=0.208,	  p=0.024).	  However,	  amongst	  those	  with	  increased	  coronary	  18F-­‐NaF	  activity,	  a	  correlation	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was	  no	  longer	  observed	  between	  activity	  in	  the	  coronary	  vasculature	  and	  the	  aorta	  (r=0.157,	  
p=0.333).	  
	  
18F-­‐FDG	  uptake	  was	  observed	  in	  a	  circumferential	  pattern	  around	  the	  aortic	  wall	  as	  previously	  
described	  (Figure	  14).98	  Maximum	  18F-­‐FDG	  TBR	  in	  the	  ascending	  aorta	  correlated	  strongly	  with	  that	  
in	  the	  descending	  aorta	  (r=0.824,	  p<0.001)	  and	  the	  coronary	  arteries	  (r=0.543,	  p<0.001).	  18F-­‐FDG	  
activity	  was	  higher	  in	  the	  aorta	  than	  the	  coronary	  arteries	  (1.78	  ±0.25	  vs	  1.22	  ±0.21;	  p<0.001;	  Table	  
7).	  There	  was	  no	  correlation	  between	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake	  in	  the	  ascending	  aorta	  (r=0.043,	  
p=0.647),	  descending	  aorta	  (r=0.124,	  p=0.183)	  or	  the	  coronary	  arteries	  (r=0.127,	  p=0.21).	  	  
	  
Figure	  4.4	  Vascular	  PET/CT	  scans	  in	  the	  coronary	  arteries	  and	  aorta	  
	  
18F-­‐FDG.	  A)	  Intense	  18F-­‐FDG	  myocardial	  uptake	  is	  observed	  that	  obscures	  uptake	  in	  the	  coronary	  arteries,	  although	  
activity	  can	  be	  observed	  in	  the	  descending	  aorta.	  B)	  Effective	  myocardial	  suppression	  has	  been	  achieved	  and	  a	  focal	  area	  
of	  uptake	  can	  be	  observed	  in	  the	  mid-­‐LAD.	  C)	  Increased	  18F-­‐FDG	  activity	  can	  be	  observed	  in	  a	  circumferential	  pattern	  in	  
both	  the	  ascending	  and	  descending	  aortae	  that	  rarely	  overlapped	  with	  existing	  aortic	  calcium.	  
18F-­‐NaF.	  D)	  18F-­‐NaF	  uptake	  is	  observed	  in	  the	  ascending	  and	  descending	  aortae	  remote	  from	  existing	  vascular	  
calcification.	  Also	  note	  activity	  in	  in	  the	  ribs,	  sternum	  and	  vertebra.	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4.5	  Discussion	  
This	  is	  the	  first	  study	  to	  describe	  18F-­‐NaF	  uptake	  in	  the	  coronary	  arteries	  using	  PET/CT.	  We	  have	  
demonstrated	  that	  this	  technique	  is	  both	  feasible	  and	  repeatable,	  and	  that	  it	  can	  provide	  key	  insights	  
in	  to	  coronary	  artery	  plaque	  biology.	  Activity	  was	  higher	  in	  patients	  with	  atherosclerosis	  compared	  to	  
control	  subjects,	  displaying	  a	  progressive	  rise	  with	  increasing	  atherosclerotic	  burden.	  Furthermore	  
18F-­‐NaF	  uptake	  can	  be	  used	  to	  discriminate	  between	  those	  patients	  with	  active	  and	  inactive	  
coronary	  calcification.	  Those	  with	  active	  calcification	  (38%)	  were	  more	  likely	  to	  have	  clinically	  
significant	  coronary	  artery	  disease,	  have	  a	  higher	  incidence	  of	  previous	  MACE,	  lower	  serum	  HDL	  
cholesterol	  concentrations	  and	  higher	  Framingham	  risk	  prediction	  scores.	  18F-­‐NaF	  therefore	  holds	  
promise	  as	  a	  means	  of	  identifying	  high-­‐risk	  populations	  and	  refining	  the	  predictive	  power	  of	  coronary	  
artery	  calcium	  scoring.	  Finally,	  the	  spatial	  resolution	  of	  PET/CT	  allows	  localization	  of	  the	  18-­‐NaF	  signal	  
to	  specific	  coronary	  territories	  and	  plaques	  offering	  the	  possibility	  of	  identifying	  vulnerable	  or	  culprit	  
plaque	  on	  an	  individual	  basis.	  	  
	  
18F-­‐NaF	  uptake	  has	  been	  described	  recently	  in	  the	  aorta111	  and	  carotid	  arteries,112	  and	  is	  believed	  to	  
reflect	  active	  vascular	  calcification.	  Although	  histological	  validation	  of	  this	  hypothesis	  is	  lacking,	  
mechanistic	  information	  can	  be	  extrapolated	  from	  18F-­‐NaF	  uptake	  in	  bone	  that	  has	  been	  studied	  for	  
over	  thirty	  years.	  In	  that	  tissue,	  18F-­‐NaF	  is	  incorporated	  directly	  into	  exposed	  hydroxyapatite	  crystal	  
via	  an	  exchange	  mechanism	  with	  hydroxyl	  groups.113	  It	  therefore	  detects	  novel	  areas	  of	  calcification	  
as	  well	  as	  regions	  of	  remodelling	  and	  is	  used	  clinically	  in	  Paget’s	  disease,109	  primary	  osteoblastic	  
tumors	  and	  metastatic	  bone	  disease.110	  Similarly,	  we	  believe	  that	  coronary	  uptake	  reflects	  active	  
calcification	  in	  atherosclerotic	  plaque.	  Certainly	  coronary	  18F-­‐NaF	  uptake	  appears	  to	  offer	  
information	  that	  is	  additional	  and	  complementary	  to	  coronary	  artery	  calcium	  scoring.	  Whilst	  18F-­‐NaF	  
activity	  was	  most	  commonly	  observed	  overlying	  existing	  calcium	  and	  a	  strong	  correlation	  was	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observed	  with	  the	  coronary	  artery	  calcium	  score,	  41%	  of	  patients	  with	  scores	  >1000	  had	  no	  
significant	  18F-­‐NaF	  uptake	  and	  areas	  of	  increased	  tracer	  uptake	  were	  also	  found	  in	  regions	  remote	  
from	  established	  calcium.	  This	  activity	  potentially	  relates	  to	  developing	  micro-­‐calcification	  that	  is	  
frequently	  beyond	  the	  resolution	  of	  CT	  and	  believed	  to	  be	  associated	  with	  increased	  mechanical	  
stress	  and	  risk	  of	  future	  cardiovascular	  events.146,148	  18F-­‐NaF	  therefore	  appears	  to	  distinguish	  
between	  patients	  with	  dormant	  calcific	  disease,	  established	  many	  months	  or	  years	  previously,	  and	  
subjects	  with	  metabolically	  active	  disease	  where	  the	  calcification	  process	  is	  ongoing.	  Importantly	  this	  
distinction	  appears	  to	  be	  of	  clinical	  relevance,	  with	  higher	  rates	  of	  anginal	  symptoms,	  prior	  MACE	  
events	  and	  cardiovascular	  risk	  factor	  scores	  observed	  in	  those	  with	  active	  disease.	  	  
	  
Calcification	  plays	  a	  key	  role	  in	  the	  pathophysiology	  of	  atherosclerosis	  although	  its	  triggers	  remain	  
debated.	  Atherosclerotic	  plaques	  with	  healed	  rupture	  almost	  invariably	  contain	  calcium	  159,	  160	  leading	  
to	  the	  hypothesis	  that	  calcification	  forms	  part	  of	  a	  healing	  response	  to	  such	  events.144,	  161,	  162	  The	  
spatial	  resolution	  of	  PET/CT	  is	  sufficient	  to	  localize	  18F-­‐NaF	  activity	  to	  specific	  coronary	  territories,	  
suggesting	  that	  18F-­‐NaF	  might	  be	  able	  to	  identify	  the	  presence	  and	  location	  of	  recent	  plaque	  rupture.	  
This	  is	  supported	  by	  the	  PET/CT	  findings	  in	  the	  patient	  with	  recent	  myocardial	  infarction.	  Extensive	  
calcification	  was	  present	  in	  all	  three	  vessels	  yet	  increased	  18F-­‐NaF	  was	  only	  observed	  in	  the	  culprit	  
lesion,	  which	  was	  found	  to	  be	  complex	  and	  associated	  with	  thrombus	  at	  the	  time	  of	  coronary	  
angiography.	  According	  to	  this	  hypothesis,	  the	  increased	  18F-­‐NaF	  activity	  observed	  in	  patients	  with	  
stable	  coronary	  artery	  disease	  reflects	  sub-­‐clinical	  plaque	  rupture	  that	  has	  been	  demonstrated	  in	  
over	  10%	  of	  such	  patients	  undergoing	  angioscopy163,164	  and	  is	  thought	  to	  underlie	  the	  step-­‐wise	  
growth	  of	  coronary	  atheroma.	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Coronary	  calcification	  might	  occur	  as	  a	  response	  to	  intense	  plaque	  inflammation.	  Similar	  calcific	  
responses	  can	  be	  observed	  in	  other	  inflammatory	  conditions	  such	  as	  tuberculosis,	  and	  intra-­‐vascular	  
ultrasound	  studies	  have	  recently	  associated	  micro-­‐calcification	  with	  a	  large	  necrotic	  core.165	  
However,	  this	  theory	  is	  not	  supported	  by	  our	  18F-­‐FDG	  data,	  which	  failed	  to	  show	  a	  correlation	  with	  
18F-­‐NaF	  activity	  in	  either	  the	  coronary	  arteries	  or	  the	  aorta,	  indicating	  that	  inflammation	  and	  
calcification	  occur	  independently	  in	  these	  regions.	  	  	  	  
	  
By	  contrast	  to	  18F-­‐NaF,	  18F-­‐FDG	  activity	  was	  not	  increased	  in	  patients	  with	  coronary	  atherosclerosis	  
compared	  to	  controls.	  Our	  data	  were	  however	  hampered	  by	  myocardial	  uptake	  that	  rendered	  half	  of	  
the	  coronary	  territories	  uninterpretable.	  This	  largely	  reflected	  the	  imperfect	  dietary	  compliance	  that	  
occurred	  in	  a	  third	  of	  patients	  despite	  the	  detailed	  written	  instructions	  and	  verbal	  reminders	  
provided.	  Further	  studies	  are	  required	  in	  younger	  cohorts	  in	  whom	  compliance	  may	  be	  improved,	  
although	  our	  data	  do	  suggest	  that	  18F-­‐FDG	  may	  be	  of	  limited	  use	  in	  the	  assessment	  of	  stable	  
coronary	  disease.	  Inflammation	  has	  a	  more	  prominent	  role	  in	  acute	  coronary	  syndromes	  and	  
therefore	  18-­‐FDG	  may	  provide	  more	  information	  in	  these	  patients.	  Indeed	  a	  recent	  study	  




PET/CT	  is	  expensive	  especially	  when	  compared	  to	  circulating	  biomarkers	  of	  calcification	  activity,	  and	  
this	  may	  limit	  its	  clinical	  use.	  However,	  we	  have	  demonstrated	  that	  amongst	  those	  with	  increased	  
18F-­‐NaF	  uptake,	  activity	  in	  the	  coronaries	  did	  not	  correlate	  with	  that	  in	  the	  aorta,	  suggesting	  that	  it	  is	  
driven	  by	  local	  rather	  than	  systemic	  factors.	  Blood-­‐based	  biomarkers	  are	  therefore	  unlikely	  to	  
provide	  an	  accurate	  indication	  of	  coronary	  calcification	  activity,	  and	  instead	  will	  tend	  to	  reflect	  that	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within	  larger	  vessels	  or	  skeletal	  bone.	  In	  our	  opinion	  the	  added	  costs	  of	  PET/CT	  are	  therefore	  justified	  
by	  its	  unique	  ability	  to	  measure	  calcification	  activity	  specific	  to	  the	  coronary	  vasculature.	  Moreover,	  
18F-­‐NaF	  is	  a	  very	  simple	  and	  relatively	  cheap	  ligand	  to	  produce.	  
	  
The	  majority	  of	  our	  patients	  had	  either	  concomitant	  aortic	  stenosis	  or	  aortic	  sclerosis.	  Although	  
atherosclerosis	  and	  aortic	  stenosis	  often	  co-­‐exist	  and	  share	  many	  common	  etiological	  factors	  and	  
histopathological	  similarities,	  it	  is	  nevertheless	  important	  to	  confirm	  these	  findings	  in	  a	  cohort	  of	  
patients	  more	  representative	  of	  the	  clinical	  population	  with	  atherosclerosis	  in	  the	  absence	  of	  aortic	  
stenosis.	  	  
	  
Finally,	  risk	  prediction	  scores	  are	  intended	  to	  predict	  events	  in	  asymptomatic	  patients	  and	  are	  
therefore	  not	  strictly	  applicable	  to	  subjects	  with	  an	  established	  clinical	  diagnosis	  of	  ischemic	  heart	  
disease	  or	  aortic	  valve	  disease.	  Given	  these	  issues,	  we	  acknowledge	  that	  our	  data	  with	  respect	  to	  risk	  
prediction	  are	  preliminary	  and	  need	  validation	  in	  further	  prospective	  clinical	  trials.	  However,	  these	  
scores	  remained	  higher	  in	  patients	  with	  increased	  coronary	  NaF	  uptake	  even	  after	  patients	  with	  prior	  
MACE	  were	  excluded	  from	  the	  analysis.	  We	  therefore	  believe	  that	  this	  approach	  has	  helped	  to	  
establish	  an	  association	  between	  18F-­‐NaF	  activity	  and	  the	  presence	  of	  traditional	  cardiovascular	  risk	  
factors,	  and	  provides	  a	  potential	  assessment	  of	  the	  risk	  of	  future	  cardiovascular	  events.	  	  
	  
Conclusion	  	  
18F-­‐NaF	  appears	  to	  hold	  promise	  as	  a	  non-­‐invasive	  method	  for	  investigating	  the	  role	  of	  active	  
calcification	  in	  coronary	  atherosclerosis.	  There	  was	  a	  strong	  correlation	  with	  established	  coronary	  
calcium,	  but	  41%	  of	  patients	  with	  calcium	  scores	  >1000	  had	  no	  significant	  18F-­‐NaF	  uptake.	  This	  
suggests	  that	  18F-­‐NaF	  uptake	  provides	  different	  information,	  relating	  to	  metabolically	  active	  calcific	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plaque,	  and	  developing	  micro-­‐calcification.	  Moreover,	  this	  information	  appears	  to	  be	  of	  clinical	  
significance	  in	  relation	  to	  symptomatic	  status,	  prior	  MACE	  events	  and	  cardiovascular	  risk	  scores.	  	  
Prospective	  studies	  to	  determine	  the	  relationship	  between	  18F-­‐NaF	  uptake,	  morphological	  plaque	  
characteristics	  and	  future	  cardiovascular	  events	  are	  now	  needed	  in	  subjects	  with	  stable	  and	  unstable	  
coronary	  artery	  disease.	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5.1	  Summary	  
Objectives:	  To	  assess	  the	  prognostic	  significance	  of	  mid-­‐wall	  and	  infarct	  patterns	  of	  late	  gadolinium	  
enhancement	  (LGE)	  in	  aortic	  stenosis.	  	  
	  
Background:	  	  Myocardial	  fibrosis	  occurs	  in	  aortic	  stenosis	  as	  part	  of	  the	  hypertrophic	  response.	  It	  can	  
be	  detected	  by	  LGE,	  which	  is	  associated	  with	  an	  adverse	  prognosis	  in	  a	  range	  of	  other	  cardiac	  
conditions.	  	  
	  
Methods:	  Between	  January	  2003	  and	  October	  2008,	  consecutive	  patients	  with	  moderate	  or	  severe	  
aortic	  stenosis	  undergoing	  cardiovascular	  magnetic	  resonance	  with	  administration	  of	  gadolinium	  
contrast	  were	  enrolled	  into	  a	  registry.	  Patients	  were	  categorised	  into	  absent,	  mid-­‐wall	  or	  infarct	  
patterns	  of	  LGE	  by	  blinded	  independent	  observers.	  Patients	  follow-­‐up	  was	  completed	  using,	  patient	  
questionnaires,	  source	  record	  data	  and	  the	  National	  Strategic	  Tracing	  Scheme.	  	  
	  
Results:	  143	  patients	  (aged	  68±14	  years;	  97	  male)	  were	  followed	  up	  for	  2.0±1.4	  years.	  72	  underwent	  
aortic	  valve	  replacement	  and	  27	  died	  (24	  cardiac,	  3	  sudden	  cardiac	  deaths).	  Compared	  to	  those	  with	  
no	  LGE	  (n=49),	  univariate	  analysis	  revealed	  that	  patients	  with	  mid-­‐wall	  fibrosis	  (n=54)	  had	  an	  eight-­‐
fold	  increase	  in	  all-­‐cause	  mortality	  despite	  similar	  aortic	  stenosis	  severity	  and	  coronary	  artery	  disease	  
burden.	  Patients	  with	  an	  infarct	  pattern	  (n=40)	  had	  a	  six-­‐fold	  increase.	  Mid-­‐wall	  fibrosis	  (Hazard	  Ratio	  
5.35	  [95%	  confidence	  interval,	  1.16-­‐24.56];	  P=0.03)	  and	  ejection	  fraction	  (Hazard	  Ratio	  0.96	  [95%	  CI,	  
0.94-­‐0.99];	  P=0.01)	  were	  independent	  predictors	  of	  all	  cause	  mortality	  by	  multivariate	  analysis.	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Conclusion:	  We	  have	  shown	  mid-­‐wall	  fibrosis	  to	  be	  an	  independent	  predictor	  of	  mortality	  in	  patients	  
with	  moderate	  and	  severe	  aortic	  stenosis.	  It	  has	  incremental	  prognostic	  value	  to	  ejection	  fraction	  and	  
may	  provide	  a	  useful	  method	  of	  risk	  stratification.	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5.2	  Introduction	  
	  
Aortic	  stenosis	  (AS)	  is	  a	  progressive	  condition	  that	  is	  characterised	  by	  a	  long	  and	  indolent	  
asymptomatic	  phase	  followed	  by	  a	  shorter	  symptomatic	  stage.	  The	  onset	  of	  symptoms	  is	  associated	  
with	  an	  increased	  morbidity	  and	  a	  high	  mortality.166	  However	  there	  is	  marked	  heterogeneity	  between	  
symptom	  onset	  and	  severity	  of	  valvular	  stenosis.	  There	  are	  several	  potential	  explanations	  for	  this	  
apparent	  mismatch	  but	  the	  hypertrophic	  response	  of	  the	  left	  ventricle	  may	  contribute	  to	  the	  
development	  of	  symptoms	  and	  adverse	  events.	  
	  
Aortic	  stenosis	  results	  in	  increased	  pressure	  afterload	  and	  ventricular	  wall	  stress,	  thereby	  stimulating	  
left	  ventricular	  hypertrophy	  (LVH).	  Initially,	  increased	  wall	  thickness	  maintains	  normal	  wall	  stress	  and	  
contraction52,	  53	  but	  ultimately	  this	  becomes	  maladaptive.	  Indeed,	  LVH	  is	  an	  independent	  predictor	  of	  
cardiac	  mortality,	  regardless	  of	  etiology.56-­‐58	  Histopathologic	  studies	  have	  demonstrated	  fibrosis	  in	  
the	  left	  ventricle	  of	  patients	  with	  aortic	  stenosis	  and	  arterial	  hypertension.84,	  167	  It	  has	  been	  
postulated	  that	  increasing	  myocyte	  size	  eventually	  leads	  to	  myocyte	  apoptosis	  and	  subsequently	  
replacement	  fibrosis	  and	  that	  this	  sequence	  is	  responsible	  for	  the	  progression	  from	  LVH	  to	  heart	  
failure.168	  Myocardial	  fibrosis	  has	  also	  been	  linked	  to	  the	  development	  of	  arrhythmia	  and	  sudden	  
cardiac	  death	  in	  a	  variety	  of	  conditions.169-­‐172	  
	  
Cardiovascular	  magnetic	  resonance	  (CMR)	  is	  able	  to	  detect	  replacement	  myocardial	  fibrosis	  non-­‐
invasively	  by	  late	  gadolinium	  enhancement	  (LGE).173	  Recent	  studies	  have	  demonstrated	  a	  mid-­‐wall	  
pattern	  of	  enhancement	  in	  patients	  with	  aortic	  stenosis	  in	  the	  absence	  of	  coronary	  artery	  disease.120,	  
121	  Although	  the	  presence	  of	  LGE	  is	  associated	  with	  an	  adverse	  prognosis	  in	  other	  cardiac	  
conditions,124-­‐128	  this	  has	  not	  been	  assessed	  in	  aortic	  stenosis.	  We	  sought	  to	  determine	  the	  prognostic	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As	  described	  in	  Chapter	  2	  all	  patients	  referred	  between	  January	  2003	  and	  October	  2009	  for	  CMR	  at	  
the	  Royal	  Brompton	  Hospital	  were	  enrolled	  into	  a	  registry.	  Patients	  in	  whom	  late	  gadolinium	  
enhancement	  was	  performed	  were	  followed	  up	  as	  described	  below.	  	  
	  
Data	  Collection	  
Demographic	  and	  medical	  history	  was	  documented	  from	  source	  patient	  record	  data	  and	  patient	  
questionnaires.	  The	  presence	  of	  coronary	  artery	  disease	  was	  defined	  as	  a	  prior	  coronary	  
revascularisation,	  or	  the	  presence	  of	  significant	  coronary	  artery	  stenosis	  as	  assessed	  by	  single	  photon	  
emission	  computed	  tomography,	  invasive	  coronary	  angiography	  (>50%	  lumen	  diameter	  narrowing),	  
or	  computed	  tomography	  coronary	  angiography.	  A	  patient	  was	  considered	  to	  have	  hypertension	  
based	  on	  an	  established	  clinical	  diagnosis	  rather	  than	  individual	  blood	  pressure	  readings.	  	  
	  
Cardiovascular	  Magnetic	  Resonance	  	  
CMR	  including	  late	  gadolinium	  enhancement	  was	  performed	  in	  each	  patient	  as	  described	  in	  Chapter	  
2.	  	  Image	  analysis	  included	  an	  assessment	  of	  the	  aortic	  valve	  area,	  indexed	  left	  ventricular	  mass	  and	  
volumes	  and	  ejection	  fraction.	  The	  presence	  and	  pattern	  of	  LGE	  was	  assessed	  by	  two	  independent	  
observers	  and	  categorised	  as	  either	  no	  LGE,	  an	  infarct	  pattern	  or	  mid-­‐wall	  LGE.	  Patients	  with	  a	  mixed	  
pattern	  of	  LGE	  were	  categorized	  according	  to	  the	  predominant	  pattern	  of	  fibrosis.	  LGE	  was	  also	  
quantified	  and	  expressed	  as	  the	  percentage	  of	  total	  LV	  mass	  (Chapter	  2).	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Clinical	  End	  points	  
The	  primary	  end-­‐point	  of	  the	  study	  was	  all-­‐cause	  mortality.	  The	  secondary	  end-­‐point	  was	  cardiac	  
mortality.	  Mortality	  data	  was	  obtained	  from	  hospital	  notes	  and	  the	  National	  Strategic	  Tracing	  Service	  
(NSTS):	  a	  national	  database	  for	  all	  National	  Health	  Service	  patients	  in	  the	  United	  Kingdom.	  	  Cause	  of	  
death	  was	  established	  from	  medical	  notes	  and	  /	  or	  death	  certification	  records	  and	  an	  assessment	  
made	  as	  to	  whether	  this	  represented	  a	  sudden	  cardiac	  death.	  Data	  regarding	  which	  patients	  had	  
undergone	  aortic	  valve	  replacement	  (AVR)	  during	  the	  follow	  up	  period	  was	  also	  collected.	  	  
	  
Statistical	  analysis	  
Continuous	  variables	  were	  expressed	  as	  mean	  ±	  SD	  and	  compared	  using	  one-­‐way	  analysis	  of	  variance	  
or	  unpaired	  Student’s	  t	  -­‐test	  where	  appropriate.	  	  Categorical	  variables	  were	  expressed	  as	  
percentages	  and	  analyzed	  using	  the	  χ2-­‐test.	  All	  continuous	  variables	  were	  tested	  for	  normal	  
distribution	  using	  the	  Shapiro-­‐Wilk	  test.	  Variables	  with	  a	  skewed	  distribution	  were	  log	  transformed	  
and	  the	  geometric	  mean	  with	  the	  95%	  confidence	  intervals	  reported.	  Where	  log	  transformation	  did	  
not	  normalize	  the	  data,	  analysis	  was	  performed	  using	  non-­‐parametric	  tests:	  Mann-­‐Whitney	  rank	  sum	  
test	  or	  the	  Kruskal-­‐Wallis	  tests	  as	  appropriate.	  
	  
Kaplan-­‐Meier	  curves	  were	  used	  to	  estimate	  the	  survival	  distributions	  with	  regard	  to	  all	  cause	  
mortality	  and	  cardiac	  mortality	  for	  patients	  with	  no	  LGE,	  mid-­‐wall	  LGE	  and	  infarct	  LGE.	  Differences	  in	  
the	  survival	  patterns	  of	  the	  patients	  in	  the	  3	  groups	  were	  assessed	  using	  the	  Log	  Rank	  Test.	  
Univariate	  and	  multivariate	  survival	  analyses	  (Cox	  proportional	  hazard	  regression)	  were	  performed	  to	  
determine	  independent	  predictors	  of	  all	  cause	  mortality	  and	  cardiac	  mortality.	  All	  analyses	  were	  
performed	  using	  Stata	  statistical	  package	  version	  10.0	  (Stata	  Corporation,	  College	  Station,	  TX).	  All	  
authors	  had	  full	  access	  to	  and	  take	  full	  responsibility	  for	  the	  integrity	  of	  the	  data.	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5.4	  Results	  
	  
CMR	  was	  performed	  on	  143	  consecutive	  patients	  (aged	  68	  ±14	  years;	  97	  male)	  with	  an	  average	  aortic	  
valve	  area	  of	  0.99	  ±0.31	  cm2.	  Overall,	  57	  patients	  (40%)	  had	  moderate	  and	  86	  (60%)	  severe	  aortic	  
stenosis.	  CMR	  estimation	  of	  aortic	  valve	  severity	  correlated	  closely	  with	  echocardiographic	  data.	  
Coronary	  artery	  disease	  was	  assessed	  in	  all	  patients	  (83%	  had	  invasive	  coronary	  angiography)	  and	  
was	  present	  in	  eighty-­‐one	  patients	  (57%)	  (Table	  5.1).	  	  
	  
Patterns	  of	  Late	  Gadolinium	  Enhancement	  
Three	  patterns	  of	  LGE	  were	  observed:	  no	  gadolinium	  enhancement	  (no	  LGE	  group);	  localised	  
enhancement	  consistent	  with	  prior	  myocardial	  infarction	  (infarct	  LGE	  group);	  and	  a	  mid-­‐wall	  pattern	  
of	  enhancement	  (mid-­‐wall	  LGE	  group)	  (Figure	  5.1).	  Inter-­‐observer	  agreement	  in	  determining	  the	  
pattern	  of	  LGE	  was	  very	  good	  with	  a	  κ	  value	  of	  0.89.	  	  
	  
LGE	  was	  absent	  in	  49	  (34%)	  patients.	  There	  was	  a	  typical	  pattern	  of	  prior	  myocardial	  infarction	  in	  40	  
(28%)	  patients,	  and	  mid-­‐wall	  fibrosis	  in	  54	  (38%)	  patients	  (Table	  5.1).	  In	  eight	  patients	  (6%),	  there	  was	  
a	  dual	  pattern	  of	  both	  myocardial	  infarction	  and	  mid-­‐wall	  fibrosis.	  These	  patients	  were	  categorized	  
according	  to	  their	  predominant	  pattern	  and	  the	  statistical	  analysis	  was	  performed	  on	  this	  basis.	  
Seven	  were	  placed	  in	  the	  infarct	  group	  and	  one	  in	  to	  the	  mid-­‐wall	  group.	  	  
	  
One	  patient	  with	  mid-­‐wall	  LGE	  who	  died	  underwent	  autopsy.	  Assessment	  of	  the	  macroscopic	  
appearance	  of	  the	  cut	  surface	  of	  the	  heart	  showed	  myocardial	  fibrosis,	  which	  was	  confirmed	  
histologically	  using	  Trichome	  stain	  (Figure	  5.2).	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Table	  5.1.	  	  Baseline	  characteristics	  of	  143	  patients	  with	  aortic	  stenosis	  according	  to	  the	  pattern	  of	  
LGE	  (mid-­‐wall,	  infarct	  or	  no	  LGE).	  
	  
	  
	   No	  LGE	   Mid-­‐wall	  LGE	   Infarct	  LGE	  	   P	  Value	  







	   -­‐	  




















Clinical	  History	  	  %	  
	   	   	   	   	  
	   AF	  	  
21	   18	   18	   0.915	  
	   Diabetes	  Mellitus	  	  
25	   19	   32	   0.378	  
	   Hypertension	  	  
56	   55	   50	   0.838	  
	   Bicuspid	  Aortic	  Valve	  	  
29	   17	   23	   0.401	  
Documented	  CAD	  %	  
	  
37	   42	   98	   <0.001	  
	   	  1vd	  	  
16	   17	   15	  
<0.001	  	   	  2vd	  	  
2	   6	   20	  
	   	  3vd	  	  
2	   13	   28	  
	   	  Previous	  PCI	  	  
10	   9	   30	   0.010	  
	   	  Previous	  CABG	  	  
20	   8	   28	   0.040	  
Medication	  %	  
	   	   	   	   	  
	   ACE	  Inhibitor	  	  
56	   48	   61	   0.480	  
	   Beta	  Blocker	  	  














67	   60	   82	   0.079	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Continuous	  variables	  presented	  as	  mean	  ±	  SD,	  categorical	  variables	  as	  percentages.	  LGE-­‐	  Late	  Gadolinium	  Enhancement,	  LA	  –	  
Left	  Atrial,	  LVED	  –	  Left	  Ventricular	  End	  Diastolic,	  LV	  –	  Left	  Ventricular,	  RVEF	  –	  Right	  Ventricular	  Ejection	  Fraction,	  CAD	  –	  
Coronary	  Artery	  Disease,	  AF	  –	  Atrial	  Fibrillation,	  ACE	  –	  Angiotensin	  Converting	  Enzyme	  
	  
	   	  
	   	  	   No	  LGE	   Mid-­‐wall	  LGE	   Infarct	  LGE	  	   P	  Value	  
	   	   	   	   	  
CMR	  DATA	  	   	   	   	   	  




	  	  	  	  	  	  	  1.00±0.31	  
	  
	  	  	  	  	  	  	  	  0.91±0.26	  
	  
	  	  	  	  	  0.111	  
	  
Peak	  Aortic	  Valve	  Gradient	  by	  
echo	  mmHg	   70±26	   70±26	   69±16	   0.99	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Figure	  5.1.	  Patterns	  of	  Late	  Gadolinium	  Enhancement	  in	  Aortic	  Stenosis	  	  
	  
	  	  
Images	  show	  the	  different	  patterns	  of	  LGE	  observed	  in	  patients	  with	  aortic	  stenosis.	  A)	  No	  LGE.	  B)	  Infarct	  LGE	  with	  a	  
subendocardial	  pattern	  observed	  in	  the	  septum	  and	  anterior	  wall.	  C)	  Two	  focal	  areas	  of	  mid-­‐wall	  LGE	  in	  the	  lateral	  wall	  of	  
the	  left	  ventricle	  (red	  arrows);	  D)	  Mid-­‐wall	  LGE	  in	  a	  more	  linear	  pattern	  affecting	  the	  septum.	  E)	  F)	  Short	  and	  long-­‐axis	  
views	  of	  mid-­‐wall	  LGE	  (red	  arrows)	  of	  the	  infero-­‐lateral	  wall	  in	  the	  same	  patient.	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Figure	  5.2.	  Histology	  of	  the	  myocardium,	  following	  Trichome	  staining,	  in	  a	  patient	  who	  had	  mid-­‐



























Patients	  with	  no	  LGE	  were	  younger,	  more	  likely	  to	  be	  female	  and	  less	  likely	  to	  be	  on	  diuretic	  therapy.	  
The	  severity	  of	  aortic	  stenosis	  and	  prevalence	  of	  cardiovascular	  risk	  factors	  were	  similar	  to	  the	  other	  
groups.	  As	  anticipated,	  patients	  with	  an	  infarct	  pattern	  of	  LGE	  had	  more	  severe	  coronary	  artery	  
disease,	  lower	  ejection	  fractions	  and	  higher	  indexed	  LV	  volumes	  than	  the	  other	  groups	  (Table	  5.1).	  	  
	  
Patients	  with	  mid-­‐wall	  LGE	  had	  the	  highest	  indexed	  LV	  mass	  (P=0.005)	  despite	  the	  fact	  that	  AS	  
severity	  and	  hypertension	  prevalence	  were	  similar	  between	  all	  three	  groups.	  Interestingly,	  ejection	  
fraction	  (P=0.007)	  and	  stroke	  volume	  were	  lower	  (p=0.01)	  in	  patients	  with	  mid-­‐wall	  LGE	  compared	  to	  
those	  with	  no	  LGE,	  even	  though	  both	  groups	  had	  a	  similar	  degree	  of	  coronary	  artery	  disease.	  	  Whilst	  
there	  was	  an	  apparent	  trend	  to	  a	  correlation	  between	  ejection	  fraction	  and	  the	  mid-­‐wall	  LGE	  burden	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(Pearson’s:	  R=	  -­‐0.26;	  P=0.08),	  this	  did	  not	  reach	  statistical	  significance.	  Indexed	  left	  atrial	  volumes	  
were	  used	  as	  a	  marker	  of	  diastolic	  dysfunction174	  and	  there	  was	  no	  difference	  in	  this	  variable	  
between	  the	  three	  groups	  (Table	  5.1).	  	  
	  
Mortality	  Data	  
Patients	  were	  followed	  up	  for	  an	  average	  of	  2.0	  ±1.4	  years	  (median	  1.7	  years).	  None	  of	  the	  patients	  
were	  lost	  to	  follow-­‐up	  and	  overall,	  27	  patients	  (19%)	  died	  (Table	  5.2).	  Univariate	  analysis	  revealed	  
that	  compared	  to	  patients	  with	  no	  LGE,	  there	  was	  an	  eight-­‐fold	  increase	  in	  all-­‐cause	  mortality	  in	  
patients	  with	  mid-­‐wall	  fibrosis	  (HR	  8.59,	  95%	  CI	  1.97,	  37.38;	  P=0.004)	  and	  a	  six-­‐fold	  increase	  in	  
mortality	  in	  those	  with	  myocardial	  infarction	  (HR	  6.46,	  95%	  CI	  1.39-­‐30.00;	  P=0.017)	  (Table	  5.3,	  Figure	  
5.3).	  As	  fibrosis	  burden	  increased,	  prognosis	  worsened:	  with	  every	  1%	  increase	  in	  the	  percentage	  LGE	  
mass	  the	  risk	  of	  mortality	  appeared	  to	  increase	  by	  5%	  (HR	  1.05	  [95%	  CI	  1.01-­‐1.09];	  P=0.005).	  A	  lower	  
ejection	  fraction	  and	  an	  increased	  LV	  end-­‐diastolic	  volume	  also	  predicted	  an	  increased	  all-­‐cause	  
mortality	  on	  univariate	  analysis	  (Table	  5.3).	  After	  multivariate	  analysis,	  ejection	  fraction	  (HR	  0.96	  
[95%	  CI,	  0.94-­‐0.99];	  P=0.009)	  and	  the	  mid-­‐wall	  pattern	  of	  LGE	  (HR,	  5.35	  [95%	  CI,	  1.16-­‐24.56];	  
P=0.034)	  were	  identified	  as	  independent	  predictors	  of	  subsequent	  all	  cause	  mortality	  (Table	  5.4).	  	  
	  
Twenty-­‐three	  of	  the	  twenty-­‐seven	  deaths	  were	  from	  cardiac	  causes	  (Table	  5.2).	  There	  was	  a	  five-­‐fold	  
increase	  in	  cardiac	  mortality	  in	  the	  infarct	  group	  	  (HR	  5.44,	  95%	  CI	  1.15,	  25.68;	  P=0.032)	  and	  a	  six-­‐fold	  
increase	  in	  the	  mid-­‐wall	  group	  (HR	  6.68,	  95%	  CI	  1.51,	  29.64;	  P=	  0.012)	  (Figure	  5.4).	  
Three	  of	  the	  deaths	  were	  adjudicated	  as	  sudden	  cardiac	  deaths	  and	  all	  were	  in	  the	  mid-­‐wall	  group.	  
Each	  of	  these	  subjects	  had	  died	  suddenly	  at	  home	  with	  no	  prior	  symptoms	  or	  signs	  of	  heart	  failure.	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Aortic	  Valve	  Replacement	  
During	  follow-­‐up,	  72	  (50%)	  patients	  underwent	  AVR	  (8	  patients	  percutaneously)	  with	  no	  difference	  in	  
rates	  between	  the	  three	  groups	  (Table	  5.2).	  Aortic	  valve	  replacement	  was	  associated	  with	  an	  
improved	  survival	  in	  the	  univariate	  analysis	  (P=0.01)	  and	  multivariate	  analyses	  (HR	  0.32	  95%	  CI	  0.13,	  
0.76	  P=0.01)	  (Tables	  5.3	  and	  5.4).	  In	  patients	  with	  mid-­‐wall	  fibrosis,	  those	  undergoing	  AVR	  had	  a	  
mortality	  rate	  of	  54	  per	  1000	  patient	  years	  compared	  to	  219	  per	  1000	  patient	  years	  in	  those	  who	  did	  
not	  (Table	  5.2).	  The	  two	  groups	  were	  well	  matched	  with	  no	  significant	  differences	  in	  age	  (P=0.64),	  
aortic	  valve	  area	  (P=0.32),	  ejection	  fraction	  (P=0.24),	  indexed	  LVEDV	  (P=0.29),	  indexed	  LV	  mass	  
(P=0.60),	  documented	  CAD	  (P=0.77),	  hypertension	  rates	  (P=0.10)	  or	  diabetes	  (P=0.23).	  Two	  patients	  
were	  turned	  down	  for	  surgery	  in	  the	  mid-­‐wall	  group	  and	  they	  were	  excluded	  from	  this	  analysis.	  
	  




No	  LGE	   Mid-­‐wall	  LGE	   Infarct	  LGE	   P	  Value	  
Subsequent	  AVR	  %	  
	  
55	   46	   53	   0.66	  
Deaths	  	  
	  
2	  	   16	   9	   0.003	  
Cardiac	  Deaths	   2	  	   13	   8	   0.016	  
	  
Sudden	  Cardiac	  Deaths	  
	  
0	  	   3	   0	  	   -­‐	  
All	  cause	  Mortality	  rate*	  
	  
15.7	   142.7	   173.1	   -­‐	  
Cardiac	  Mortality	  rate*	   15.7	   130.2	   123.2	   -­‐	  
	  
All	  cause	  Mortality	  rate*	  in	  AVR	  
patients	  
	  
13.7	   53.8	   73.6	   -­‐2	  
All	  cause	  Mortality	  rate*	  in	  non-­‐AVR	  
patients	  
	  
18.2	   218.8	   190.0	   -­‐	  
Subsequent	  aortic	  valve	  replacement,	  all-­‐cause	  mortality,	  cardiac	  mortality	  and	  sudden	  cardiac	  deaths	  according	  to	  the	  
pattern	  of	  LGE	  (mid-­‐wall,	  infarct	  or	  no	  LGE).	  In	  addition	  all	  cause	  mortality	  rates	  are	  displayed	  for	  patients	  who	  
subsequently	  had	  an	  AVR	  during	  the	  period	  of	  follow	  up	  and	  for	  those	  who	  did	  not	  (patients	  turned	  down	  for	  surgery	  have	  
been	  excluded	  from	  this	  analysis:	  n=2	  in	  the	  mid=wall	  group,	  n=4	  in	  the	  infarct	  group).	  P	  values	  for	  mortality	  rates	  are	  given	  
in	  Table	  3	  and	  Figures	  3	  and	  4.	  AVR-­‐	  Aortic	  Valve	  Replacement,	  LGE-­‐	  Late	  Gadolinium	  Enhancement	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Table	  5.3.	  Cox	  proportional	  hazards	  model	  –	  Univariate	  analysis	  for	  all-­‐cause	  mortality	  
	  



















































65.4%	   53.5%	   1.62	   0.72,	  3.62	   0.25	  
ACE	  inhibitors	  
	  
53.9%	   54.6%	   0.95	   0.44,	  2.05	   0.89	  
Beta	  Blockers	  
	  
42.3%	   43.2%	   1.00	   0.45,	  2.18	   1.00	  
Ejection	  Fraction	  	  	  %	  
	  
45.0	  ±	  21.6	   60.6	  ±	  18.4	   0.96	   0.94,	  0.98	   <0.001	  
	  
AV	  Area	  	  	  cm2	  
	  
0.96	  ±	  0.31	   0.99	  ±	  0.31	   0.68	   0.19,	  2.40	   0.55	  
Indexed	  Mass	  *	  g/m2	  
	  
116.6	  ±	  34.5	   103.1±	  28.3	   1.01	   1.00,	  1.02	   0.06	  






3.06	   1.03,	  9.08	   0.04	  
LGE	  PATTERN	  
	   	   	   	   	  
	   No	  LGE	   7.4%	   40.5%	   1.00	   -­‐	   -­‐	  
	   Infarct	  LGE	  	   33.3%	   26.7%	   6.46	   1.39,	  30.00	   0.017	  
	   Mid-­‐wall	  LGE	   59.3%	   32.8%	   8.59	   1.97,	  37.38	   0.004	  
%	  LGE	  Mass	  	  
	  
12.6	  ±	  10.3	   6.7	  ±	  9.1	   1.05	   1.01,	  1.09	   0.005	  
	  The	  following	  were	  found	  to	  be	  significant	  predictors	  of	  all-­‐cause	  mortality:	  subsequent	  AVR,	  ejection	  fraction,	  indexed	  
LVEDV,	  an	  infarct	  pattern	  of	  LGE,	  mid-­‐wall	  LGE,	  and	  the	  %	  LGE	  mass.	  	  AVR-­‐	  Aortic	  Valve	  Replacement,	  LGE-­‐	  Late	  Gadolinium	  
Enhancement,	  LVEDV-­‐	  Left	  ventricular	  end-­‐diastolic	  volume.	  
	   	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   130	  
Table	  5.4.	  Cox	  regression	  multivariate	  analysis	  for	  all	  cause	  mortality	  
	  
	  
Variable	   Hazard	  Ratio	   Confidence	  
Intervals	  
P	  value	  
Ejection	  Fraction	   0.96	   0.94,	  0.99	   0.01	  
Indexed	  LVEDV	   0.68	   0.18,	  2.61	   0.57	  
Mid-­‐wall	  LGE	   5.35	   1.16,	  24.56	   0.03	  
Infarct	  LGE	   2.56	   0.48,	  13.64	   0.27	  
Subsequent	  AVR	   0.32	   0.13,	  0.76	   0.01	  
	  
Ejection	  fraction,	  mid-­‐wall	  LGE	  and	  subsequent	  AVR	  all	  emerged	  as	  independent	  predictors	  of	  all	  cause	  






Figure	  5.3.	  Kaplan-­‐Meier	  survival	  estimates	  by	  pattern	  of	  late	  gadolinium	  enhancement	  for	  all	  




There	  was	  a	  significant	  increase	  in	  all	  cause	  mortality	  in	  the	  mid-­‐wall	  (orange	  dashed	  line)	  and	  infarct	  groups	  (green	  line)	  
compared	  to	  the	  no-­‐LGE	  group	  (blue	  dotted	  line).	  Amongst	  patients	  followed	  up	  for	  more	  than	  4	  years	  there	  were	  no	  
further	  deaths.	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Figure	  5.4.	  Kaplan-­‐Meier	  survival	  estimates	  by	  pattern	  of	  late	  gadolinium	  enhancement	  (LGE)	  for	  




Ejection	  fraction,	  mid-­‐wall	  LGE	  and	  subsequent	  AVR	  all	  emerged	  as	  independent	  predictors	  of	  all	  cause	  mortality.	  AVR-­‐	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5.5	  Discussion	  
	  
Aortic	  stenosis	  is	  the	  most	  common	  indication	  for	  valve	  replacement	  in	  Europe	  and	  North	  America	  
175.	  Its	  clinical	  importance	  continues	  to	  rise	  with	  a	  progressively	  ageing	  population	  and	  the	  expansion	  
of	  percutaneous	  valve	  implantation.	  Here,	  we	  have	  investigated	  whether	  myocardial	  fibrosis,	  as	  
assessed	  by	  CMR,	  can	  predict	  prognosis	  in	  this	  condition.	  For	  the	  first	  time,	  we	  have	  demonstrated	  
that	  mid-­‐wall	  fibrosis/	  LGE	  is	  an	  independent	  predictor	  of	  survival	  in	  aortic	  stenosis	  and	  appears	  to	  be	  
of	  incremental	  prognostic	  value	  to	  ejection	  fraction.	  	  
	  
LGE	  has	  been	  associated	  with	  adverse	  clinical	  outcomes	  across	  a	  range	  of	  different	  cardiac	  conditions	  
including	  hypertrophic	  cardiomyopathy,	  dilated	  cardiomyopathy	  and	  myocardial	  infarction.124-­‐127	  We	  
here	  extend	  this	  to	  patients	  with	  AS.	  Patients	  with	  no	  LGE	  had	  a	  relatively	  good	  prognosis	  in	  contrast	  
to	  those	  with	  a	  mid-­‐wall	  or	  infarct	  pattern	  of	  enhancement	  who	  experienced	  an	  eight-­‐	  and	  six-­‐fold	  
increase	  in	  mortality	  respectively.	  
	  
The	  poor	  prognosis	  associated	  with	  prior	  myocardial	  infarction	  is	  well	  established	  in	  this	  and	  other	  
settings,124,	  127	  and	  is	  thought	  to	  be	  related	  to	  arrhythmogenicity	  and	  adverse	  remodelling	  with	  
progression	  to	  heart	  failure.	  The	  findings	  in	  relation	  to	  mid-­‐wall	  fibrosis	  are	  less	  expected.	  Even	  
though	  patients	  with	  prior	  infarction	  had	  a	  lower	  ejection	  fraction	  and	  more	  severe	  coronary	  artery	  
disease,	  patients	  with	  mid-­‐wall	  fibrosis	  had	  a	  higher	  mortality.	  With	  increasing	  burden	  of	  mid-­‐wall	  
LGE,	  prognosis	  worsened	  and	  in	  the	  multivariate	  survival	  analysis,	  mid-­‐wall	  fibrosis	  emerged	  as	  an	  
independent	  marker	  of	  all-­‐cause	  mortality.	  Myocardial	  infarction	  was	  not	  independently	  associated	  
probably	  because	  of	  its	  close	  association	  with	  ejection	  fraction.	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Mid-­‐wall	  fibrosis	  in	  aortic	  stenosis	  
Fibrosis	  is	  a	  common	  pathologic	  alteration	  in	  patients	  with	  AS	  and	  concurrent	  LVH.167	  In	  the	  
hypertrophied	  myocardium,	  areas	  of	  fibrosis	  co-­‐localise	  with	  areas	  of	  myocyte	  apoptosis	  87	  and	  a	  
pathological	  sequence	  of	  myocyte	  hypertrophy	  followed	  by	  apoptosis	  and	  replacement	  fibrosis	  has	  
been	  described.168	  Several	  possible	  triggers	  to	  this	  apoptotic	  process	  have	  been	  postulated	  including	  
direct	  mechanical	  forces	  76,	  77	  and	  angiotensin	  II.77,	  78	  Ischemia	  has	  also	  been	  suggested.	  Increased	  
myocardial	  mass	  and	  afterload	  leads	  to	  increased	  myocardial	  oxygen	  demand.	  The	  capillary	  bed	  does	  
not	  expand	  sufficiently	  to	  increase	  oxygen	  supply	  and	  capillary	  flow	  reserve	  is	  reduced	  80,	  176	  thereby	  
inducing	  ischemia.	  Galiuto	  et	  al	  demonstrated	  that	  patients	  with	  severe	  aortic	  stenosis	  and	  no	  
coronary	  artery	  disease	  have	  impaired	  myocardial	  perfusion,	  and	  increased	  cardiomyocyte	  
apoptosis.81	  However	  the	  concept	  that	  mid-­‐wall	  fibrosis	  is	  due	  to	  hypoperfusion	  remains	  unproven	  
and	  one	  might	  expect	  ischemia	  due	  to	  hypertrophy	  to	  be	  greatest	  in	  the	  subendocardium	  not	  the	  
mid-­‐wall.	  	  
	  
Mid-­‐wall	  LGE	  is	  associated	  with	  an	  increased	  LV	  mass,120,	  121	  being	  on	  average	  11g/m2	  higher	  in	  our	  
study	  than	  in	  those	  without	  fibrosis.	  The	  explanation	  for	  this	  increase	  is	  not	  clear	  given	  that	  there	  
were	  no	  differences	  in	  the	  severity	  of	  aortic	  valve	  disease	  or	  rates	  of	  hypertension	  between	  the	  
groups.	  Other	  factors	  are	  likely	  to	  be	  involved	  including	  age,	  male	  sex	  65,	  69,	  177	  use	  of	  beta-­‐blockers	  178,	  
179	  and	  different	  genotypes.69,	  70,	  180	  Alternatively	  it	  may	  be	  explained	  by	  differences	  in	  the	  global	  
measure	  of	  afterload	  ZVa,	  which	  has	  not	  been	  measured	  in	  this	  study.73	  	  	  
	  
It	  is	  unlikely	  that	  mid-­‐wall	  fibrosis	  occurs	  secondary	  to	  coronary	  artery	  disease.	  Previous	  studies	  have	  
reported	  that	  mid-­‐wall	  LGE	  occurs	  in	  patients	  with	  aortic	  stenosis	  and	  normal	  coronary	  arteries.120,	  121	  
In	  our	  study,	  the	  presence	  of	  coronary	  artery	  disease	  was	  well	  characterised,	  with	  no	  difference	  in	  its	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presence	  between	  the	  mid-­‐wall	  and	  the	  no	  LGE	  groups.	  Furthermore,	  over	  half	  of	  those	  with	  mid-­‐wall	  
LGE	  had	  unobstructed	  coronary	  arteries.	  
	  
Mechanism	  of	  adverse	  prognosis	  	  
The	  adverse	  prognosis	  associated	  with	  mid-­‐wall	  fibrosis	  in	  aortic	  stenosis	  appears	  to	  be	  
predominantly	  cardiac	  in	  aetiology.	  Mid-­‐wall	  LGE	  predicted	  a	  six-­‐fold	  increase	  in	  cardiac	  mortality	  
compared	  to	  no	  LGE	  and	  81%	  of	  deaths	  in	  this	  group	  were	  cardiac	  in	  nature.	  	  
	  
Using	  CMR	  we	  have	  confirmed	  that	  the	  ejection	  fraction	  serves	  as	  a	  powerful	  prognostic	  marker	  in	  
aortic	  stenosis	  181	  and	  shown	  that	  it	  was	  impaired	  in	  the	  mid-­‐wall	  group	  compared	  to	  the	  no	  LGE	  
group.	  Previous	  studies	  have	  demonstrated	  an	  association	  between	  mid-­‐wall	  fibrosis	  and	  low	  flow	  
severe	  aortic	  stenosis.123	  	  Impaired	  left	  ventricular	  function	  is	  therefore	  likely	  to	  be	  a	  major	  
contributor	  to	  the	  adverse	  prognosis	  in	  these	  patients.	  However,	  on	  multivariate	  analysis,	  mid-­‐wall	  
fibrosis	  still	  predicted	  an	  increased	  mortality	  after	  adjustment	  for	  the	  effects	  of	  ejection	  fraction,	  
which	  suggests	  the	  contribution	  of	  other	  factors.	  	  
	  
One	  potential	  mechanism	  may	  be	  arrhythmogenicity.	  Fibrosis	  can	  serve	  as	  a	  structural	  substrate	  for	  
arrhythmia182	  and	  its	  detection,	  using	  LGE,	  in	  patients	  with	  dilated	  cardiomyopathy	  or	  previous	  
myocardial	  infarction	  has	  been	  linked	  with	  an	  increased	  incidence	  of	  arrhythmia	  and	  sudden	  cardiac	  
death.125,	  183	  In	  this	  study	  all	  three	  patients	  with	  aortic	  stenosis	  who	  had	  a	  sudden	  cardiac	  death	  were	  
in	  the	  mid-­‐wall	  group.	  However	  our	  study	  design	  was	  not	  adequately	  powered	  to	  examine	  this	  end	  
point	  and	  our	  protocol	  did	  not	  include	  routine	  ambulatory	  monitoring.	  	  In	  addition	  other	  patients	  
may	  have	  died	  suddenly	  without	  there	  being	  sufficient	  documentation	  to	  allow	  their	  identification	  
within	  this	  study.	  It	  is	  therefore	  not	  possible	  to	  make	  any	  definitive	  assertions	  about	  the	  contribution	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of	  malignant	  arrhythmia	  to	  the	  adverse	  prognosis	  associated	  with	  mid-­‐wall	  LGE	  in	  aortic	  stenosis.	  
Further	  work	  is	  required	  to	  evaluate	  this	  question	  but	  in	  our	  opinion	  the	  effect	  of	  mid-­‐wall	  fibrosis	  on	  
LV	  function	  is	  likely	  to	  represent	  the	  predominant	  mechanism.	  
	  
Aortic	  valve	  replacement	  
Nearly	  half	  of	  our	  cohort	  underwent	  AVR	  during	  follow	  up.	  The	  high	  rates	  of	  surgery	  probably	  
underlie	  our	  observation	  that	  aortic	  stenosis	  severity	  was	  not	  predictive	  of	  mortality.	  AVR	  is	  the	  only	  
available	  treatment	  capable	  of	  improving	  the	  prognosis	  of	  patients	  with	  symptomatic	  severe	  AS,	  and	  
in	  our	  study	  was	  predictive	  of	  an	  improved	  outcome	  after	  multivariate	  analysis.	  
	  
It	  is	  interesting	  to	  note	  that	  AVR	  appeared	  to	  modulate	  the	  poor	  prognosis	  associated	  with	  mid-­‐wall	  
fibrosis.	  After	  excluding	  patients	  turned	  down	  for	  surgery	  patients	  with	  mid-­‐wall	  LGE	  who	  had	  an	  AVR	  
were	  four	  times	  less	  likely	  to	  die	  over	  the	  course	  of	  the	  follow-­‐up	  than	  those	  who	  did	  not	  undergo	  
AVR	  (Table	  2).	  This	  is	  despite	  the	  two	  groups	  being	  well	  matched	  in	  terms	  of	  age,	  indexed	  LVEDV,	  
ejection	  fraction,	  aortic	  valve	  area,	  indexed	  LV	  mass,	  hypertension,	  diabetes	  mellitus	  and	  
concomitant	  coronary	  artery	  disease.	  	  Furthermore,	  over	  half	  of	  the	  patients	  with	  mid-­‐wall	  fibrosis	  
who	  died	  had	  moderate	  aortic	  stenosis	  and	  would	  not	  have	  been	  considered	  for	  AVR	  under	  
conventional	  management	  practice.	  Myocardial	  fibrosis	  may	  therefore	  have	  a	  role	  in	  the	  risk	  
stratification	  of	  patients	  being	  considered	  for	  surgery.	  	  
	  
Interestingly	  it	  would	  appear	  that	  once	  established	  mid-­‐wall	  fibrosis	  is	  not	  reversible	  following	  AVR.	  
Weidemann	  et	  al	  showed	  no	  change	  in	  the	  degree	  of	  LGE	  9-­‐months	  post	  AVR.122	  	  In	  our	  study	  CMR	  was	  
repeated	  in	  one	  patient	  a	  year	  after	  surgery.	  The	  presence	  of	  mid-­‐wall	  fibrosis	  and	  the	  %	  LGE	  mass	  
remained	  unchanged	  (4.6%	  at	  baseline	  vs.	  4.4%	  after	  1	  year).	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In	  accordance	  the	  adverse	  prognosis	  associated	  with	  mid-­‐wall	  fibrosis	  also	  persists	  to	  a	  degree	  
following	  AVR.	  The	  mortality	  rate	  amongst	  patient	  in	  the	  mid-­‐wall	  group	  who	  underwent	  AVR	  was	  53.8	  
per	  1000	  patient-­‐years	  compared	  to	  13.7	  per	  1000	  patient-­‐years	  in	  the	  no	  LGE	  group.	  
	  
The	  benefit	  of	  AVR	  in	  mid-­‐wall	  fibrosis	  may	  instead	  be	  related	  to	  the	  prevention	  of	  subsequent	  fibrosis	  
and	  the	  further	  associated	  increases	  in	  left	  ventricular	  dysfunction	  and	  tendency	  to	  arrhythmia.	  	  
	  
Limitations	  
The	  symptomatic	  status	  of	  our	  cohort	  was	  not	  assessed.	  This	  is	  an	  important	  prognostic	  marker	  in	  
aortic	  stenosis	  and	  it	  would	  be	  interesting	  to	  investigate	  its	  association	  with	  the	  presence	  of	  late	  
gadolinium	  enhancement.	  Twenty-­‐seven	  patients	  died	  during	  the	  course	  of	  our	  study,	  so	  that	  fitting	  
more	  than	  three	  variables	  in	  to	  the	  multivariate	  analysis	  may	  be	  problematic.	  Post-­‐hoc	  analysis	  
performed	  using	  the	  homoscedastic	  adjustment	  inflation	  factor	  suggested	  there	  was	  no	  evidence	  of	  
over	  fitting	  in	  our	  model	  nevertheless	  a	  multi-­‐centre	  study	  involving	  a	  larger	  cohort	  with	  longer	  
follow	  up	  is	  required	  for	  confirmation	  of	  our	  findings	  and	  definitive	  conclusions	  about	  differential	  risk	  
based	  on	  multivariate	  analysis.	  Further	  attention	  must	  also	  be	  paid	  to	  the	  mechanisms	  underlying	  the	  
increased	  mortality	  (including	  the	  incidence	  of	  arrhythmia,	  sudden	  cardiac	  death	  and	  symptoms)	  and	  
the	  role	  of	  AVR	  in	  modulating	  this	  risk.	  	  Ultimately	  such	  studies	  may	  pave	  the	  way	  for	  randomised	  
control	  trials	  of	  anti-­‐fibrotic	  medications	  in	  the	  treatment	  of	  this	  common	  clinical	  condition.	  	  
	  
At	  the	  Royal	  Brompton	  Hospital	  local	  guidelines	  recommend	  CMR	  for	  all	  patients	  with	  severe	  aortic	  
stenosis.	  However	  patients	  with	  moderate	  disease	  were	  referred	  at	  the	  discretion	  of	  their	  clinician	  
and	  therefore	  there	  may	  have	  been	  some	  referral	  bias	  in	  this	  group.	  Finally	  established	  LGE	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techniques	  detect	  areas	  of	  replacement	  fibrosis	  within	  the	  myocardium.	  Diffuse	  interstitial	  fibrosis	  
can	  be	  detected	  using	  T1	  mapping	  techniques	  184	  and	  this	  has	  not	  been	  assessed	  in	  our	  study.	  Whilst	  
this	  form	  of	  fibrosis	  predominates	  in	  aortic	  stenosis,	  T1	  mapping	  has	  not	  been	  validated,	  whereas	  LGE	  
is	  already	  established	  in	  everyday	  clinical	  practice.	  	  
	  
Conclusions	  
We	  have	  shown	  that	  CMR-­‐detected	  mid-­‐wall	  fibrosis	  is	  an	  independent	  predictor	  of	  mortality	  in	  
patients	  with	  moderate	  and	  severe	  aortic	  stenosis	  and	  is	  of	  incremental	  value	  in	  the	  prognostic	  
model	  to	  ejection	  fraction.	  It	  may	  prove	  a	  useful	  method	  of	  risk	  stratification	  in	  patients	  with	  
advanced	  aortic	  valve	  disease	  or	  as	  a	  future	  target	  for	  anti-­‐fibrotic	  medication.	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Cardiovascular	  magnetic	  resonance	  (CMR)	  is	  the	  gold	  standard	  non-­‐invasive	  method	  for	  determining	  
left	  ventricular	  (LV)	  mass	  and	  volume	  but	  has	  not	  been	  used	  previously	  to	  characterise	  the	  LV	  
remodelling	  response	  in	  aortic	  stenosis.	  We	  sought	  to	  investigate	  the	  degree	  and	  patterns	  of	  
hypertrophy	  in	  aortic	  stenosis	  using	  CMR.	  	  
	  
Methods	  	  
Patients	  with	  moderate/	  severe	  aortic	  stenosis,	  normal	  coronary	  arteries	  and	  no	  other	  significant	  
valve	  lesions	  or	  cardiomyopathy	  were	  scanned	  by	  CMR	  with	  valve	  severity	  assessed	  by	  planimetry	  
and	  velocity	  mapping.	  The	  extent	  and	  patterns	  of	  hypertrophy	  were	  investigated	  based	  upon	  
measurements	  of	  indexed	  LV	  mass,	  indexed	  LV	  volume	  and	  the	  relative	  wall	  mass.	  Asymmetric	  forms	  
of	  remodelling	  and	  hypertrophy	  were	  defined	  as	  a	  ventricular	  wall	  thickening	  >12mm	  that	  was	  >1.5-­‐
fold	  the	  thickness	  of	  the	  opposing	  myocardial	  segment.	  	  
	  
Results	  
Ninety-­‐one	  patients	  (61±21	  years;	  57	  male)	  with	  aortic	  stenosis	  (aortic	  valve	  area	  0.93±0.32cm2)	  were	  
studied.	  The	  degree	  of	  hypertrophy	  was	  unrelated	  to	  aortic	  stenosis	  severity	  (r=0.068,	  P=0.53).	  
Furthermore	  there	  was	  wide	  variation	  in	  LV	  morphology	  comprising	  normal	  ventricular	  geometry	  
(n=11),	  concentric	  remodelling	  (n=11),	  asymmetric	  remodelling	  (n=11),	  concentric	  hypertrophy	  
(n=34),	  asymmetric	  hypertrophy	  (n=14)	  and	  LV	  decompensation	  (n=10).	  Asymmetric	  forms	  of	  
remodelling	  and	  hypertrophy	  displayed	  considerable	  overlap	  in	  appearance	  (wall	  thickness	  17±2mm)	  
to	  patients	  with	  hypertrophic	  cardiomyopathy.	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Conclusions	   	  
We	  have	  characterised	  six	  patterns	  of	  LV	  adaption	  in	  response	  to	  aortic	  stenosis	  and	  have	  	  	  
demonstrated	  that	  the	  degree	  of	  hypertrophy	  is	  independent	  of	  the	  severity	  of	  valve	  narrowing.	  This	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6.2	  INTRODUCTION	  
Aortic	  stenosis	  is	  characterised	  by	  progressive	  narrowing	  of	  the	  aortic	  valve	  and	  can	  be	  considered	  
the	  paradigm	  for	  left	  ventricular	  pressure	  overload.	  The	  ventricle	  responds	  to	  this	  pressure	  overload	  
by	  triggering	  a	  hypertrophic	  response,	  leading	  to	  an	  increase	  in	  myocyte	  size,	  left	  ventricular	  wall	  
thickness	  and	  mass.	  	  Initially	  this	  response	  restores	  wall	  stress52,	  53	  but	  ultimately	  proves	  maladaptive	  
and	  predicts	  an	  adverse	  prognosis	  in	  both	  hypertension	  and	  aortic	  stenosis.4,	  56,	  58	  	  
	  
There	  is	  wide	  individual	  variation	  in	  both	  the	  degree	  and	  pattern	  of	  hypertrophy	  observed	  in	  aortic	  
stenosis.	  Indeed,	  four	  different	  patterns	  of	  anatomic	  adaption	  have	  been	  categorized	  using	  
echocardiographic	  measurements	  of	  left	  ventricular	  mass,	  volumes	  and	  the	  relative	  wall	  thickness.185,	  
186	  These	  patterns	  are:	  normal	  ventricular	  geometry,	  concentric	  remodelling,	  concentric	  hypertrophy,	  
and	  eccentric	  hypertrophy.	  Asymmetric	  patterns	  have	  also	  been	  reported,187	  188	  however	  they	  have	  
not	  been	  included	  in	  the	  above	  or	  other	  definitions.	  	  
	  
The	  assessment	  of	  left	  ventricular	  remodelling	  and	  hypertrophy	  by	  echocardiography	  has	  several	  
limitations	  when	  compared	  to	  cardiovascular	  magnetic	  resonance	  (CMR).	  This	  technique	  offers	  the	  
more	  precise	  measurements	  of	  left	  ventricular	  mass,	  volume	  and	  wall	  thickness189-­‐191	  but	  has	  not	  
previously	  been	  used	  to	  characterise	  the	  hypertrophic	  response	  of	  the	  left	  ventricle	  to	  aortic	  stenosis.	  	  
The	  aim	  of	  this	  study	  was	  to	  use	  CMR	  to	  investigate	  both	  the	  different	  morphological	  patterns	  of	  LV	  
adaption	  observed	  in	  this	  condition	  and	  the	  factors	  affecting	  the	  magnitude	  of	  the	  hypertrophic	  
response.	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6.3	  METHODS	  
	  
Patients	  with	  Aortic	  Stenosis	  
As	  described	  in	  Chapters	  2	  and	  5	  patients	  with	  aortic	  stenosis	  who	  were	  referred	  to	  the	  Royal	  
Brompton	  Hospital	  for	  CMR	  were	  enrolled	  into	  a	  registry.	  Briefly	  patients	  with	  moderate	  or	  severe	  
disease	  were	  considered	  for	  this	  study	  regardless	  of	  whether	  late	  gadolinium	  enhancement	  had	  been	  
performed.	  In	  order	  to	  study	  the	  effects	  of	  aortic	  stenosis	  on	  the	  ventricle	  in	  isolation,	  the	  patient	  
group	  was	  carefully	  selected	  to	  avoid	  those	  with	  confounding	  drivers	  of	  left	  ventricular	  remodelling.	  
Stringent	  exclusion	  criteria	  were	  therefore	  employed	  as	  described	  in	  Chapter	  2.	  Briefly	  patients	  with	  
other	  forms	  of	  cardiac	  disease	  were	  excluded	  with	  the	  exception	  of	  those	  with	  mild	  or	  moderate	  
hypertension	  (based	  on	  an	  established	  clinical	  diagnosis).	  Comprehensive	  baseline	  clinical	  
characteristics	  and	  history	  were	  obtained	  using	  a	  standardised	  structured	  proforma	  and	  were	  
completed	  from	  source	  clinic	  record	  data	  and	  patient	  questionnaires.	  	  
	  
CMR	  Protocol	  
CMR	  was	  performed	  on	  Avanto	  1.5T	  magnetic	  resonance	  scanners	  and	  analysed	  as	  described	  in	  
Chapters	  2	  and	  5.	  Left	  ventricular	  dilatation	  and	  hypertrophy	  were	  defined	  as	  an	  indexed	  left	  
ventricular	  end-­‐diastolic	  volume	  and	  mass	  above	  the	  95th	  percentile	  respectively	  after	  correcting	  for	  
age	  and	  gender	  according	  to	  the	  widely	  used	  normal	  ranges	  published	  Maceira	  et	  al.134	  Similarly	  left	  
ventricular	  ejection	  fraction	  was	  reduced	  if	  <95th	  percentile.134	  Wall	  thickness	  measurements	  were	  
made	  as	  described	  in	  Chapter	  3.	  	  Asymmetric	  left	  ventricular	  wall	  thickening	  was	  defined	  as	  a	  regional	  
wall	  thickening	  of	  greater	  than	  12	  mm	  that	  was	  >1.5-­‐fold	  the	  thickness	  of	  the	  opposing	  myocardial	  
segment.	  Criteria	  had	  to	  be	  fulfilled	  on	  two	  adjacent	  short-­‐axis	  slices.	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The	  Relative	  Wall	  Mass	  
The	  relative	  wall	  mass	  is	  the	  conceptual	  equivalent	  of	  the	  echocardiogram-­‐derived	  relative	  wall	  
thickness192-­‐194	  and	  is	  calculated	  by	  dividing	  the	  left	  ventricular	  mass	  by	  the	  left	  ventricular	  end	  
diastolic	  volume.	  Both	  index	  wall	  thickness	  to	  cavity	  size,	  but	  the	  relative	  wall	  mass	  is	  based	  on	  the	  
geometry	  of	  the	  ventricle	  as	  a	  whole	  and	  not	  2-­‐dimensional	  measurements	  of	  wall	  thickness.	  
However,	  because	  the	  relative	  wall	  mass	  lacks	  a	  well-­‐defined	  normal	  reference	  range,	  age	  and	  sex-­‐
matched	  healthy	  volunteers	  without	  co-­‐existent	  coronary	  artery	  disease,	  hypertension,	  aortic	  
stenosis	  or	  other	  forms	  of	  heart	  disease	  were	  recruited	  and	  scanned	  contemporaneously	  in	  order	  to	  
facilitate	  its	  quantification.	  
	  
	  
Definition	  of	  the	  Patterns	  of	  Left	  Ventricular	  Hypertrophy	  and	  Remodelling	  
Patients	  were	  subsequently	  categorised	  into	  six,	  pre-­‐defined	  patterns	  of	  left	  ventricular	  anatomic	  
adaption	  according	  to	  the	  indexed	  LV	  mass,	  indexed	  LV	  volume	  and	  the	  relative	  wall	  mass.	  Normal	  
ventricular	  structure,	  characterised	  by	  normal	  relative	  wall	  mass	  and	  normal	  LV	  indexed	  mass	  and	  
volume.	  Concentric	  remodelling,	  characterised	  by	  an	  increased	  relative	  wall	  mass	  but	  normal	  indexed	  
LV	  mass.	  Asymmetric	  remodelling,	  similar	  to	  concentric	  remodelling	  but	  with	  evidence	  of	  asymmetric	  
wall	  thickening.	  Concentric	  Hypertrophy,	  characterised	  by	  an	  increased	  relative	  wall	  mass	  and	  
indexed	  LV	  mass.	  Asymmetric	  hypertrophy,	  similar	  to	  concentric	  hypertrophy	  but	  with	  evidence	  of	  
asymmetric	  wall	  thickening.	  Eccentric	  hypertrophy,	  characterised	  by	  a	  normal	  relative	  wall	  mass	  and	  
a	  dilated	  left	  ventricle.	  	  
	  
Statistical	  analysis	  
Continuous	  variables	  were	  expressed	  as	  mean	  ±	  standard	  deviation,	  and	  compared	  using	  unpaired	  
Student’s	  t-­‐test	  or	  one-­‐way	  analysis	  of	  variance	  where	  appropriate.	  Categorical	  variables	  were	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expressed	  as	  percentages	  and	  analyzed	  using	  the	  chi-­‐squared	  test.	  Correlation	  between	  normally	  
distributed	  data	  was	  performed	  using	  Pearson’s	  correlation.	  All	  statistical	  analysis	  was	  performed	  
using	  Stata	  10.1	  software	  (StataCorp,	  Texas,	  USA).	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Ninety-­‐one	  patients	  (61±21	  years;	  57	  male)	  were	  assessed	  and	  had	  moderate	  (31%)	  or	  severe	  (69%)	  
aortic	  stenosis	  and	  a	  mean	  aortic	  valve	  area	  (AVA)	  of	  0.93±0.32	  cm2	  (Table	  6.1).	  Ninety-­‐one	  healthy	  
control	  subjects	  were	  identified	  and	  matched	  for	  age	  and	  sex	  (mean	  age	  61±10	  years,	  61%	  male).	  
Relative	  wall	  mass	  in	  this	  group	  was	  0.88±0.14	  (95%	  confidence	  intervals:	  0.60	  to	  1.16)	  g/mL	  and	  
displayed	  an	  apparent	  weak	  association	  with	  age	  (r=0.189,	  P=0.073).	  M/V	  was	  higher	  in	  males	  than	  
females	  but	  this	  difference	  was	  small	  (0.91±0.13	  vs	  0.84±0.15;	  P=0.02)	  and	  there	  was	  little	  difference	  
in	  the	  upper	  95%	  confidence	  interval.	  The	  relative	  wall	  mass	  was	  subsequently	  calculated	  for	  each	  
patient	  in	  the	  aortic	  stenosis	  group	  and	  values	  above	  1.16	  g/mL	  were	  considered	  elevated.	  
	  
Determinants	  of	  Left	  Ventricular	  Hypertrophy	  	  
Indexed	  left	  ventricular	  mass	  was	  unrelated	  to	  aortic	  stenosis	  severity	  both	  in	  terms	  of	  the	  aortic	  
valve	  area	  (r=0.068	  P=0.53,	  Figure	  6.1)	  and	  the	  aortic	  valve	  area	  indexed	  to	  body	  surface	  area	  (r=	  -­‐
0.046,	  P=0.666).	  There	  was	  no	  difference	  in	  the	  degree	  of	  hypertrophy	  between	  patients	  with	  
moderate	  and	  severe	  disease	  (mean	  difference	  in	  mass	  3.9	  g/m2;	  95%	  CI,	  -­‐7.6	  to	  15.5	  g/m2,	  
P=0.50).	  Male	  sex	  was	  the	  only	  variable	  associated	  with	  an	  increased	  indexed	  LV	  mass,	  being	  13.8	  
g/m2	  (95%	  CI,	  2.8	  to	  24.7	  g/m2,	  P=0.02)	  higher	  in	  men	  (Table	  6.2).	  There	  was	  also	  an	  apparent	  
trend	  to	  an	  increased	  mass	  with	  co-­‐existent	  hypertension	  (mean	  difference	  9.9	  g/m2;	  95%	  CI,	  -­‐1.1	  
to	  20.9	  g/m2,	  P=0.08).	  	  
	  
	   	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   146	  
Table	  6.1.	  Characteristics	  of	  patients	  with	  different	  forms	  of	  remodelling	  and	  hypertrophy	  
	  


















11	   11	   11	   34	   14	   10	  
Male	  sex	  (%)	  
	  
45	   55	   82	   65	   64	   60	  
Age	  (years)	  
	  
52±26	   54±21	   70±12	   57±18	   75±11	   69±18	  
CMR	  DATA	   	   	  
	   Indexed	  LVEDV	  	  
(mL/m2)	  
76±9	   55±12	   56±9	   77±19	   78±24	   126±34	  
	   Indexed	  Mass	  	  	  
(g/m2)	  
63±11	   75±10	   78±7	   113±21	   110±24	   106±18	  
	   Relative	  wall	  mass	  	  
(g/mL)	  
0.84±0.16	   1.39±0.31	   1.43±0.28	   1.51±0.28	   1.47±0.33	   0.88±0.19	  
	   Maximal	  wall	  
thickness	  (mm)	  
11±2	   13±3	   17±2	   15±2	   17±2	   13±2	  
	   Ejection	  Fraction	  	  
(%)	  
73±5	   77±9	   76±15	   70±13	   67±14	   42	  
(30-­‐48)	  
	   Impaired	  Ejection	  
Fraction	  (%)	  
0	   0	   0	   15	   14	   100	  
	   Aortic	  valve	  area	  	  
(cm2)	  
0.85±0.30	   0.90±0.43	   1.10±0.32	   0.98±0.34	   0.86±0.25	   0.80±0.16	  
	   Peak	  Velocity	  	  
(m/s)	  
3.6±0.4	   3.6±0.8	   3.42±0.67	   4.0±0.97	   3.80±0.76	   3.8±0.8	  
	   Severe	  AS	  (%)	   73	   64	   45	   65	   78	   100	  
	   Bicuspid	  valve	  (%)	   55	   45	   27	   41	   29	   40	  
	   Hypertension	  (%)	   9	   18	   64	   38	   64	   50	  
	   Diabetes	  Mellitus	  
(%)	  
18	   0	   18	   15	   7	   30	  
	   ACEi	  /	  ARB	  (%)	   20	   10	   55	   39	   36	   22	  
	   Beta	  blocker	  (%)	  
	  
20	   10	   37	   18	   18	   20	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Table	  6.2.	  The	  association	  between	  the	  indexed	  left	  ventricular	  mass	  and	  different	  independent	  variables	  
	  
Variable	  
Mean	  difference	  in	  
Indexed	  Mass	  (g)	  
Confidence	  Intervals	   p	  value	  
Age	  >66	  years	   7.5	   -­‐3.4	  –	  18.4	   0.17	  
Male	  	   13.8	   2.8	  –	  24.7	   0.02	  
Moderate	  Aortic	  Stenosis	   3.9	   -­‐7.6	  –	  15.5	   0.50	  
Bicuspid	  	   -­‐7.3	   -­‐18.4	  –	  3.9	   0.20	  
Hypertension	   9.9	   -­‐1.1	  –	  20.9	   0.08	  
Diabetes	  mellitus	   11.9	   -­‐3.6	  –	  27.4	   0.13	  
ACE	  Inhibitor	  /	  ARB	   11.2	   -­‐1.00	  –	  23.3	   0.07	  
β-­‐Blocker	   3.2	   -­‐11.2	  –	  17.6	   0.66	  
Male	  sex	  was	  the	  only	  variable	  associated	  with	  a	  significant	  increase	  in	  the	  indexed	  LV	  mass,	  being	  13.8g/m2	  higher	  in	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Left	  Ventricular	  Characteristics	  of	  Patients	  with	  Aortic	  Stenosis	  
Twelve	  per	  cent	  (n=11)	  of	  subjects	  had	  normal	  left	  ventricular	  structure	  and	  24%	  left	  ventricular	  
remodelling	  (n=22;	  11	  asymmetric	  and	  11	  concentric)	  (Table	  6.1,	  Figure	  6.2).	  Left	  ventricular	  
hypertrophy	  was	  the	  most	  prevalent	  pattern	  and	  occurred	  in	  53%	  (n=48)	  of	  subjects	  (concentric	  71%;	  
asymmetric	  29%).	  Absolute	  wall	  thickness	  was	  similar	  between	  patients	  with	  remodelling	  and	  
hypertrophy	  (15±3	  vs	  16±2mm;	  P=0.16)	  but	  the	  indexed	  mass	  was	  significantly	  higher	  in	  those	  with	  
hypertrophy	  (112±22	  vs	  76±9	  g/m2;	  P<0.001)	  and	  the	  LVEDV	  lower	  in	  those	  with	  remodelling	  (78±20	  
vs	  56±10	  ml/m2;	  P<0.001).	  In	  the	  majority	  of	  patients	  with	  hypertrophy,	  left	  ventricular	  ejection	  
fraction	  was	  preserved	  but	  it	  was	  impaired	  in	  15%	  (n=7;	  mean	  ejection	  fraction	  of	  48%).	  Criteria	  for	  
eccentric	  hypertrophy	  was	  met	  in	  11%	  (n=10).	  However,	  each	  patient	  in	  this	  group	  had	  impaired	  
systolic	  function	  and	  a	  reduced	  ejection	  fraction	  (45±16%;	  p<0.001	  vs	  normal	  group).	  This	  is	  different	  
from	  the	  classical	  definition	  of	  eccentric	  hypertrophy,	  observed	  in	  athletes	  and	  aortic	  regurgitation	  in	  
whom	  ejection	  fraction	  is	  preserved.	  This	  group	  was	  therefore	  reclassified	  as	  having	  LV	  
decompensation	  (Figure	  6.2).	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Schematic	  representation	  of	  the	  left	  ventricular	  structure	  alongside	  CMR	  short-­‐axis	  images	  of	  the	  left	  ventricle	  in	  end-­‐
diastole.	  Normal	  ventricular	  structure,	  characterised	  by	  a	  normal	  LV	  indexed	  mass	  and	  volume,	  and	  a	  normal	  relative	  wall	  
mass.	  Concentric	  remodelling,	  characterised	  by	  an	  increased	  relative	  wall	  mass	  and	  normal	  indexed	  LV	  mass.	  	  Asymmetric	  
remodelling,	  similar	  to	  concentric	  remodelling	  except	  that	  in	  addition	  there	  is	  evidence	  of	  asymmetric	  wall	  thickening.	  
Concentric	  Hypertrophy,	  characterised	  by	  an	  increased	  relative	  wall	  mass	  and	  indexed	  LV	  mass.	  Asymmetric	  hypertrophy,	  
similar	  to	  concentric	  hypertrophy	  except	  that	  in	  addition	  there	  is	  evidence	  of	  asymmetric	  wall	  thickening.	  Left	  Ventricular	  
Decompensation,	  characterised	  by	  a	  dilated	  left	  ventricle	  and	  normal	  relative	  wall	  mass.	  The	  LV	  mass	  is	  increased	  primarily	  
due	  to	  LV	  dilatation.	  é	  increased;	  ê	  decreased;	  =	  normal;	  ✔	  present;	  ✖	  absent.	  














Normal	   =	   =	   =	   ✖	   =	  
Concentric	  Remodelling	   =	  
	  
ê	   é	   ✖	   =/é	  
Asymmetric	  Remodelling	   =	  
	  
ê	   é	   ✔	   =/é	  
Concentric	  Hypertrophy	   é	   =	   é	   ✖	   =/ê	  
Asymmetric	  Hypertrophy	   é	   =	   é	   ✔	   =/ê	  
LV	  Decompensation	   é	   é	   =	   ✖	   ê	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There	  was	  no	  clear	  relationship	  between	  aortic	  stenosis	  severity	  and	  the	  pattern	  of	  LV	  
remodelling/hypertrophy	  except	  that	  those	  with	  LV	  decompensation	  appeared	  to	  have	  the	  most	  
severe	  disease.	  	  However,	  our	  study	  was	  not	  powered	  to	  detect	  differences	  between	  these	  groups.	  	  
	  
Asymmetric	  versus	  Concentric	  Patterns	  of	  Wall	  Thickness	  	  
An	  asymmetric	  pattern	  of	  left	  ventricular	  wall	  thickness	  was	  observed	  in	  25	  patients	  with	  remodelling	  
or	  hypertrophy	  (Table	  6.3).	  Compared	  to	  concentric	  patterns,	  patients	  were	  older	  (72±11	  vs	  56±19	  
years,	  P<0.001),	  more	  likely	  to	  have	  hypertension	  (64	  vs	  33%,	  P=0.01)	  and	  had	  a	  greater	  maximal	  wall	  
thickness	  (17±2	  vs	  15±3mm,	  P<0.001).	  The	  site	  of	  asymmetry	  was	  most	  often	  in	  the	  basal	  septum	  
(Figure	  6.3)	  and	  affected	  two	  segments	  of	  the	  17-­‐segment	  model	  in	  72%	  of	  subjects	  (1	  segment	  in	  
24%;	  3	  segments	  in	  4%).	  In	  7%,	  it	  affected	  the	  basal	  anterior	  wall	  but	  otherwise	  focal	  wall	  thickening	  
was	  not	  observed	  outwith	  the	  septum.	  	  
	  
	  
Figure	  6.3.	  Site	  of	  maximal	  wall	  thickening	  in	  asymmetric	  hypertrophy	  and	  remodelling	  based	  on	  
the	  17-­‐segment	  model	  of	  the	  left	  ventricle.	  (This	  often	  involved	  more	  than	  one	  segment)	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Table	  6.3.	  	   Comparison	  of	  characteristics	  of	  patients	  with	  asymmetric	  and	  concentric	  forms	  of	  









	   Concentric	   Asymmetric	   p-­‐value	  
Number	  	   45	   25	   -­‐	  
Age	  (years)	   56±19	   72±11	   <0.01	  
Male	  sex	  (%)	   62	   68	   0.41	  
Indexed	  Mass	  (g/m2)	   103±25	   96±25	   0.23	  
Max	  wall	  thickness	  (mm)	   15±3	   17±2	   <0.01	  
Remodelling	  (%)	   24	  	   44	   0.09	  
Aortic	  valve	  area	  (cm2)	   0.96±0.36	   0.96±0.30	   0.83	  
Ejection	  Fraction	   72±12	   71±15	   0.79	  
Indexed	  LVEDV	  (mL/m2)	   72±20	   69±22	   0.57	  
Hypertension	  (%)	   33	   64	   0.01	  
Diabetes	  Mellitus	  (%)	   11	   12	   0.91	  
ACE	  inhibitor	  	  /	  ARB	  use	  (%)	   33	   45	   0.45	  
Beta-­‐blocker	  (%)	   16	   27	   0.32	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6.5	  DISCUSSION	  
	  
This	  is	  the	  first	  study	  to	  use	  CMR	  to	  investigate	  both	  the	  magnitude	  of	  the	  hypertrophic	  response	  and	  
the	  different	  morphological	  patterns	  of	  remodelling/	  hypertrophy	  observed	  in	  patients	  with	  aortic	  
stenosis.	  We	  have	  demonstrated	  that	  the	  degree	  of	  hypertrophy	  is	  independent	  of	  the	  severity	  of	  
valve	  stenosis	  severity	  and	  have	  categorized	  patients	  into	  six	  distinct	  patterns	  of	  left	  ventricular	  
adaption.	  These	  patterns	  provide	  a	  more	  detailed	  description	  of	  the	  left	  ventricular	  myocardial	  
response	  to	  pressure	  overload	  in	  this	  condition	  and	  they	  include	  a	  high	  prevalence	  of	  asymmetric	  
forms	  of	  remodelling	  and	  hypertrophy.	  Furthermore	  in	  the	  absence	  of	  other	  triggers	  to	  remodelling	  
no	  patients	  fulfilled	  criteria	  for	  eccentric	  hypertrophy.	  Instead	  a	  decompensated	  form	  of	  remodelling	  
associated	  with	  left	  ventricular	  dilatation,	  wall	  thinning	  and	  systolic	  impairment	  was	  observed.	  	  
	  	  
Magnitude	  of	  the	  Hypertrophic	  Response	  
The	  magnitude	   of	   left	   ventricular	   hypertrophy	   varied	   widely	   but	   was	   unrelated	   to	   the	   severity	   of	  
aortic	   stenosis,	   such	   that	   patients	   with	   severe	   valve	   narrowing	   were	   observed	   to	   have	   normal	  
ventricular	   structure	  whilst	   patients	  with	  moderate	   disease	   often	   had	   extensive	   hypertrophy.	   This	  
observation	  is	  important	  because	  increased	  LV	  mass	  is	  associated	  with	  the	  presence	  of	  mid-­‐wall	  late	  
gadolinium	  enhancement,	  which	  is	  associated	  with	  an	  increased	  mortality.195	  Indeed,	  left	  ventricular	  
hypertrophy	  is	  an	   independent	  predictor	  of	  cardiac	  mortality,	  regardless	  of	  aetiology.4,	  56-­‐58	  There	   is	  
therefore	   a	   strong	   rationale	   for	   considering	   the	   hypertrophic	   response	   alongside	   the	   degree	   of	  
valvular	  narrowing	  when	  making	  an	  assessment	  of	  the	  overall	  disease	  severity.	   	  Further	  studies	  are	  
required	   to	   assess	   whether,	   for	   example,	   patients	   with	   moderate	   disease	   but	   an	   advanced	  
hypertrophic	  response	  would	  benefit	  from	  earlier	  intervention.	  	  
	  
Modern	  Imaging	  Techniques	  in	  Aortic	  Stenosis	   Dr	  Marc	  Dweck	  
	   153	  
Male	  gender	  was	  the	  only	  variable	  associated	  with	  an	  increased	  left	  ventricular	  mass	  69,	  196	  although	  
an	   apparent	   trend	   was	   observed	   with	   concomitant	   hypertension.	   The	   latter	   is	   consistent	   with	   an	  
analysis	   of	   the	   Simvastatin	   and	  Ezetimibe	   in	  Aortic	   Stenosis	   (SEAS)	   trial	   showing	   that	  hypertension	  
together	  with	  aortic	  stenosis	  predicted	  increased	  left	  ventricular	  mass	  independent	  of	  other	  known	  
confounders.71	   Strict	   blood	  pressure	   control	  may	   therefore	   provide	   an	   important	   clinical	  means	  of	  
blunting	   the	   hypertrophic	   response.	   Finally	   genetic	   factors	   may	   have	   a	   role.	   They	   modulate	   the	  
magnitude	  of	  hypertrophy	  in	  response	  to	  a	  number	  of	  physiological	  and	  pathological	  triggers.67,	  68,	  180	  
Indeed,	   polymorphisms	   of	   the	   angiotensin-­‐converting	   enzyme	   I/D	   genotype	   have	   been	   associated	  
with	  different	  degrees	  of	  wall	  thickening	  and	  hypertrophy69	  and	  regression	  of	  this	  process	  after	  aortic	  
valve	  replacement.70	  
	  
Six	  Patterns	  of	  Remodelling	  and	  Hypertrophy	  in	  Aortic	  Stenosis	  
In	  line	  with	  previous	  echocardiographic	  definitions,	  we	  have	  observed	  normal	  left	  ventricular	  
structure,	  concentric	  remodelling,	  and	  concentric	  hypertrophy,	  in	  a	  cohort	  of	  patients	  with	  aortic	  
stenosis.	  	  However,	  no	  patient	  in	  our	  cohort	  met	  criteria	  for	  eccentric	  hypertrophy,	  rather	  those	  with	  
a	  dilated	  left	  ventricle	  had	  a	  decompensated	  form	  of	  LV	  remodelling	  associated	  with	  significant	  
impairment	  of	  left	  ventricular	  function.	  Furthermore	  we	  have	  confirmed	  that	  two	  additional	  
geometric	  patterns	  also	  occur	  commonly,	  namely	  asymmetric	  remodelling	  and	  asymmetric	  
hypertrophy.	  An	  asymmetric	  pattern	  of	  wall	  thickening	  was	  in	  fact	  observed	  in	  27%	  of	  our	  cohort	  
being	  particularly	  prevalent	  amongst	  the	  elderly	  and	  in	  those	  with	  hypertension.	  This	  confirms	  the	  
findings	  of	  Tuseth	  et	  al	  who	  described	  asymmetric	  patterns	  of	  wall	  thickening	  in	  22%	  of	  patients	  in	  
aortic	  stenosis	  using	  echocardiography.188	  We	  therefore	  propose	  that	  there	  are	  six	  and	  not	  four	  
common	  geometric	  patterns	  of	  LV	  adaption	  in	  aortic	  stenosis	  (Figure	  6.1).	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Asymmetric	  wall	  thickening	  was	  most	  frequently	  observed	  in	  the	  septum	  at	  the	  basal	  and	  mid-­‐cavity	  
levels	  with	  a	  mean	  of	  17	  mm	  and	  a	  maximum	  of	  22	  mm.	  	  Current	  guidelines	  recommend	  
consideration	  of	  the	  diagnosis	  of	  hypertrophic	  cardiomyopathy	  if	  regional	  wall	  thickness	  exceeds	  15	  
mm.197	  Our	  data	  therefore	  suggests	  considerable	  overlap	  in	  the	  appearances	  of	  asymmetric	  wall	  
thickening	  in	  these	  two	  conditions	  and	  underlines	  the	  fact	  that	  the	  morphological	  diagnosis	  of	  
hypertrophic	  cardiomyopathy	  may	  be	  challenging	  or	  impossible	  in	  the	  context	  of	  an	  increased	  
afterload.	  It	  should	  be	  noticed	  that	  the	  guidelines	  also	  indicate	  that	  hypertrophic	  cardiomyopathy	  
should	  be	  diagnosed	  only	  in	  the	  absence	  of	  another	  condition,	  which	  could	  explain	  the	  hypertrophic	  
responses.	  Nevertheless	  in	  clinical	  practice	  the	  question	  often	  arises	  as	  to	  whether	  patients	  with	  an	  
increased	  afterload	  might	  also	  have	  HCM.	  Furthermore	  it	  is	  plausible	  that	  specific	  genotypes,	  related	  
to	  those	  causing	  hypertrophic	  cardiomyopathy,	  predispose	  to	  an	  asymmetric	  rather	  than	  concentric	  
remodelling	  response	  to	  an	  increased	  afterload.	  In	  line	  with	  this	  theory,	  patients	  with	  hypertension	  
and	  asymmetric	  thickening	  have	  a	  higher	  familial	  incidence	  of	  hypertrophic	  cardiomyopathy	  and	  
more	  myocardial	  disarray.198	  
	  
Left	  Ventricular	  Remodelling	  
Recent	  studies	  have	  suggested	  that	  Identification	  of	  left	  ventricular	  remodelling	  is	  of	  importance	  
because	  it	  can	  be	  associated	  with	  paradoxical	  low	  flow	  aortic	  stenosis,	  in	  which	  the	  small	  cavity	  size	  
and	  resultant	  low	  stroke	  volume	  results	  in	  a	  paradoxically	  low	  transvalvular	  aortic	  valve	  gradient.199	  
Left	  ventricular	  remodelling,	  in	  both	  its	  concentric	  and	  asymmetric	  forms,	  was	  characterized	  by	  a	  
normal	  LV	  mass.	  This	  was	  despite	  an	  increased	  relative	  wall	  mass	  and	  absolute	  wall	  thickness	  
measurements	  that	  were	  similar	  to	  patients	  with	  hypertrophy.	  This	  apparent	  contradiction	  is	  
explained	  by	  the	  small	  cavity	  size	  associated	  with	  remodelling.	  This	  ensures	  that	  increases	  in	  wall	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thickness	  have	  a	  much	  less	  profound	  effect	  on	  LV	  mass	  than	  in	  patients	  with	  hypertrophy,	  who	  have	  





Left	  ventricular	  decompensation	  can	  be	  considered	  as	  the	  end-­‐stage	  of	  the	  hypertrophic	  process	  in	  
which	  the	  left	  ventricle	  has	  failed	  in	  the	  face	  of	  an	  increased	  afterload.	  Although	  ejection	  fraction	  was	  
impaired	  in	  all	  patients	  in	  this	  group,	  not	  all	  patients	  with	  a	  reduction	  in	  ejection	  fraction	  conformed	  
to	  this	  phenotype:	  41%	  had	  either	  concentric	  or	  asymmetric	  hypertrophy.	  It	  is	  likely	  that	  these	  
patients	  are	  in	  the	  early	  stages	  of	  left	  ventricular	  decompensation	  but	  have	  not	  yet	  proceeded	  to	  
overt	  LV	  dilatation.	  They	  represent	  an	  important	  group	  to	  identify	  because	  prompt	  surgery	  might	  
avoid	  a	  further	  deterioration	  in	  ejection	  fraction,	  which	  is	  associated	  with	  poorer	  post-­‐operative	  
recovery	  181,	  and	  may	  prove	  irreversible.	  
	  
The	  Relative	  Wall	  Mass	  
CMR	  is	  widely	  accepted	  as	  the	  gold	  standard	  investigation	  for	  the	  measurement	  of	  left	  ventricular	  
mass	  and	  volume,190,	  191	  and	  affords	  more	  accurate	  measurement	  of	  wall	  thickness	  through	  improved	  
contrast	  between	  the	  blood	  pool	  and	  myocardium,	  and	  the	  ability	  to	  image	  in	  multiple	  planes.189	  We	  
believe	  that	  the	  CMR-­‐derived	  relative	  wall	  mass	  is	  superior	  to	  the	  relative	  wall	  thickness,	  as	  a	  means	  
of	  indexing	  wall	  thickness	  to	  cavity	  size,	  because	  it	  is	  based	  upon	  the	  geometry	  of	  the	  left	  ventricle	  as	  
a	  whole	  and	  is	  not	  limited	  by	  the	  echocardiographic	  windows	  obtained.	  In	  addition,	  the	  relative	  wall	  
mass	  is	  easily	  calculated	  as	  left	  ventricular	  mass	  and	  volumes	  are	  routinely	  quantified	  by	  CMR.	  
Buchner	  et	  al	  have	  previously	  published	  measurements	  for	  this	  variable	  in	  30	  health	  volunteers	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reporting	  values	  of	  0.76±0.18	  g/mL	  and	  an	  upper	  limit	  of	  normal	  of	  1.12	  g/mL.193	  This	  is	  very	  similar	  
to	  the	  findings	  in	  our	  larger	  control	  cohort,	  and	  demonstrates	  consistency	  of	  this	  measurement.	  The	  
apparent	  trend	  to	  a	  modest	  rise	  in	  the	  relative	  wall	  mass	  with	  increasing	  age,	  may	  reflect	  the	  higher	  
arterial	  blood	  pressure	  and	  stiffness	  seen	  in	  older	  individuals.	  
	  
Study	  Limitations	  
In	  our	  institution	  local	  guidelines	  recommend	  CMR	  for	  all	  patients	  with	  severe	  aortic	  stenosis.	  
However	  patients	  with	  moderate	  disease	  were	  referred	  at	  the	  discretion	  of	  their	  clinician	  and	  
therefore	  there	  may	  have	  been	  some	  referral	  bias	  in	  this	  group.	  In	  addition,	  we	  had	  incomplete	  data	  
on	  the	  duration	  of	  aortic	  stenosis.	  In	  practice,	  this	  is	  difficult	  to	  adjudicate	  because	  the	  majority	  of	  
patients	  will	  have	  subclinical	  disease	  for	  many	  years	  before	  a	  murmur	  is	  detected	  and	  the	  diagnosis	  
established.	  The	  symptomatic	  status	  of	  our	  cohort	  was	  not	  assessed	  and	  it	  would	  be	  interesting	  to	  
investigate	  its	  association	  with	  the	  pattern	  of	  remodeling.	  
	  
Multi-­‐centre	  longitudinal	  trials	  are	  required	  to	  provide	  prognostic	  information	  and	  specifically	  to	  
determine	  whether	  and	  how	  patients	  transition	  between	  these	  various	  geometric	  patterns.	  In	  the	  era	  
of	  transcatheter	  aortic	  valve	  implantation	  (TAVI),	  where	  earlier	  treatment	  may	  have	  benefit,	  it	  will	  
also	  be	  important	  to	  assess	  if	  the	  different	  patterns	  of	  remodelling	  and	  hypertrophy	  show	  variable	  
potential	  for	  reverse	  remodelling	  following	  intervention.	  
	  
In	  clinical	  practice	  aortic	  stenosis	  is	  often	  associated	  with	  aortic	  or	  mitral	  regurgitation,	  coronary	  
artery	  disease	  and	  myocardial	  infarction200	  that	  result	  in	  a	  composite	  form	  of	  ventricular	  adaption	  in	  
many	  patients.	  In	  our	  study,	  we	  rigorously	  excluded	  patients	  with	  these	  co-­‐morbidities	  so	  that	  the	  
patterns	  of	  left	  ventricular	  remodelling	  and	  hypertrophy	  observed	  can	  be	  considered	  the	  direct	  result	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of	  aortic	  valve	  narrowing	  and	  the	  associated	  increase	  in	  afterload.	  However,	  this	  has	  resulted	  in	  a	  
selection	  bias	  against	  more	  elderly	  patients	  and	  does	  limit	  the	  generalizability	  of	  our	  findings.	  	  
	  
In	  patients	  with	  left	  ventricular	  hypertrophy	  the	  ejection	  fraction	  may	  over	  estimate	  LV	  systolic	  
function.	  Other	  measures	  such	  the	  corrected	  mid-­‐wall	  shortening	  may	  better	  reflect	  myocardial	  




There	  is	  marked	  variation	  in	  the	  hypertrophic	  response	  of	  the	  LV	  to	  aortic	  stenosis.	  The	  degree	  of	  
hypertrophy	  is	  independent	  of	  the	  severity	  of	  valve	  narrowing	  and	  it	  can	  be	  characterised	  into	  six	  
distinct	  patterns	  of	  LV	  adaption,	  including	  asymmetric	  patterns	  that	  show	  considerable	  overlap	  with	  
hypertrophic	  cardiomyopathy.	  This	  variation	  highlights	  the	  importance	  of	  detailing	  the	  left	  ventricular	  
remodelling	  response	  in	  all	  patients	  with	  aortic	  stenosis,	  particularly	  given	  the	  adverse	  prognosis	  
associated	  with	  increased	  levels	  of	  hypertrophy.	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CONCLUSIONS	  
7.1	  SUMMARY	  OF	  FINDINGS	  
	  
The	  studies	  in	  this	  thesis	  have	  successfully	  applied	  PET/CT	  to	  the	  study	  of	  inflammation	  and	  
calcification	  within	  the	  valves	  of	  patients	  with	  aortic	  stenosis	  and	  used	  CMR	  to	  study	  the	  left	  
ventricular	  hypertrophic	  response	  and	  myocardial	  fibrosis.	  In	  so	  doing	  they	  have	  provided	  some	  key	  
insights	  in	  to	  the	  pathogenesis	  of	  this	  common	  cardiac	  condition.	  	  
	  
Uptake	  of	  18F-­‐NaF	  and	  18F-­‐FDG	  in	  the	  aortic	  valve	  
In	  this	  study	  the	  assessment	  of	  valvular	  calcification	  and	  inflammation	  using	  PET/CT	  was	  shown	  to	  be	  
feasible	  and	  its	  quantification	  reproducible.	  Indeed	  measures	  of	  inter-­‐observer	  and	  intra-­‐observer	  
reproducibility	  were	  excellent	  for	  both	  18F-­‐NaF	  and	  18F-­‐FDG.	  However	  the	  PET/CT	  scans	  were	  not	  
performed	  a	  second	  time	  in	  our	  patients	  and	  so	  further	  studies	  are	  required	  to	  assess	  inter-­‐scan	  
reproducibility.	  	  In	  addition	  satisfactory	  reproducibility	  was	  only	  achieved	  for	  18F-­‐FDG	  measurements	  
when	  peripheral	  regions	  of	  the	  valve	  were	  excluded	  (the	  centre-­‐valve	  technique).	  Myocardial	  uptake	  
of	  18F-­‐FDG	  presents	  a	  major	  challenge	  in	  assessing	  tracer	  activity	  in	  both	  the	  valve	  and	  the	  coronary	  
vessels.	  This	  reflects	  the	  non-­‐specific	  nature	  of	  18F-­‐FDG	  due	  to	  the	  central	  role	  that	  glucose	  plays	  in	  
the	  body’s	  metabolism.	  More	  specific	  tracers	  for	  inflammation	  are	  keenly	  awaited	  and	  these	  include	  
ligands	  targeted	  to	  the	  macrophage	  peripheral	  benzodiazepine201,	  202	  and	  somatostatin	  receptors.203	  
Indeed	  improved	  tracer	  development	  will	  be	  the	  key	  to	  unlocking	  the	  potential	  of	  PET/CT	  as	  both	  a	  
clinical	  and	  research	  tool.	  By	  contrast	  18F-­‐NaF	  is	  not	  routinely	  taken	  up	  by	  the	  myocardium	  or	  indeed	  
other	  structures	  lying	  in	  close	  proximity	  to	  the	  heart.	  This	  allows	  activity	  in	  the	  valve,	  myocardium	  
and	  aorta	  to	  be	  measured	  without	  the	  problem	  of	  spill-­‐over	  and	  adds	  greatly	  to	  the	  potential	  to	  this	  
tracer	  as	  a	  means	  of	  studying	  calcification	  in	  the	  cardiovascular	  system.	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Uptake	  of	  both	  18F-­‐NaF	  and	  18F-­‐FDG	  was	  increased	  in	  patients	  with	  aortic	  sclerosis	  and	  stenosis	  
compared	  to	  controls,	  displaying	  a	  progressive	  rise	  with	  increasing	  valve	  severity.	  	  However,	  
calcification	  appears	  to	  be	  the	  predominant	  pathological	  process	  particularly	  in	  the	  latter	  stages	  of	  
the	  disease	  and	  would	  therefore	  appear	  to	  be	  a	  better	  target	  for	  future	  medical	  therapies.	  	  
These	  observations	  further	  support	  the	  growing	  opinion	  that	  whilst	  similar,	  aortic	  stenosis	  and	  
atherosclerosis	  are	  in	  fact	  different	  disease	  processes.	  	  Aortic	  stenosis	  appears	  to	  be	  established	  in	  
a	  manner	  akin	  to	  atherosclerosis,	  with	  the	  increased	  18F-­‐FDG	  activity	  observed	  in	  the	  early	  stages	  
reflecting	  the	  role	  of	  lipid	  deposition	  and	  inflammation.	  However,	  the	  pathogenesis	  of	  these	  two	  
conditions	  appears	  to	  diverge	  once	  osteoblast	  activity	  has	  been	  established	  in	  the	  valve.	  
Thereafter	  progressive	  calcification	  predominates	  in	  a	  manner	  that	  is	  quite	  distinct	  from	  the	  
pathogenesis	  of	  atherosclerosis	  and	  appears	  to	  be	  independent	  and	  disproportionate	  to	  the	  
degree	  of	  valvular	  inflammation.	  Consequently	  disease	  progression	  in	  these	  patients	  is	  more	  likely	  
to	  be	  regulated	  by	  the	  mediators	  of	  calcium	  homeostasis	  than	  atherogenesis.	  In	  support	  of	  this	  
concept,	  whilst	  atherosclerotic	  risk	  factors	  and	  serum	  C-­‐reactive	  protein	  concentrations	  predict	  
the	  development	  of	  aortic	  stenosis,	  they	  do	  not	  predict	  subsequent	  disease	  progression.204,	  205	  
Rather	  this	  is	  best	  predicted	  by	  the	  degree	  of	  valvular	  calcification	  at	  baseline.205	  
	  
Uptake	  of	  18F-­‐NaF	  and	  18F-­‐FDG	  in	  the	  coronary	  arteries	  
Current	  risk	  stratification	  of	  patients	  with	  coronary	  artery	  disease	  relies	  on	  the	  detection	  of	  flow	  
limiting	  coronary	  lesions	  that	  are	  capable	  of	  inducing	  myocardial	  ischaemia.	  However,	  contrary	  to	  this	  
approach,	  studies	  have	  consistently	  shown	  that	  the	  majority	  of	  heart	  attacks	  occur	  on	  the	  basis	  on	  
non-­‐flow	  limiting	  lesions,140,	  141	  due	  primarily	  to	  their	  increased	  prevalence.	  However,	  vulnerable	  
plaques	  are	  known	  to	  be	  associated	  with	  certain	  pathological	  processes	  such	  as	  inflammation141,151	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and	  microcalcification,145	  which	  has	  aroused	  interest	  in	  using	  PET/CT	  as	  a	  means	  of	  improving	  their	  
identification.	  	  Based	  upon	  this	  rationale,	  the	  uptake	  of	  both	  18F-­‐NaF	  and	  18-­‐FDG	  was	  assessed	  in	  the	  
coronary	  arteries	  of	  our	  aortic	  stenosis	  cohort.	  This	  was	  a	  pre-­‐defined	  aim	  of	  this	  thesis	  and	  as	  such	  
we	  included	  CT	  calcium	  scoring	  of	  the	  coronary	  arteries	  in	  our	  original	  protocol	  to	  serve	  as	  a	  marker	  
of	  atherosclerotic	  burden.	  	  
	  
18F-­‐NaF	  in	  particular	  appeared	  to	  show	  promise	  as	  a	  novel	  pathological	  biomarker	  in	  atherosclerosis.	  
Whilst	  a	  strong	  correlation	  was	  observed	  between	  uptake	  of	  this	  tracer	  and	  the	  coronary	  calcium	  
score,	  41%	  of	  patients	  with	  scores	  >1000	  had	  no	  significant	  18F-­‐NaF	  uptake.	  This	  suggests	  that	  18F-­‐
NaF	  uptake	  provides	  complementary	  information	  to	  the	  calcium	  score,	  relating	  to	  metabolic	  activity	  
and	  developing	  micro-­‐calcification.	  Indeed	  on	  the	  basis	  of	  these	  two	  parameters,	  patients	  could	  be	  
divided	  in	  to	  three	  groups:	  those	  without	  calcific	  coronary	  artery	  disease	  and	  those	  with	  active	  and	  
inactive	  calcific	  coronary	  atherosclerosis.	  Importantly	  increased	  metabolic	  activity	  of	  the	  calcific	  
plaque	  appears	  to	  be	  of	  clinical	  significance	  being	  associated	  with	  anginal	  symptoms,	  a	  higher	  
incidence	  of	  prior	  MACE	  events	  and	  elevated	  Framingham	  risk	  scores.	  Further	  work	  is	  required	  to	  
establish	  whether	  increased	  18F-­‐NaF	  can	  truly	  identify	  plaques	  at	  risk	  of	  rupture	  (see	  Future	  
Directions)	  but	  this	  study	  has	  raised	  hope	  that	  this	  technique	  might	  prove	  useful	  as	  a	  non-­‐invasive	  
means	  of	  studying	  plaque	  pathology	  and	  improving	  patient	  risk-­‐stratification.	  
	  
Interest	  has	  surrounded	  the	  use	  of	  18F-­‐FDG	  as	  a	  measure	  of	  coronary	  inflammation	  for	  many	  years	  
but	  convincing	  data	  as	  to	  its	  efficacy	  in	  this	  role	  is	  still	  lacking.	  Again	  this	  is	  likely	  to	  reflect	  the	  non-­‐
specific	  nature	  of	  its	  uptake.	  In	  our	  studies,	  intense	  myocardial	  uptake	  of	  18F-­‐FDG	  was	  observed	  in	  a	  
third	  of	  patients	  (even	  despite	  the	  strict	  dietary	  restrictions),	  which	  frequently	  resulted	  in	  spill-­‐over	  in	  
to	  the	  coronary	  vessels	  and	  rendered	  half	  of	  these	  territories	  uninterpretable.	  Furthermore	  when	  the	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interpretable	  regions	  were	  analysed,	  there	  was	  no	  significant	  difference	  in	  coronary	  18F-­‐FDG	  activity	  
between	  those	  with	  and	  without	  atherosclerosis.	  Whilst	  our	  cohort	  was	  largely	  made	  up	  of	  patient	  
with	  stable	  coronary	  disease,	  this	  result	  is	  somewhat	  surprising	  given	  the	  central	  role	  that	  
inflammation	  is	  known	  to	  play	  in	  the	  development	  and	  progression	  of	  atherosclerosis.	  This	  calls	  in	  to	  
doubt	  the	  ability	  of	  this	  technique	  to	  measure	  inflammation	  within	  the	  coronary	  vessels,	  which	  are	  
much	  smaller	  than	  the	  aortic	  and	  carotid	  vessels	  in	  which	  18F-­‐FDG	  PET	  has	  been	  established.	  	  
However	  it	  remains	  possible	  that	  better	  results	  might	  be	  achieved	  in	  a	  younger	  cohort	  in	  whom	  
dietary	  compliance	  is	  likely	  to	  be	  better	  and	  in	  those	  with	  unstable	  coronary	  disease	  in	  whom	  the	  
inflammatory	  signal	  will	  be	  greater.	  	  
	  
Prognostic	  Role	  of	  myocardial	  fibrosis	  in	  aortic	  stenosis	  
Using	  a	  second	  cohort	  of	  patients,	  this	  thesis	  has	  gone	  on	  to	  investigate	  the	  hypertrophic	  response	  of	  
the	  left	  ventricle	  in	  aortic	  stenosis.	  Previous	  studies	  have	  generally	  used	  echocardiography	  for	  this	  
purpose.	  Cardiovascular	  magnetic	  resonance	  offers	  several	  advantages	  in	  the	  assessment	  of	  left	  
ventricular	  structure	  including	  improved	  estimation	  of	  left	  ventricular	  mass,	  volume	  and	  wall	  
thickness	  in	  addition	  to	  its	  ability	  to	  non-­‐invasively	  identify	  regions	  of	  replacement	  fibrosis	  and	  prior	  
myocardial	  infarction.	  The	  late	  gadolinium	  enhancement	  technique	  has	  been	  used	  to	  identify	  such	  
regions	  in	  a	  range	  of	  cardiac	  conditions	  and	  its	  presence	  has	  been	  linked	  to	  an	  adverse	  prognosis	  in	  
dilated	  cardiomyopathy,	  hypertrophic	  cardiomyopathy	  and	  myocardial	  infarction.124-­‐128	  	  
	  
Both	  mid-­‐wall	  and	  infarct	  patterns	  of	  late	  gadolinium	  enhancement	  have	  previously	  been	  reported	  in	  
aortic	  stenosis120,	  121	  and	  the	  aim	  of	  this	  study	  was	  to	  assess	  their	  prevalence	  and	  prognostic	  
importance	  in	  a	  large	  cohort	  of	  these	  patients.	  The	  results	  demonstrated	  that	  both	  infarct	  and	  mid-­‐
wall	  patterns	  of	  LGE	  are	  common	  in	  patients	  with	  moderate	  and	  severe	  disease	  occurring	  in	  28%	  and	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38%	  of	  our	  population	  respectively.	  Mid-­‐wall	  fibrosis	  was	  observed	  in	  patients	  with	  an	  increased	  left	  
ventricular	  mass	  and	  in	  those	  with	  both	  moderate	  and	  severe	  valve	  narrowing.	  The	  association	  of	  
fibrosis	  with	  an	  advanced	  hypertrophic	  response	  has	  been	  described	  before120,	  121	  and	  suggests	  that	  
mid-­‐wall	  LGE	  might	  act	  as	  an	  early	  marker	  of	  ventricular	  decompensation.	  Certainly	  it	  appears	  to	  be	  
associated	  with	  an	  adverse	  prognosis.	  Univariate	  analysis	  revealed	  that	  patients	  with	  mid-­‐wall	  
fibrosis	  had	  an	  eight-­‐fold	  increase	  in	  all-­‐cause	  mortality	  despite	  similar	  aortic	  stenosis	  severity	  and	  
coronary	  artery	  disease	  burden.	  Patients	  with	  an	  infarct	  pattern	  had	  a	  six-­‐fold	  increase.	  Moreover	  
multivariate	  analysis	  demonstrated	  for	  the	  first	  time	  that	  CMR-­‐detected	  mid-­‐wall	  fibrosis	  was	  an	  
independent	  predictor	  of	  mortality	  in	  aortic	  stenosis	  and	  had	  incremental	  value	  in	  the	  prognostic	  
model	  to	  ejection	  fraction.	  	  
	  
Differences	  in	  the	  magnitude	  and	  patterns	  of	  the	  hypertrophic	  response	  
The	  subsequent	  study	  aimed	  to	  assess	  the	  relationship	  between	  the	  degree	  of	  aortic	  valve	  narrowing	  
and	  the	  magnitude	  of	  the	  hypertrophic	  response.	  As	  far	  as	  possible	  patients	  with	  concomitant	  
triggers	  to	  remodelling	  were	  excluded	  so	  that	  assessment	  of	  left	  ventricular	  geometry	  could	  be	  
attributed	  to	  aortic	  valve	  disease.	  Based	  upon	  this	  cohort,	  the	  study	  demonstrated	  significant	  
individual	  variation	  in	  the	  degree	  of	  left	  ventricular	  hypertrophy,	  which	  was	  poorly	  related	  to	  the	  
degree	  of	  valve	  narrowing	  and	  more	  closely	  linked	  to	  gender	  and	  concomitant	  hypertension.	  This	  is	  
an	  important	  observation	  because	  it	  underlines	  the	  fact	  that	  the	  progression	  of	  valve	  narrowing	  and	  
left	  ventricular	  hypertrophy	  do	  not	  necessarily	  go	  hand	  in	  hand.	  Given	  the	  prognostic	  importance	  
associated	  with	  myocardial	  fibrosis	  and	  its	  link	  with	  advanced	  hypertrophy,	  this	  indicates	  that	  the	  
ventricular	  response	  should	  be	  carefully	  considered	  along	  side	  the	  degree	  of	  valve	  narrowing	  when	  
assessing	  patients	  with	  aortic	  stenosis.	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Finally	  this	  same	  cohort	  was	  used	  to	  examine	  the	  patterns	  of	  remodelling	  and	  hypertrophy	  in	  aortic	  
stenosis	  and	  demonstrated	  that	  asymmetric	  patterns	  of	  wall	  thickening	  are	  common,	  with	  important	  
potential	  implications	  for	  the	  diagnosis	  of	  hypertrophic	  cardiomyopathy	  in	  patients	  with	  an	  increased	  
afterload.	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7.2	  FUTURE	  DIRECTIONS	  	  
	  
A	  number	  of	  questions	  have	  arisen	  from	  the	  results	  of	  this	  thesis	  and	  the	  peer	  review	  it	  has	  
generated.206,	  207	  As	  described	  below	  our	  research	  group	  hopes	  to	  explore	  these	  in	  future	  studies,	  
indeed	  they	  have	  formed	  the	  basis	  of	  several	  major	  research	  grant	  applications.	  	  
	  
Positron	  Emission	  Tomography	  
	  
Follow	  up	  studies	  
Having	  established	  the	  feasibility	  and	  reproducibility	  of	  quantifying	  18F-­‐NaF	  and	  18F-­‐FDG	  uptake	  in	  
the	  aortic	  valve,	  the	  key	  question	  is	  whether	  this	  technique	  can	  truly	  provide	  a	  measure	  of	  disease	  
activity.	  In	  order	  to	  answer	  this	  issue,	  we	  plan	  to	  follow	  our	  PET/CT	  cohort	  over	  the	  next	  two	  years	  
and	  assess	  whether	  tracer	  activity	  predicts	  the	  progression	  of	  valve	  narrowing.	  Each	  patient	  will	  
undergo	  repeat	  echocardiography	  performed	  by	  the	  same	  technician	  on	  the	  same	  machine	  using	  the	  
same	  protocol	  after	  both	  1	  and	  2	  years.	  Furthermore	  we	  shall	  repeat	  CT	  calcium	  scoring	  of	  the	  aortic	  
valve	  after	  2	  years	  have	  elapsed.	  	  If	  it	  can	  be	  established	  that	  this	  technique	  predicts	  changes	  in	  
aortic	  valve	  gradient	  or	  calcium	  score	  then	  this	  will	  pave	  the	  way	  for	  its	  use	  as	  a	  clinical	  tool	  and	  end-­‐
point	  in	  clinical	  trials	  of	  novel	  therapies.207	  
	  
Histology	  studies	  
18F-­‐NaF	  is	  believed	  to	  localise	  to	  areas	  of	  exposed	  hydroxyapatite	  crystal,	  which	  is	  an	  important	  
component	  of	  both	  vascular	  calcification	  and	  skeletal	  bone.	  However	  this	  is	  based	  upon	  studies	  
conducted	  on	  bone.113	  	  Histological	  validation	  and	  kinetic	  modeling	  of	  vascular	  18F-­‐NaF	  is	  lacking	  and	  
required	  to	  establish	  with	  certainty	  its	  mechanism	  of	  uptake	  in	  the	  valve	  and	  coronary	  arteries.	  We	  
have	  ethical	  permission	  to	  examine	  the	  valves	  of	  patients	  who	  participated	  in	  our	  PET/CT	  study	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should	  they	  undergo	  subsequent	  aortic	  valve	  replacement,	  and	  this	  will	  provide	  the	  opportunity	  for	  
histological	  correlation.	  By	  contrast	  histological	  validation	  of	  coronary	  uptake	  is	  not	  straightforward.	  
However	  we	  have	  submitted	  a	  grant	  to	  perform	  kinetic	  modeling	  of	  carotid	  18F-­‐NaF	  uptake	  in	  
patients	  undergoing	  endarterectomy,	  in	  whom	  atherosclerotic	  tissue	  will	  subsequently	  be	  available	  
for	  pathological	  comparison.	  	  	  
	  
Randomised	  control	  trial	  of	  anti-­‐calcific	  medication	  in	  aortic	  stenosis	  
	  
To	  date,	  there	  are	  no	  effective	  medical	  treatments	  for	  aortic	  stenosis.	  These	  are	  urgently	  required	  as	  
they	  might	  avoid	  the	  need	  for	  invasive	  cardiac	  surgery	  in	  patients	  that	  are	  often	  elderly	  and	  not	  
ideally	  suited	  to	  a	  major	  operation.	  Treatment	  strategies	  to	  date	  have	  focused	  upon	  targeting	  lipid	  
deposition	  and	  inflammation	  without	  success.	  The	  data	  from	  this	  thesis	  suggests	  that	  calcification	  is	  
in	  fact	  the	  dominant	  pathological	  process	  and	  therefore	  the	  better	  target	  for	  therapeutic	  
intervention.	  	  
	  	  
Patients	  with	  osteoporosis	  have	  an	  increased	  incidence	  of	  aortic	  stenosis	  and	  display	  more	  rapid	  
rates	  of	  disease	  progression.34	  208	  Both	  conditions	  are	  characterized	  by	  abnormalities	  in	  calcium	  
metabolism	  and	  are	  governed	  by	  common	  systemic	  regulatory	  systems.	  These	  pathways	  help	  co-­‐
ordinate	  calcium	  homeostasis	  via	  the	  action	  of	  osteoblasts	  and	  osteoclasts	  and	  include	  the	  
OPG/RANK/	  RANKL	  axis.40	  OPG	  is	  a	  decoy	  receptor	  for	  RANKL:	  a	  potent	  stimulator	  of	  osteoclast	  
differentiation	  and	  bone	  resorption.209	  Increased	  expression	  of	  RANKL	  and	  reduced	  levels	  of	  OPG	  
have	  been	  observed	  in	  osteoporosis	  and	  have	  led	  to	  the	  development	  of	  denusomab,	  a	  novel	  anti-­‐
RANKL	  monoclonal	  antibody,	  as	  a	  highly	  efficacious	  and	  well-­‐tolerated	  osteoporosis	  treatment.210	  
Interestingly	  the	  OPG/RANK/RANKL	  axis	  also	  appears	  to	  regulate	  vascular	  and	  aortic	  valve	  
calcification	  (Figure	  2).	  Mice	  with	  targeted	  inactivation	  of	  OPG	  develop	  high-­‐turnover	  osteoporosis	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and	  extensive	  vascular	  calcification,211	  212	  whilst	  increased	  expression	  of	  RANKL	  and	  reduced	  levels	  of	  
OPG	  have	  been	  observed	  within	  stenotic	  aortic	  valves.41	  
	  
We	  therefore	  believe	  that	  there	  is	  a	  strong	  rationale	  for	  investigating	  RANKL	  inhibition	  as	  a	  treatment	  
strategy	   for	   aortic	   stenosis.213	   Indeed	   we	   have	   recently	   submitted	   a	   grant	   for	   a	   double	   blind	  
randomised	  placebo-­‐controlled	  trial	  of	  denosumab	  to	  assess	  its	  effect	  of	  on	  aortic	  jet	  velocity	  in	  230	  
patients	  with	  aortic	  stenosis.	  Patients	  with	  an	  aortic	  jet	  velocity	  of	  ≥2.5	  m/s	  will	  be	  recruited	  into	  the	  
trial	  and	  randomised	  to	  denosumab	  60	  mg	  subcutaneous	  or	  matched	  placebo	  every	  6	  months	  for	  up	  
to	   3	   years.	   They	   will	   undergo	   baseline	   assessments	   of	   Doppler	   echocardiography,	   computed	  
tomography	  and	  sodium	  18-­‐fluoride	  positron	  emission	   tomography,	  and	  be	   followed	  up	  6-­‐monthly	  
for	   Doppler	   echocardiography,	   annually	   for	   computed	   tomography,	   and	   at	   3	   and	   12	   months	   for	  
sodium	  18-­‐fluoride	  PET.	  Disease	  progression	  will	  be	  determined	  by	   the	   rate	  of	   change	   in	  aortic	   jet	  
velocity	  and	  the	  aortic	  valve	  calcium	  score.	  If	  successful,	  this	  study	  will	  pave	  the	  way	  for	  a	  larger	  and	  
definitive	  multicentre	  randomised	  controlled	  trial	  of	  this	  therapeutic	  approach.	  	  
	  
Coronary	  studies	  
We	  have	  provided	  preliminary	  data	  that	  indicates	  18F-­‐NaF	  may	  prove	  to	  be	  a	  useful	  tool	  in	  the	  study	  
of	  coronary	  artery	  pathology	  and	  as	  a	  means	  of	  improving	  risk	  prediction.	  The	  next	  step	  is	  to	  identify	  
the	  exact	  mechanism	  for	  the	  increased	  PET	  signal	  in	  the	  coronary	  vasculature.	  It	  is	  possible	  that	  
active	  calcification	  may	  reflect	  a	  healing	  response	  to	  plaque	  rupture	  or	  alternatively	  a	  response	  to	  
chronic	  inflammation	  within	  the	  necrotic	  plaque	  core.	  We	  have	  received	  a	  grant	  to	  investigate	  this	  
issue.	  We	  will	  study	  40	  patients	  with	  stable	  coronary	  artery	  disease	  and	  40	  following	  acute	  coronary	  
syndromes.	  All	  patients	  will	  undergo	  18F-­‐NaF	  PET/CT	  in	  addition	  to	  CT	  coronary	  angiography	  (to	  give	  
us	  additional	  data	  with	  respect	  to	  soft	  plaque),	  invasive	  angiography	  and	  virtual	  histology	  intra-­‐
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vascular	  ultrasound	  (VH-­‐IVUS).	  This	  multi-­‐modal	  imaging	  protocol	  should	  allow	  us	  to	  identify	  
accurately	  the	  plaque	  characteristics	  associated	  with	  18F-­‐NaF	  uptake.	  If	  we	  confirm	  its	  relationship	  
to	  either	  recent	  plaque	  rupture	  or	  a	  large	  necrotic	  core	  then	  this	  tracer	  would	  hold	  considerable	  
promise	  as	  a	  clinical	  tool	  in	  predicting	  future	  adverse	  cardiac	  events.	  In	  addition	  it	  might	  provide	  a	  
novel	  biomarker	  that	  could	  be	  used	  to	  assess	  the	  numerous	  anti-­‐atherosclerotic	  drug	  targets	  
currently	  being	  developed	  by	  the	  pharmaceutical	  industry.	  
	  
ECG	  and	  Respiratory	  Gating	  
Whilst	  the	  heart	  spends	  much	  of	  its	  time	  still	  in	  diastole,	  significant	  motion	  occurs	  in	  the	  aortic	  valve	  
and	  coronary	  arteries	  during	  the	  course	  of	  the	  cardiac	  cycle.	  Furthermore	  these	  structures	  move	  as	  a	  
result	  of	  the	  changes	  in	  intra-­‐thoracic	  pressure	  that	  accompany	  respiration.	  The	  attenuation	  
correction	  CT	  and	  PET	  scans	  will	  be	  affected	  equally	  by	  these	  processes	  nevertheless,	  motion	  artifact	  
may	  limit	  the	  ability	  of	  PET/CT	  to	  localise	  uptake	  to	  specific	  coronary	  plaques	  or	  regions	  of	  the	  valve.	  	  
However	  this	  problem	  can	  be	  overcome	  using	  ECG	  and	  respiratory	  gating.	  In	  collaboration	  with	  the	  
imaging	  research	  group	  at	  Cedars-­‐Sinai	  Medical	  Center	  in	  Los	  Angeles	  and	  Siemens	  we	  intend	  to	  use	  
such	  gating	  to	  minimize	  the	  effects	  of	  motion	  in	  our	  future	  PET/CT	  projects.	  The	  basis	  for	  our	  
approach	  is	  to	  only	  include	  diastolic	  PET	  data	  (when	  the	  coronary	  arteries	  and	  valve	  are	  still),	  which	  
can	  then	  be	  refined	  by	  adjusting	  for	  respiratory	  motion.	  	  We	  anticipate	  that	  this	  strategy	  will	  improve	  
the	  resolution	  with	  which	  we	  are	  able	  to	  detect	  PET	  uptake	  within	  the	  heart.	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Cardiovascular	  Magnetic	  Resonance	  and	  Late	  Gadolinium	  Enhancement	  
We	  have	  established	  that	  mid-­‐wall	  LGE	  is	  associated	  with	  an	  adverse	  prognosis	  in	  a	  prospective	  
registry.	  However,	  there	  is	  some	  potential	  referral	  bias	  in	  this	  population	  given	  their	  requirement	  for	  
a	  CMR	  scan.	  Furthermore	  the	  mechanism	  for	  the	  adverse	  prognosis	  remains	  unclear,	  potentially	  
being	  related	  to	  impaired	  left	  ventricular	  function	  and	  increased	  arrhythmogenicity.206	  	  
	  
We	  have	  been	  awarded	  a	  research	  grant	  in	  order	  to	  address	  these	  issues.	  As	  part	  of	  the	  study	  we	  will	  
recruit	  a	  population	  of	  240	  adults,	  comprising	  control	  subjects,	  and	  patients	  with	  the	  full	  spectrum	  of	  
aortic	  stenosis	  disease	  including	  a	  group	  about	  to	  undergo	  aortic	  valve	  replacement.	  This	  will	  include	  
a	  large	  proportion	  of	  patients	  who	  originally	  took	  part	  in	  the	  PET	  studies.	  At	  baseline	  all	  subjects	  will	  
undergo	  a	  standardised	  clinical	  assessment	  including	  a	  quality	  of	  life	  questionnaire,	  a	  six-­‐minute	  walk	  
test	  and	  72-­‐hour	  Holter	  monitoring.	  In	  addition	  CMR	  scanning	  will	  be	  performed	  with	  LGE	  of	  the	  
myocardium	  and	  valve.	  Clinical	  assessment	  will	  be	  repeated	  after	  1	  and	  2	  years	  of	  follow-­‐up	  and	  
patients	  will	  also	  be	  contacted	  by	  phone	  and	  mail	  after	  3,	  4	  and	  5	  years.	  We	  hope	  that	  this	  study	  will	  
confirm	  the	  prognostic	  role	  of	  mid-­‐wall	  LGE	  in	  a	  prospectively	  recruited	  population	  of	  aortic	  stenosis	  
and	  provide	  explanation	  for	  its	  adverse	  prognosis.	  	  
	  	  
T1	  mapping	  
The	  late	  gadolinium	  enhancement	  technique	  is	  limited	  by	  the	  fact	  that	  it	  only	  identifies	  regional	  
differences	  in	  replacement	  myocardial	  fibrosis.	  In	  patients	  with	  aortic	  stenosis,	  the	  predominant	  
form	  is	  in	  fact	  diffuse	  interstitial	  fibrosis	  that	  is	  evenly	  distributed	  throughout	  the	  myocardium	  and	  
therefore	  not	  detected.	  CMR	  T1	  mapping	  systems	  have	  recently	  been	  developed	  that	  can	  identify	  
and	  quantify	  this	  form	  of	  fibrosis.	  This	  technique	  is	  therefore	  likely	  to	  become	  the	  preferred	  
assessment	  of	  myocardial	  fibrosis	  in	  aortic	  stenosis,	  having	  already	  undergone	  histological	  validation	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and	  been	  shown	  to	  correlate	  with	  symptomatic	  status	  and	  exercise	  tolerance.214,	  215	  However	  to	  date	  
no	  study	  has	  confirmed	  the	  prognostic	  importance	  of	  T1	  mapping	  in	  aortic	  stenosis.	  In	  collaboration	  
with	  Siemens,	  who	  have	  provided	  us	  with	  a	  novel	  T1	  mapping	  sequence	  for	  use	  at	  3T,	  and	  the	  Royal	  
Brompton	  Hospital,	  we	  shall	  therefore	  perform	  this	  technique	  in	  all	  the	  patients	  recruited	  in	  to	  the	  
above	  study.	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7.3	  	   CLINICAL	  PERSPECTIVE	  
	  
Aortic	  stenosis	  is	  the	  most	  common	  form	  of	  valve	  disease	  in	  the	  western	  world	  yet	  we	  lack	  any	  
effective	  medical	  therapies	  capable	  of	  halting	  its	  progression.	  In	  part	  this	  reflects	  our	  incomplete	  
understanding	  of	  the	  pathological	  mechanisms,	  which	  underlie	  this	  condition.	  Histopathological	  
studies	  are	  limited	  by	  the	  availability	  of	  valves	  in	  the	  earlier	  stages	  of	  the	  disease	  and	  by	  an	  inability	  
to	  monitor	  disease	  progression.	  	  
	  
Non-­‐invasive	  imaging	  modalities	  offer	  us	  the	  opportunity	  to	  study	  the	  pathophysiology	  in	  all	  stages	  
of	  the	  disease	  process	  and	  have	  provided	  us	  with	  some	  important	  insights	  during	  the	  course	  of	  this	  
thesis.	  We	  have	  demonstrated	  that	  calcification	  and	  inflammation	  are	  both	  active	  within	  the	  valve	  at	  
all	  stages	  of	  the	  disease	  and	  increase	  as	  the	  disease	  advances.	  However	  calcification	  appears	  to	  be	  
the	  dominant	  process	  particularly	  in	  the	  latter	  stages	  and	  is	  therefore	  likely	  to	  be	  a	  more	  effective	  
therapeutic	  target.	  	  
	  
In	  addition	  we	  have	  shown	  that	  the	  effects	  of	  valve	  narrowing	  on	  the	  left	  ventricular	  myocardium	  are	  
also	  of	  importance.	  In	  particular	  there	  appears	  to	  be	  considerable	  variation	  in	  both	  the	  magnitude	  
and	  pattern	  of	  left	  ventricular	  hypertrophy	  and	  that	  decompensation	  of	  this	  process,	  as	  detected	  by	  
mid-­‐wall	  late	  gadolinium	  enhancement,	  heralds	  an	  adverse	  prognosis.	  Given	  that	  the	  degree	  of	  
hypertrophy	  is	  poorly	  related	  to	  the	  severity	  of	  valve	  narrowing,	  it	  is	  our	  opinion	  that	  the	  left	  
ventricular	  remodeling	  response	  should	  be	  considered	  carefully	  alongside	  standard	  measures	  of	  
valve	  narrowing	  when	  assessing	  overall	  valve	  severity.	  	  
	  
These	  insights	  pave	  the	  way	  for	  larger	  multi-­‐centre	  trials	  to	  assess	  whether	  PET/CT	  and	  CMR	  might	  
allow	  for	  better	  prediction	  of	  aortic	  stenosis	  progression	  and	  decompensation	  and	  act	  as	  surrogate	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